{"f27ab36ff6a2aed53fcc28f19a3688a239afa4ef": [["IntroductionEndotracheal intubation for oxygenation, ventilation, and airway protection is a key intervention in trauma care, but it is not without risks.", [["Endotracheal", "ANATOMY", 12, 24], ["airway", "ANATOMY", 70, 76], ["trauma", "DISEASE", 113, 119], ["airway", "MULTI-TISSUE_STRUCTURE", 70, 76], ["Endotracheal intubation", "TREATMENT", 12, 35], ["oxygenation", "TREATMENT", 40, 51], ["ventilation", "TREATMENT", 53, 64], ["airway protection", "TREATMENT", 70, 87], ["trauma care", "TREATMENT", 113, 124], ["airway", "ANATOMY", 70, 76], ["not without", "UNCERTAINTY", 136, 147]]], ["The American College of Surgeons Committee on Trauma Advanced Trauma Life Advanced Trauma Life Support (ATLS) course teaches that a Glasgow Coma Scale (GCS) score of 8 or lower mandates intubation for airway protection [1] .", [["airway", "ANATOMY", 201, 207], ["Trauma", "DISEASE", 46, 52], ["Trauma", "DISEASE", 62, 68], ["Trauma", "DISEASE", 83, 89], ["Coma", "DISEASE", 140, 144], ["airway", "MULTI-TISSUE_STRUCTURE", 201, 207], ["a Glasgow Coma Scale", "TEST", 130, 150], ["GCS) score", "TEST", 152, 162], ["airway protection", "TREATMENT", 201, 218]]], ["Likewise, the Eastern Association for the Surgery of Trauma (EAST) practice management guidelines (PMGs) give a level 1 recommendation for intubation for patients with a GCS of 8 [2, 3] .", [["Trauma", "DISEASE", 53, 59], ["GCS", "DISEASE", 170, 173], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["intubation", "TREATMENT", 139, 149], ["a GCS", "TEST", 168, 173]]], ["Indeed, real-world trauma center practice varies, and some clinicians may have an even more conservative threshold for intubation.", [["trauma", "DISEASE", 19, 25], ["intubation", "TREATMENT", 119, 129]]], ["A review of one center's indications for intubation revealed that 25% of patients were intubated for \"altered mental status\", but had a GCS > 8 [4] .", [["GCS", "DISEASE", 136, 139], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["intubation", "TREATMENT", 41, 51], ["intubated", "TREATMENT", 87, 96], ["\"altered mental status\"", "PROBLEM", 101, 124], ["a GCS", "TEST", 134, 139]]], ["Following this, a 2012 update to the aforementioned EAST guidelines gave a level 3 recommendation for intubating patients with \"moderate\" cognitive impairment (GCS 9-12) [3] .IntroductionDespite these high-level recommendations, there is no direct evidence to support this practice.", [["cognitive impairment", "DISEASE", 138, 158], ["GCS", "DISEASE", 160, 163], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["intubating", "TREATMENT", 102, 112], ["\"moderate\" cognitive impairment", "PROBLEM", 127, 158], ["GCS", "TEST", 160, 163], ["this practice", "TREATMENT", 268, 281], ["no direct evidence to", "UNCERTAINTY", 238, 259]]], ["Endotracheal intubation preserves oxygenation and ventilation and may prevent aspiration in injured patients, but intubation also puts patients at risk of hypotension, exposes them to sedating and paralyzing medications, risks ventilator-associated complications, and usually mandates an intensive care unit stay.", [["Endotracheal", "ANATOMY", 0, 12], ["hypotension", "DISEASE", 155, 166], ["patients", "ORGANISM", 100, 108], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 100, 108], ["patients", "SPECIES", 135, 143], ["Endotracheal intubation", "TREATMENT", 0, 23], ["ventilation", "TREATMENT", 50, 61], ["aspiration", "PROBLEM", 78, 88], ["intubation", "TREATMENT", 114, 124], ["hypotension", "PROBLEM", 155, 166], ["sedating", "TREATMENT", 184, 192], ["paralyzing medications", "TREATMENT", 197, 219], ["risks ventilator", "TREATMENT", 221, 237], ["associated complications", "PROBLEM", 238, 262], ["intubation", "OBSERVATION", 13, 23], ["oxygenation", "OBSERVATION_MODIFIER", 34, 45], ["aspiration", "OBSERVATION", 78, 88], ["hypotension", "OBSERVATION", 155, 166]]], ["Therefore, while the \"GCS 8\" rule has reasonable face validity, it deserves more careful consideration.IntroductionGiven the lack of strong evidentiary support for intubating patients for a GCS of 8 or less, we sought to investigate the treatment effect of intubation in trauma patients with a GCS less than 8 using a nationally representative database.", [["GCS", "DISEASE", 190, 193], ["trauma", "DISEASE", 271, 277], ["GCS", "DISEASE", 294, 297], ["patients", "ORGANISM", 175, 183], ["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 278, 286], ["the \"GCS", "TEST", 17, 25], ["intubating", "TREATMENT", 164, 174], ["a GCS", "TEST", 188, 193], ["intubation", "TREATMENT", 257, 267], ["a GCS", "TEST", 292, 297]]], ["We recognize that obtunded patients with a severely depressed GCS are likely to benefit from intubation, but suggest that there is an inherent difference between those who fall in the bottom quartile of GCS and those in the range of 6-8.", [["depressed", "DISEASE", 52, 61], ["GCS", "DISEASE", 62, 65], ["GCS", "DISEASE", 203, 206], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["obtunded", "PROBLEM", 18, 26], ["a severely depressed GCS", "PROBLEM", 41, 65], ["intubation", "TREATMENT", 93, 103], ["GCS", "TEST", 203, 206]]], ["Indeed, there is some support for this in the literature [5, 6] .", [["some", "OBSERVATION_MODIFIER", 17, 21], ["support", "OBSERVATION", 22, 29]]], ["Therefore, we chose to study patients with a \"marginal\" GCS, under the hypothesis that for patients with a GCS between 6 and 8, intubation would have no effect on mortality, but would increase the length of stay.Patients and methodsWe conducted a retrospective cohort study using the 2016 National Trauma Data Bank (NTDB) [7] .", [["GCS", "DISEASE", 56, 59], ["GCS", "DISEASE", 107, 110], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 91, 99], ["Patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 91, 99], ["Patients", "SPECIES", 212, 220], ["a \"marginal\" GCS", "PROBLEM", 43, 59], ["a GCS", "TEST", 105, 110], ["intubation", "TREATMENT", 128, 138], ["a retrospective cohort study", "TEST", 245, 273]]], ["The NTDB is a centralized, nationally representative dataset created and maintained by the American College of Surgeons (ACS).", [["ACS", "DISEASE", 121, 124]]], ["Over 700 centers contribute to it across all levels of trauma designation; contribution to the NTDB is an ACS requirement for Level I and II centers.", [["trauma", "DISEASE", 55, 61], ["NTDB", "DISEASE", 95, 99], ["ACS", "DISEASE", 106, 109], ["trauma", "PROBLEM", 55, 61], ["the NTDB", "PROBLEM", 91, 99], ["an ACS requirement", "PROBLEM", 103, 121], ["trauma", "OBSERVATION", 55, 61], ["ACS", "OBSERVATION", 106, 109]]], ["This dataset is frequently used in large-scale retrospective studies [8] .Patients and methodsWe excluded patients that were transferred to another hospital, either from the emergency department or later in their hospital stay because we could not ascertain the primary outcomes of interest in these patients.", [["Patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 300, 308], ["Patients", "SPECIES", 74, 82], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 300, 308]]], ["We excluded patients aged < 16 years, patients who arrived without signs of life or vital signs indicating they were dead on arrival, and those with an advance directive limiting care.Patients and methodsIntubation was identified using procedure codes.", [["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 38, 46], ["Patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 38, 46], ["Patients", "SPECIES", 184, 192], ["vital signs", "TEST", 84, 95], ["methodsIntubation", "TREATMENT", 197, 214], ["procedure codes", "TREATMENT", 236, 251]]], ["We counted patients as having been intubated on arrival if they carried an ICD-9 or ICD-10 code for endotracheal intubation and the timestamp associated with that code was within 1 h of arrival.", [["endotracheal", "ANATOMY", 100, 112], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["intubated", "TREATMENT", 35, 44], ["an ICD", "TREATMENT", 72, 78], ["ICD", "TREATMENT", 84, 87], ["endotracheal intubation", "TREATMENT", 100, 123]]], ["A summary of included ICD codes is shown in Table 5 in Appendix 1.", [["ICD codes", "TREATMENT", 22, 31], ["Appendix", "ANATOMY", 55, 63]]], ["We also defined patients as 'intubated' if their ED dispositions were listed as \"operating room,\" indicating that they underwent immediate operation and thus required intubation.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["immediate operation", "TREATMENT", 129, 148], ["intubation", "TREATMENT", 167, 177]]], ["These patients accounted for a minority (10.4%) of the intubated cohort.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["the intubated cohort", "TREATMENT", 51, 71]]], ["A patient was considered to have been intubated in the field if there was no intubation code, but his or her initial GCS carried an NTDB qualifier code indicating that they were intubated, sedated, or chemically paralyzed.", [["GCS", "DISEASE", 117, 120], ["patient", "ORGANISM", 2, 9], ["patient", "SPECIES", 2, 9], ["intubated", "TREATMENT", 38, 47], ["her initial GCS", "TEST", 105, 120], ["intubated", "TREATMENT", 178, 187], ["sedated", "TREATMENT", 189, 196]]], ["These patients were excluded.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["A flow diagram of inclusions and exclusions is shown in Fig. 1 .Patients and methodsHypotension was defined as a presenting systolic blood pressure (SBP) of less than 90 mmHg.", [["blood", "ANATOMY", 133, 138], ["Hypotension", "DISEASE", 84, 95], ["Patients", "ORGANISM", 64, 72], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["Patients", "SPECIES", 64, 72], ["A flow diagram", "TEST", 0, 14], ["Hypotension", "PROBLEM", 84, 95], ["a presenting systolic blood pressure", "TEST", 111, 147], ["SBP", "TEST", 149, 152], ["flow diagram", "OBSERVATION", 2, 14], ["Hypotension", "OBSERVATION", 84, 95]]], ["The data were inspected for missingness.", [["The data", "TEST", 0, 8], ["missingness", "PROBLEM", 28, 39]]], ["Of the 6676 patients, 4 were missing a value for mortality, 2 for sex, 333 for race, and 238 for hospital length of stay.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["Aside from intensive care unit (ICU) length of stay (LOS), 92% of patients in this cohort had complete records.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74]]], ["To reduce the risk of bias associated with casewise deletion, we used multiple imputation with chained equations [9] .", [["casewise deletion", "DNA", 43, 60], ["casewise deletion", "PROBLEM", 43, 60], ["multiple imputation with chained equations", "TREATMENT", 70, 112]]], ["With respect to ICU LOS, the majority of those missing values (926/934; 99.1%) were missing because the patients were noted not to have been admitted to the ICU.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112]]], ["Thus, the analysis treating ICU LOS as the outcome was performed as a complete-case analysis.Patients and methodsWe next tabulated descriptive statistics between those that were intubated and those that were not.", [["Patients", "ORGANISM", 93, 101], ["Patients", "SPECIES", 93, 101], ["the analysis", "TEST", 6, 18], ["a complete-case analysis", "TEST", 68, 92], ["intubated", "TREATMENT", 178, 187]]], ["Differences were expressed using Pearson's chi-squared, Student's t test, or Mann-Whitney U test, as appropriate.", [["Student's t test", "TEST", 56, 72]]], ["The primary exposure variable in our analysis was ED intubation.", [["our analysis", "TEST", 33, 45], ["ED intubation", "TREATMENT", 50, 63], ["variable", "OBSERVATION_MODIFIER", 21, 29]]], ["To explore potential bias incurred by the inclusion of direct-to-operating room patients that were not otherwise coded as intubated, we conducted a sensitivity analysis in which the mortality risk was re-examined, excluding these patients.", [["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 230, 238], ["intubated", "TREATMENT", 122, 131], ["a sensitivity analysis", "TEST", 146, 168]]], ["In a sub-analysis of mortality risk, the cohort was stratified by head injury, as defined as any abbreviated injury scale (AIS) head score > 0.", [["head", "ANATOMY", 66, 70], ["head injury", "DISEASE", 66, 77], ["head", "ORGANISM_SUBDIVISION", 66, 70], ["head injury", "PROBLEM", 66, 77], ["any abbreviated injury scale", "PROBLEM", 93, 121], ["head score", "TEST", 128, 138]]], ["A sensitivity analysis was also performed for the stratification; for this analysis, we redefined head injury as AIS > 1.", [["head", "ANATOMY", 98, 102], ["head injury", "DISEASE", 98, 109], ["AIS", "DISEASE", 113, 116], ["head", "ORGANISM_SUBDIVISION", 98, 102], ["A sensitivity analysis", "TEST", 0, 22], ["this analysis", "TEST", 70, 83], ["head injury", "PROBLEM", 98, 109], ["AIS", "TEST", 113, 116], ["head", "ANATOMY", 98, 102], ["injury", "OBSERVATION", 103, 109]]], ["Finally, as intoxication may be a factor that influences clinicians' decisions to observe patients without intubation, we performed a separate analysis, stratified by alcohol intoxication.", [["alcohol", "CHEMICAL", 167, 174], ["alcohol", "CHEMICAL", 167, 174], ["patients", "ORGANISM", 90, 98], ["alcohol", "SIMPLE_CHEMICAL", 167, 174], ["patients", "SPECIES", 90, 98], ["intubation", "TREATMENT", 107, 117], ["a separate analysis", "TEST", 132, 151], ["alcohol intoxication", "PROBLEM", 167, 187]]], ["For these purposes, intoxication was defined as a measured level above the legal limit.", [["intoxication", "PROBLEM", 20, 32], ["legal limit", "OBSERVATION", 75, 86]]], ["To control for potential confounders, regression analyses (logistic for the primary outcome and linear for the secondary outcomes) were used.", [["regression analyses", "TEST", 38, 57], ["the secondary outcomes)", "TREATMENT", 107, 130]]], ["Because both LOS variables had skewed distributions, we log-transformed them before using them as outcomes in our linear regression models.", [["LOS", "OBSERVATION_MODIFIER", 13, 16], ["skewed", "OBSERVATION_MODIFIER", 31, 37], ["distributions", "OBSERVATION_MODIFIER", 38, 51]]], ["Furthermore, given that the likelihood of exposure (intubation) is dependent on several factors likely to be correlated with the outcome (mortality)-including GCSwe used inverse probability weighting to adjust for severity of illness and patient factors.Patients and methodsInverse probability weighting (IPW) is one method of reducing confounding in observational studies.", [["illness", "DISEASE", 226, 233], ["patient", "ORGANISM", 238, 245], ["Patients", "ORGANISM", 254, 262], ["patient", "SPECIES", 238, 245], ["Patients", "SPECIES", 254, 262], ["intubation", "TREATMENT", 52, 62], ["illness", "PROBLEM", 226, 233], ["observational studies", "TEST", 351, 372]]], ["For example, severity of injury, deranged physiology, and GCS are known to be associated with the outcome of mortality but may also be associated with intubation, the exposure of interest.", [["GCS", "DISEASE", 58, 61], ["injury", "PROBLEM", 25, 31], ["deranged physiology", "PROBLEM", 33, 52], ["GCS", "PROBLEM", 58, 61], ["intubation", "TREATMENT", 151, 161], ["severity", "OBSERVATION_MODIFIER", 13, 21], ["injury", "OBSERVATION", 25, 31]]], ["To mitigate this confounding, IPW uses propensity scores (PS), [10] which employ a regression analysis to estimate a patient's likelihood of exposure, to 'weight' each patient such that those that are less likely to be exposed contribute more 'weight' than those who are more likely [11] .", [["patient", "ORGANISM", 117, 124], ["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 117, 124], ["patient", "SPECIES", 168, 175], ["a regression analysis", "TEST", 81, 102]]], ["PS and IPW can be used in a variety of ways; in inverse probability weight regression adjustment (IPWRA), a regression model is used to estimate PS (and therefore IPW = 1/PS); another regression model including several covariates as well as the PSs is fitted to estimate the strength of an association with the outcome of interest [12] .", [["PS", "TREATMENT", 0, 2], ["IPW", "TREATMENT", 7, 10], ["a regression model", "TREATMENT", 106, 124], ["IPW", "TEST", 163, 166], ["another regression model", "TREATMENT", 176, 200], ["the PSs", "TREATMENT", 241, 248]]], ["This is often expressed as an average treatment effect (ATE), which is the theoretical average of the differences between treatment and exposure outcomes for each patient.", [["patient", "ORGANISM", 163, 170], ["patient", "SPECIES", 163, 170], ["treatment", "TREATMENT", 122, 131]]], ["This treatment effect is unobservable at the individual level as we cannot know the outcome given the counterfactual for any given patient, but these statistical methods allow us to estimate the average effect [13] .Patients and methodsThis study was determined by our Institutional Review Board to be exempt from review.", [["patient", "ORGANISM", 131, 138], ["Patients", "ORGANISM", 216, 224], ["patient", "SPECIES", 131, 138], ["Patients", "SPECIES", 216, 224], ["This study", "TEST", 236, 246]]], ["The American College of Surgeons is not responsible for any claims arising from works based on the original data, text, tables, or figures.", [["the original data", "TEST", 95, 112]]], ["All statistical analyses were performed using Stata version 15.1 (College Station, TX).", [["All statistical analyses", "TEST", 0, 24], ["Stata version", "TEST", 46, 59]]], ["A two-tailed p value of < 0.05 was considered significant in the final analysis.ResultsAfter exclusions, there were 718,892 patients remaining; 6676 had a GCS score of 6-8 and were included in the analysis.", [["GCS", "DISEASE", 155, 158], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["A two-tailed p value", "TEST", 0, 20], ["the final analysis", "TEST", 61, 79], ["a GCS score", "TEST", 153, 164], ["the analysis", "TEST", 193, 205]]], ["4,078 were intubated within 1 h of arrival to the ED.", [["intubated", "TREATMENT", 11, 20]]], ["Table 1 shows patient characteristics.", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21]]], ["Intubated patients had a higher mortality rate (17.5% vs 11.4%).", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["Intubated", "TREATMENT", 0, 9], ["a higher mortality rate", "PROBLEM", 23, 46]]], ["There was an association between lower GCS score and intubation (64.3% of patients with GCS = 6 intubated vs 56.9% with GCS = 8).", [["GCS", "DISEASE", 88, 91], ["GCS", "DISEASE", 120, 123], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["lower GCS score", "PROBLEM", 33, 48], ["intubation", "TREATMENT", 53, 63], ["GCS", "TEST", 88, 91], ["intubated vs", "TEST", 96, 108], ["GCS", "TEST", 120, 123]]], ["Intubated patients were also younger, more often males, more often hypotensive on arrival (8.7% vs 4.5%), and more severely injured (median ISS 19 vs 10).ResultsUsing IPWRA analysis adjusted for GCS, age, sex, hypotension, maximum head, chest, and abdomen/pelvis abbreviated injury scale (AIS) scores, we determined that the average treatment effect (ATE) of intubation was associated with increased odds of mortality (OR 1.05, 95% CI 1.03-1.06).", [["head", "ANATOMY", 231, 235], ["chest", "ANATOMY", 237, 242], ["abdomen", "ANATOMY", 248, 255], ["pelvis", "ANATOMY", 256, 262], ["hypotensive", "DISEASE", 67, 78], ["GCS", "DISEASE", 195, 198], ["hypotension", "DISEASE", 210, 221], ["patients", "ORGANISM", 10, 18], ["head", "ORGANISM_SUBDIVISION", 231, 235], ["chest", "ORGANISM_SUBDIVISION", 237, 242], ["abdomen", "ORGAN", 248, 255], ["pelvis", "ORGAN", 256, 262], ["patients", "SPECIES", 10, 18], ["Intubated", "TREATMENT", 0, 9], ["hypotensive", "PROBLEM", 67, 78], ["median ISS", "TEST", 133, 143], ["IPWRA analysis", "TEST", 167, 181], ["GCS", "TEST", 195, 198], ["hypotension", "PROBLEM", 210, 221], ["maximum head, chest, and abdomen/pelvis abbreviated injury scale", "PROBLEM", 223, 287], ["intubation", "TREATMENT", 359, 369], ["increased odds of mortality", "PROBLEM", 390, 417], ["CI", "TEST", 432, 434], ["hypotension", "OBSERVATION", 210, 221], ["head", "ANATOMY", 231, 235], ["chest", "ANATOMY", 237, 242], ["abdomen", "ANATOMY", 248, 255], ["pelvis", "ANATOMY", 256, 262]]], ["In both the intubated and non-intubated groups, increasing severity of injury, hypotension, age, and decreasing GCS were also associated with increased mortality.", [["hypotension", "DISEASE", 79, 90], ["GCS", "DISEASE", 112, 115], ["increasing severity of injury", "PROBLEM", 48, 77], ["hypotension", "PROBLEM", 79, 90], ["decreasing GCS", "PROBLEM", 101, 115], ["increased mortality", "PROBLEM", 142, 161], ["increasing", "OBSERVATION_MODIFIER", 48, 58], ["severity", "OBSERVATION_MODIFIER", 59, 67], ["injury", "OBSERVATION", 71, 77], ["hypotension", "OBSERVATION", 79, 90], ["increased", "OBSERVATION_MODIFIER", 142, 151], ["mortality", "OBSERVATION", 152, 161]]], ["In a sensitivity analysis excluding the 424 patients that were not otherwise coded for intubation but proceeded from trauma bay to operating room, the associated mortality risk was the same (OR 1.05, 95% CI 1.03-1.06).ResultsThere were 1,524 head-injured patients (defined by any head AIS > 0).", [["head", "ANATOMY", 242, 246], ["head", "ANATOMY", 280, 284], ["trauma", "DISEASE", 117, 123], ["patients", "ORGANISM", 44, 52], ["head", "ORGANISM_SUBDIVISION", 242, 246], ["patients", "ORGANISM", 255, 263], ["head", "ORGANISM_SUBDIVISION", 280, 284], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 255, 263], ["a sensitivity analysis", "TEST", 3, 25], ["intubation", "TREATMENT", 87, 97], ["CI", "TEST", 204, 206], ["any head AIS", "TEST", 276, 288]]], ["In our stratified analysis, a similar result was Intubation was associated with a statistically significant 13.7% increase in ICU LOS (95% CI 8.0-19.6%) and a 26.8% increase in overall length of stay (95% CI 19.8-34.3%), translating to mean increases from 4.8 to 5.5 days and 6.0 to 7.7 days, respectively (Table 4) (Fig. 2 ).DiscussionFor patients with a GCS between 6 and 8, we found that intubation was associated with increased odds of mortality.", [["GCS", "DISEASE", 356, 359], ["patients", "ORGANISM", 340, 348], ["patients", "SPECIES", 340, 348], ["Intubation", "TREATMENT", 49, 59], ["ICU LOS", "TEST", 126, 133], ["CI", "TEST", 139, 141], ["CI", "TEST", 205, 207], ["a GCS", "TEST", 354, 359], ["intubation", "TREATMENT", 391, 401], ["increased odds of mortality", "PROBLEM", 422, 449], ["increase", "OBSERVATION_MODIFIER", 114, 122], ["increase", "OBSERVATION_MODIFIER", 165, 173], ["overall", "OBSERVATION_MODIFIER", 177, 184], ["length", "OBSERVATION_MODIFIER", 185, 191]]], ["This association was consistent irrespective of the presence of head injury.", [["head", "ANATOMY", 64, 68], ["head injury", "DISEASE", 64, 75], ["head", "ORGANISM_SUBDIVISION", 64, 68], ["head injury", "PROBLEM", 64, 75], ["head", "ANATOMY", 64, 68], ["injury", "OBSERVATION", 69, 75]]], ["Furthermore, intubation was associated with longer ICU and hospital length of stay.", [["intubation", "TREATMENT", 13, 23]]], ["These findings bring into question the established dogma that mandates intubation for GCS \u2264 8.", [["GCS", "DISEASE", 86, 89], ["intubation", "TREATMENT", 71, 81], ["GCS", "TEST", 86, 89]]], ["As stated in the Introduction, EAST gives a level 1 recommendation to intubate this cohort of patients [2, 3] .", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102]]], ["However, many of the studies cited in the PMG were designed to answer different questions or study different subsets of these patients, including the safety of cricothyroidotomy [14] or neuromuscular blockade, [15] and a comparison of early vs late intubation [16] .", [["neuromuscular", "ANATOMY", 186, 199], ["neuromuscular blockade", "DISEASE", 186, 208], ["PMG", "SIMPLE_CHEMICAL", 42, 45], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["the studies", "TEST", 17, 28], ["cricothyroidotomy", "TREATMENT", 160, 177], ["neuromuscular blockade", "TREATMENT", 186, 208], ["early vs late intubation", "TREATMENT", 235, 259]]], ["Of the 31 studies cited as supporting evidence for this recommendation, 16 were for the purposes of studying prehospital intubation.", [["the 31 studies", "TEST", 3, 17], ["prehospital intubation", "TREATMENT", 109, 131]]], ["This is not to say that these studies (or the guidelines based on them) are not valuable, but they do not constitute direct evidence that there is an outcome benefit to intubating all trauma patients presenting with GCS \u2264 8.DiscussionHowever, there is some existing evidence for the potential harms of intubation in trauma patients.", [["trauma", "DISEASE", 184, 190], ["GCS", "DISEASE", 216, 219], ["trauma", "DISEASE", 316, 322], ["patients", "ORGANISM", 191, 199], ["patients", "ORGANISM", 323, 331], ["patients", "SPECIES", 191, 199], ["patients", "SPECIES", 323, 331], ["these studies", "TEST", 24, 37], ["GCS", "TEST", 216, 219], ["intubation", "TREATMENT", 302, 312], ["intubation", "OBSERVATION", 302, 312]]], ["One study examining the effect of intubating patients for \"combativeness\" found that these patients, as compared to a matched non-intubated group, incurred longer hospital length of stay, increased rates of pneumonia, and poorer discharge status [17] .", [["pneumonia", "DISEASE", 207, 216], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 91, 99], ["One study", "TEST", 0, 9], ["intubating", "TREATMENT", 34, 44], ["combativeness", "PROBLEM", 59, 72], ["pneumonia", "PROBLEM", 207, 216], ["pneumonia", "OBSERVATION", 207, 216]]], ["Furthermore, there is some literature to suggest that it may be appropriate to observe some patients with a GCS less than 8 without intubation.", [["GCS", "DISEASE", 108, 111], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["a GCS", "TEST", 106, 111], ["intubation", "TREATMENT", 132, 142]]], ["A small observational study, noting that many emergency department providers advocate intubation for GCS \u2264 8 in intoxicated (non-trauma) patients, reported safe management without intubation in all of the included GCS \u2264 8 patients [18] .", [["GCS", "DISEASE", 101, 104], ["trauma", "DISEASE", 129, 135], ["GCS", "DISEASE", 214, 217], ["patients", "ORGANISM", 137, 145], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 222, 230], ["A small observational study", "TEST", 0, 27], ["intubation", "TREATMENT", 86, 96], ["GCS", "TEST", 101, 104], ["safe management", "TREATMENT", 156, 171], ["intubation", "TREATMENT", 180, 190], ["GCS", "TEST", 214, 217], ["small", "OBSERVATION_MODIFIER", 2, 7]]], ["There may be a similar cohort of trauma patients who, despite impaired cognition, may be safely managed without intubation.", [["trauma", "DISEASE", 33, 39], ["impaired cognition", "DISEASE", 62, 80], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["intubation", "TREATMENT", 112, 122]]], ["However, this is the first study to our knowledge of the effect of intubation on trauma patients with a marginal GCS.DiscussionAs a retrospective cohort study with a small effect size, this work could be categorized as Level III evidence [19] .", [["trauma", "DISEASE", 81, 87], ["GCS", "DISEASE", 113, 116], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["intubation", "TREATMENT", 67, 77], ["a retrospective cohort study", "TEST", 130, 158], ["a small effect size", "PROBLEM", 164, 183], ["marginal GCS", "OBSERVATION", 104, 116], ["small effect", "OBSERVATION_MODIFIER", 166, 178], ["size", "OBSERVATION_MODIFIER", 179, 183]]], ["However, this modest increase in mortality risk is less impactful for practice than the knowledge that there is no decrease in mortality risk.", [["this modest increase in mortality risk", "PROBLEM", 9, 47], ["decrease in mortality risk", "PROBLEM", 115, 141], ["modest", "OBSERVATION_MODIFIER", 14, 20], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["no", "UNCERTAINTY", 112, 114], ["decrease", "OBSERVATION_MODIFIER", 115, 123]]], ["This, after all, is the presumed goal of intubating those with a GCS of 8.", [["GCS", "DISEASE", 65, 68], ["a GCS", "TEST", 63, 68]]], ["Our use of inverse probability weighting was intended to help mitigate the risk of confounding.", [["inverse probability weighting", "TREATMENT", 11, 40]]], ["Beyond this, our use of a large national dataset allowed the sample size and power necessary to detect this result and generate a statistically sound study.DiscussionWe chose to define \"intubation\" as those who were intubated within an hour of arrival.", [["a statistically sound study", "TEST", 128, 155], ["intubation", "TREATMENT", 186, 196], ["intubated", "TREATMENT", 216, 225]]], ["This may prompt questions about those who potentially undergo slightly delayed intubations in the trauma bay or in the operating room soon after trauma bay evaluation.", [["trauma", "DISEASE", 98, 104], ["trauma", "DISEASE", 145, 151], ["slightly delayed intubations", "PROBLEM", 62, 90], ["trauma bay evaluation", "TEST", 145, 166]]], ["To determine whether we were missing a significant number of patients intubated outside of the first hour, we re-examined the data for the codes listed in Table 5 in Appendix 1, timestamped for the 2nd and 3rd hours after arrival.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69]]], ["Of the 2598 patients who did not meet our initial criteria for ED intubation, 133 (5.1%) were intubated in the ensuing two hours.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["ED intubation", "TEST", 63, 76], ["intubated", "TREATMENT", 94, 103]]], ["This relatively small number of delayed intubations is reassuring.DiscussionThere are a few limitations to address.", [["delayed intubations", "TREATMENT", 32, 51], ["small", "OBSERVATION_MODIFIER", 16, 21], ["number", "OBSERVATION_MODIFIER", 22, 28], ["delayed", "OBSERVATION_MODIFIER", 32, 39], ["intubations", "OBSERVATION", 40, 51]]], ["The GCS provided in the NTDB is at the time of arrival to the emergency department; we do not know whether this is the best or worst GCS for that patient, nor whether some of these patients may have received sedating medications on route.", [["GCS", "DISEASE", 4, 7], ["GCS", "DISEASE", 133, 136], ["NTDB", "CANCER", 24, 28], ["patient", "ORGANISM", 146, 153], ["patients", "ORGANISM", 181, 189], ["patient", "SPECIES", 146, 153], ["patients", "SPECIES", 181, 189], ["The GCS", "TEST", 0, 7], ["sedating medications", "TREATMENT", 208, 228]]], ["However, prehospital intubations were excluded and it seems unlikely that many non-intubated patients would have received drugs in the field.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["prehospital intubations", "TREATMENT", 9, 32], ["drugs", "TREATMENT", 122, 127]]], ["Secondly, we are not able to exclude confounding by indication as a possible reason for the association between intubation and mortality we describe.", [["intubation", "TREATMENT", 112, 122]]], ["For instance, some physical findings that may be considered indications for intubation (e.g., anisocoria, vomiting with concerns for aspiration, evidence of smoke inhalation) are not captured in the data but are associated with mortality.", [["anisocoria", "DISEASE", 94, 104], ["vomiting", "DISEASE", 106, 114], ["intubation", "TREATMENT", 76, 86], ["anisocoria", "PROBLEM", 94, 104], ["vomiting", "PROBLEM", 106, 114], ["aspiration", "PROBLEM", 133, 143], ["smoke inhalation", "TREATMENT", 157, 173]]], ["However, as the NTDB does not contain data on indication for intubation, this a known limitation of the dataset.", [["intubation", "TREATMENT", 61, 71]]], ["The fact that similar results were shown on an analysis stratified by head injury is encouraging.", [["head", "ANATOMY", 70, 74], ["head injury", "DISEASE", 70, 81], ["head", "ORGANISM_SUBDIVISION", 70, 74], ["an analysis", "TEST", 44, 55], ["head injury", "PROBLEM", 70, 81], ["head", "ANATOMY", 70, 74], ["injury", "OBSERVATION", 75, 81]]], ["The 23.3% missingness rate for intoxication is also limiting, as this might be an additional confounder.", [["missingness rate", "TEST", 10, 26], ["intoxication", "PROBLEM", 31, 43]]], ["We do not intend to suggest that there are no trauma patients with a GCS between 6 and 8 who would benefit from intubation.", [["trauma", "DISEASE", 46, 52], ["GCS", "DISEASE", 69, 72], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["trauma", "PROBLEM", 46, 52], ["a GCS", "TEST", 67, 72], ["intubation", "TREATMENT", 112, 122]]], ["Furthermore, it should be emphasized that this data only applies to those with a marginal GCS, and not those with a severely depressed mental status.", [["GCS", "DISEASE", 90, 93], ["depressed", "DISEASE", 125, 134], ["a severely depressed mental status", "PROBLEM", 114, 148]]], ["We do, however, believe that this data should prompt trauma providers to question the blanket recommendation that all patients with a GCS of 8 be intubated and use clinical judgement to determine which ones will benefit.", [["trauma", "DISEASE", 53, 59], ["GCS", "DISEASE", 134, 137], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["the blanket recommendation", "TREATMENT", 82, 108], ["a GCS", "TEST", 132, 137], ["intubated", "TREATMENT", 146, 155], ["clinical judgement", "TEST", 164, 182]]], ["Though some patients in this category will surely benefit, we have demonstrated here that for patients who have a GCS of 6-8, after adjustment for severity of injury, those who were observed without intubation suffered no increase in mortality risk and may have in fact been subject to a lower risk.", [["GCS", "DISEASE", 114, 117], ["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 94, 102], ["a GCS", "TEST", 112, 117], ["injury", "PROBLEM", 159, 165], ["intubation", "TREATMENT", 199, 209], ["increase in mortality risk", "PROBLEM", 222, 248], ["injury", "OBSERVATION", 159, 165], ["increase", "OBSERVATION_MODIFIER", 222, 230]]], ["Future directions to further elucidate the appropriate indications for intubation should include dedicated prospective studies that not only question what GCS score is the most appropriate threshold, but also investigate which other, more nuanced factors are appropriate to factor in to the decision of whether or not to intubate.ConclusionAmong patients with GCS of 6-8, intubation on arrival was associated with increased mortality, ICU days, and overall length of stay.", [["GCS", "DISEASE", 360, 363], ["patients", "ORGANISM", 346, 354], ["patients", "SPECIES", 346, 354], ["intubation", "TREATMENT", 71, 81], ["dedicated prospective studies", "TEST", 97, 126], ["GCS", "TEST", 360, 363], ["intubation", "TREATMENT", 372, 382], ["increased mortality", "PROBLEM", 414, 433], ["increased", "OBSERVATION_MODIFIER", 414, 423], ["mortality", "OBSERVATION", 424, 433]]], ["Future research should be conducted to develop evidence-based guidelines defining the population of trauma patients who may benefit from intubation for decreased level of consciousness.ConclusionAuthor contributions JSH, RPD, EJK, and DNH: conceptualization, data interpretation, and drafting of the manuscript.", [["trauma", "DISEASE", 100, 106], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["trauma", "PROBLEM", 100, 106], ["intubation", "TREATMENT", 137, 147], ["decreased level of consciousness", "PROBLEM", 152, 184], ["data interpretation", "TEST", 259, 278]]], ["DS and JBS: critical review and revision of the manuscript.ConclusionFunding During portions of this work, DNH was supported by a training grant through the National Heart, Lung, and Blood Institute.", [["Heart", "ANATOMY", 166, 171], ["Lung", "ANATOMY", 173, 177], ["Blood", "ANATOMY", 183, 188], ["Lung", "ORGAN", 173, 177], ["Blood", "ORGANISM_SUBSTANCE", 183, 188], ["revision", "TREATMENT", 32, 40], ["Heart", "ANATOMY", 166, 171], ["Lung", "ANATOMY", 173, 177]]], ["(K08HL131995).Compliance with ethical standardsConflict of interest No authors have conflicts to declare.Appendix 1See Table 5 .", [["ethical standards", "TREATMENT", 30, 47]]], ["Insertion of endotracheal airway into trachea, via natural or artificial opening endoscopic 1GZ31CAEP (ICD-10-CA/CCI) Ventilation, respiratory system NEC, invasive per orifice approach by endotracheal intubation, manual hand assisted 1GZ31CAND (ICD-10-CA/CCI) Ventilation, respiratory system NEC, invasive per orifice approach by endotracheal intubation, positive pressure", [["endotracheal airway", "ANATOMY", 13, 32], ["trachea", "ANATOMY", 38, 45], ["orifice", "ANATOMY", 168, 175], ["endotracheal", "ANATOMY", 188, 200], ["hand", "ANATOMY", 220, 224], ["orifice", "ANATOMY", 310, 317], ["endotracheal", "ANATOMY", 330, 342], ["respiratory system NEC", "DISEASE", 131, 153], ["respiratory system NEC", "DISEASE", 273, 295], ["endotracheal airway", "MULTI-TISSUE_STRUCTURE", 13, 32], ["trachea", "MULTI-TISSUE_STRUCTURE", 38, 45], ["Insertion of endotracheal airway into trachea", "TREATMENT", 0, 45], ["artificial opening endoscopic 1GZ31CAEP (ICD", "TREATMENT", 62, 106], ["CA/CCI", "TREATMENT", 110, 116], ["Ventilation", "TREATMENT", 118, 129], ["respiratory system NEC", "PROBLEM", 131, 153], ["invasive per orifice approach", "TREATMENT", 155, 184], ["endotracheal intubation", "TREATMENT", 188, 211], ["manual hand assisted 1GZ31CAND (ICD", "TREATMENT", 213, 248], ["CA/CCI", "TREATMENT", 252, 258], ["Ventilation", "TREATMENT", 260, 271], ["respiratory system NEC", "PROBLEM", 273, 295], ["invasive per orifice approach", "TREATMENT", 297, 326], ["endotracheal intubation", "TREATMENT", 330, 353], ["positive pressure", "TREATMENT", 355, 372], ["endotracheal airway", "ANATOMY", 13, 32], ["trachea", "ANATOMY", 38, 45], ["respiratory system", "ANATOMY", 131, 149], ["endotracheal", "ANATOMY", 188, 200], ["respiratory system", "ANATOMY", 273, 291], ["endotracheal intubation", "OBSERVATION", 330, 353], ["pressure", "OBSERVATION_MODIFIER", 364, 372]]]], "dcd58805ece80b63cdb7bc2cb877a3328df92489": [["Etiology and EpidemiologyCoronaviruses are large, enveloped, single-stranded RNA viruses with club-shaped spikes on their outer surface (see B) .", [["outer surface", "ANATOMY", 122, 135], ["Coronaviruses", "DISEASE", 25, 38], ["outer surface", "CELLULAR_COMPONENT", 122, 135], ["EpidemiologyCoronaviruses", "PROBLEM", 13, 38], ["stranded RNA viruses", "PROBLEM", 68, 88], ["club-shaped spikes", "PROBLEM", 94, 112], ["large", "OBSERVATION_MODIFIER", 43, 48], ["enveloped", "OBSERVATION_MODIFIER", 50, 59], ["RNA viruses", "OBSERVATION", 77, 88], ["club", "OBSERVATION_MODIFIER", 94, 98], ["shaped", "OBSERVATION_MODIFIER", 99, 105], ["spikes", "OBSERVATION_MODIFIER", 106, 112]]], ["They have the largest RNA genomes of all known viruses.", [["largest", "OBSERVATION_MODIFIER", 14, 21], ["all known", "OBSERVATION_MODIFIER", 37, 46], ["viruses", "OBSERVATION", 47, 54]]], ["Feline coronaviruses (FCoV), like canine enteric coronavirus, belong to the Group 1a coronaviruses (see .", [["Feline coronaviruses", "DISEASE", 0, 20], ["enteric coronavirus", "DISEASE", 41, 60], ["Feline coronaviruses", "ORGANISM", 0, 20], ["FCoV", "ORGANISM", 22, 26], ["canine enteric coronavirus", "ORGANISM", 34, 60], ["Group 1a coronaviruses", "ORGANISM", 76, 98], ["Feline coronaviruses", "SPECIES", 0, 20], ["canine enteric coronavirus", "SPECIES", 34, 60], ["Feline coronaviruses", "SPECIES", 0, 20], ["FCoV", "SPECIES", 22, 26], ["canine enteric coronavirus", "SPECIES", 34, 60], ["Group 1a coronaviruses", "SPECIES", 76, 98], ["Feline coronaviruses (FCoV", "PROBLEM", 0, 26], ["canine enteric coronavirus", "PROBLEM", 34, 60], ["enteric coronavirus", "ANATOMY", 41, 60]]], ["In fact, even canine enteric coronavirus has the potential to infect cats and cause diseases similar to those caused by FCoV.", [["enteric coronavirus", "DISEASE", 21, 40], ["canine enteric coronavirus", "ORGANISM", 14, 40], ["cats", "ORGANISM", 69, 73], ["FCoV", "GENE_OR_GENE_PRODUCT", 120, 124], ["canine enteric coronavirus", "SPECIES", 14, 40], ["cats", "SPECIES", 69, 73], ["canine enteric coronavirus", "SPECIES", 14, 40], ["FCoV", "SPECIES", 120, 124], ["diseases", "PROBLEM", 84, 92], ["FCoV", "PROBLEM", 120, 124], ["coronavirus", "OBSERVATION", 29, 40], ["FCoV", "OBSERVATION", 120, 124]]], ["2 Among FCoVs, there are two different serotypes, type I and type II, which use different receptors for cellular entry in vitro 3,4 but cause the same clinical manifestations.", [["cellular", "ANATOMY", 104, 112], ["FCoVs", "GENE_OR_GENE_PRODUCT", 8, 13], ["cellular", "CELL", 104, 112], ["type I and type II", "PROBLEM", 50, 68], ["different receptors", "TREATMENT", 80, 99], ["the same clinical manifestations", "PROBLEM", 142, 174], ["two", "OBSERVATION_MODIFIER", 25, 28], ["different", "OBSERVATION_MODIFIER", 29, 38], ["serotypes", "OBSERVATION", 39, 48]]], ["Type I strains predominate worldwide.", [["Type I strains", "PROBLEM", 0, 14], ["strains", "OBSERVATION_MODIFIER", 7, 14], ["predominate", "OBSERVATION_MODIFIER", 15, 26], ["worldwide", "OBSERVATION_MODIFIER", 27, 36]]], ["[5] [6] [7] Type II strains, which are thought to have evolved from genetic recombination between canine enteric coronavirus and FCoV, are more readily grown in culture and so have been more extensively studied; they possess a spike protein that resembles that of canine enteric coronavirus.Etiology and EpidemiologyFCoVs cause enteric disease in cats as well as feline infectious peritonitis (FIP), a serious systemic pyogranulomatous to granulomatous disease that progresses over a period of weeks to months and, once it occurs, is ultimately always fatal.", [["granulomatous", "ANATOMY", 439, 452], ["enteric coronavirus", "DISEASE", 271, 290], ["enteric disease", "DISEASE", 328, 343], ["feline infectious peritonitis", "DISEASE", 363, 392], ["FIP", "DISEASE", 394, 397], ["granulomatous disease", "DISEASE", 439, 460], ["canine enteric coronavirus", "ORGANISM", 98, 124], ["FCoV", "GENE_OR_GENE_PRODUCT", 129, 133], ["canine enteric coronavirus", "ORGANISM", 264, 290], ["cats", "ORGANISM", 347, 351], ["feline", "ORGANISM", 363, 369], ["spike protein", "PROTEIN", 227, 240], ["canine enteric coronavirus", "SPECIES", 98, 124], ["canine enteric coronavirus", "SPECIES", 264, 290], ["cats", "SPECIES", 347, 351], ["feline", "SPECIES", 363, 369], ["canine enteric coronavirus", "SPECIES", 98, 124], ["FCoV", "SPECIES", 129, 133], ["canine enteric coronavirus", "SPECIES", 264, 290], ["Type II strains", "PROBLEM", 12, 27], ["genetic recombination between canine enteric coronavirus", "PROBLEM", 68, 124], ["FCoV", "PROBLEM", 129, 133], ["culture", "TEST", 161, 168], ["a spike protein", "PROBLEM", 225, 240], ["canine enteric coronavirus", "PROBLEM", 264, 290], ["EpidemiologyFCoVs", "PROBLEM", 304, 321], ["enteric disease in cats", "PROBLEM", 328, 351], ["feline infectious peritonitis", "PROBLEM", 363, 392], ["a serious systemic pyogranulomatous to granulomatous disease", "PROBLEM", 400, 460], ["enteric", "OBSERVATION_MODIFIER", 328, 335], ["disease", "OBSERVATION", 336, 343], ["infectious", "OBSERVATION_MODIFIER", 370, 380], ["peritonitis", "OBSERVATION", 381, 392], ["serious", "OBSERVATION_MODIFIER", 402, 409], ["systemic", "OBSERVATION_MODIFIER", 410, 418], ["pyogranulomatous", "OBSERVATION", 419, 435], ["granulomatous", "OBSERVATION", 439, 452]]], ["FIP is a major cause of death in young and young adult cats, especially cats from multicat environments such as purebred catteries and shelters.", [["FIP", "DISEASE", 0, 3], ["death", "DISEASE", 24, 29], ["cats", "ORGANISM", 55, 59], ["cats", "ORGANISM", 72, 76], ["cats", "SPECIES", 55, 59], ["cats", "SPECIES", 72, 76], ["FIP", "PROBLEM", 0, 3], ["death", "PROBLEM", 24, 29]]], ["Wild cats, especially cheetahs, are also susceptible.", [["cats", "ORGANISM", 5, 9], ["cats", "SPECIES", 5, 9]]], ["8 The vast majority of domestic cats that develop FIP are 3 months to 3 years of age, with at least 50% of affected cats aged 12 months or younger (Figure 20-1) .", [["FIP", "DISEASE", 50, 53], ["cats", "ORGANISM", 32, 36], ["cats", "ORGANISM", 116, 120], ["cats", "SPECIES", 32, 36], ["cats", "SPECIES", 116, 120], ["FIP", "PROBLEM", 50, 53], ["domestic cats", "OBSERVATION", 23, 36]]], ["However, FIP can occur at any age, and there is a secondary peak of incidence in geriatric cats (>10 years of age), possibly as a result of suboptimal immune function.", [["FIP", "DISEASE", 9, 12], ["cats", "ORGANISM", 91, 95], ["FIP", "PROBLEM", 9, 12], ["geriatric cats", "TEST", 81, 95], ["FIP", "OBSERVATION", 9, 12]]], ["Males and sexually intact cats have been predisposed in some studies, [9] [10] [11] and a disease peak may exist in the fall and winter.", [["[9] [10] [11]", "CHEMICAL", 70, 83], ["cats", "ORGANISM", 26, 30], ["cats", "SPECIES", 26, 30], ["a disease peak", "PROBLEM", 88, 102]]], ["12 Although the disease occurs in all breeds, purebred cats are more susceptible; Abyssinians, Australian mist, Bengals, birmans, Burmese, British shorthairs, Himalayans, ragdolls, rexes, and possibly Scottish folds may be predisposed.", [["folds", "ANATOMY", 210, 215], ["cats", "ORGANISM", 55, 59], ["cats", "SPECIES", 55, 59], ["the disease", "PROBLEM", 12, 23], ["Himalayans", "TREATMENT", 159, 169], ["rexes", "TREATMENT", 181, 186], ["disease", "OBSERVATION", 16, 23], ["possibly", "UNCERTAINTY", 192, 200], ["Scottish folds", "OBSERVATION", 201, 215]]], ["[9] [10] [11] [12] [13] [14] Breed predispositions may vary geographically and temporally depending on the preferences of breeders in a region, and specific lines may be more predisposed than the breeds themselves.", [["[9] [10] [11] [12] [13] [14", "SIMPLE_CHEMICAL", 0, 27], ["Breed predispositions", "PROBLEM", 29, 50]]], ["6 The molecular basis of genetic susceptibility to FIP is currently unclear.", [["FIP", "DISEASE", 51, 54], ["genetic susceptibility to FIP", "PROBLEM", 25, 54], ["genetic susceptibility", "OBSERVATION", 25, 47], ["FIP", "OBSERVATION", 51, 54]]], ["Siblings of cats that die of FIP may be at increased risk for FIP.", [["FIP", "DISEASE", 29, 32], ["FIP", "DISEASE", 62, 65], ["cats", "ORGANISM", 12, 16], ["FIP", "ORGANISM", 29, 32], ["cats", "SPECIES", 12, 16], ["FIP", "PROBLEM", 62, 65], ["FIP", "OBSERVATION", 62, 65]]], ["15 In multiple-cat household situations, cats are repeatedly infected, shed virus, and recover, but some cats remain persistently infected and chronically shed FCoV in the absence of clinical signs (Figure 20 -2).", [["cats", "ORGANISM", 41, 45], ["cats", "ORGANISM", 105, 109], ["FCoV", "CANCER", 160, 164], ["cats", "SPECIES", 41, 45], ["cats", "SPECIES", 105, 109], ["shed virus", "PROBLEM", 71, 81], ["persistently infected", "PROBLEM", 117, 138], ["chronically shed FCoV", "PROBLEM", 143, 164], ["clinical signs", "TEST", 183, 197], ["persistently", "OBSERVATION_MODIFIER", 117, 129], ["infected", "OBSERVATION", 130, 138]]], ["More than half, and as many as 100% of cats in environments with more than six cats, become infected with FCoVs.", [["FCoVs", "DISEASE", 106, 111], ["cats", "ORGANISM", 39, 43], ["cats", "ORGANISM", 79, 83], ["FCoVs", "CANCER", 106, 111], ["cats", "SPECIES", 39, 43], ["cats", "SPECIES", 79, 83], ["FCoVs", "TREATMENT", 106, 111], ["infected", "OBSERVATION", 92, 100]]], ["6 The seroprevalence is lower in cats from single-cat households and among feral cats.", [["cats", "ORGANISM", 33, 37], ["cat", "ORGANISM", 50, 53], ["cats", "ORGANISM", 81, 85], ["cats", "SPECIES", 33, 37], ["cats", "SPECIES", 81, 85], ["single-cat households", "TREATMENT", 43, 64], ["lower", "OBSERVATION_MODIFIER", 24, 29]]], ["16 However, even though the prevalence of infection in multicat households is high, fewer than 10% of cats from large, multicat households ultimately develop FIP.", [["infection", "DISEASE", 42, 51], ["FIP", "DISEASE", 158, 161], ["cats", "ORGANISM", 102, 106], ["cats", "SPECIES", 102, 106], ["infection", "PROBLEM", 42, 51], ["FIP", "PROBLEM", 158, 161], ["infection", "OBSERVATION", 42, 51], ["high", "OBSERVATION_MODIFIER", 78, 82], ["large", "OBSERVATION_MODIFIER", 112, 117], ["FIP", "OBSERVATION", 158, 161]]], ["Thus, although the incidence of infection is high, the incidence of disease in single-or two-cat households is only around 1 in 5000; in catteries it is around 5% to 10%.", [["infection", "DISEASE", 32, 41], ["cat", "ORGANISM", 93, 96], ["infection", "PROBLEM", 32, 41], ["disease", "PROBLEM", 68, 75], ["infection", "OBSERVATION", 32, 41], ["high", "OBSERVATION_MODIFIER", 45, 49], ["disease", "OBSERVATION", 68, 75]]], ["17, 18 Provided they are unrelated by birth, cats in households with a history of FIP are not more likely to develop FIP than cats in households without FIP.", [["FIP", "DISEASE", 82, 85], ["FIP", "DISEASE", 117, 120], ["FIP", "DISEASE", 153, 156], ["cats", "ORGANISM", 45, 49], ["cats", "ORGANISM", 126, 130], ["cats", "SPECIES", 126, 130], ["FIP", "PROBLEM", 82, 85], ["FIP", "PROBLEM", 153, 156], ["FIP", "OBSERVATION", 82, 85], ["not more likely", "UNCERTAINTY", 90, 105]]], ["19 Thus, FIP is usually a sporadic disease that does not spread from one cat to another.", [["FIP", "DISEASE", 9, 12], ["cat", "ORGANISM", 73, 76], ["FIP", "PROBLEM", 9, 12], ["a sporadic disease", "PROBLEM", 24, 42], ["FIP", "OBSERVATION", 9, 12], ["sporadic", "OBSERVATION_MODIFIER", 26, 34], ["disease", "OBSERVATION", 35, 42]]], ["However, every few years, epidemics of disease can occur in catteries or shelters, with mortality rates that exceed 10%.", [["disease", "PROBLEM", 39, 46], ["mortality rates", "TEST", 88, 103], ["disease", "OBSERVATION", 39, 46]]], ["12 Because it is an enveloped virus, FCoV is readily inactivated by disinfectants and generally survives less than a day or two at room temperature.", [["FCoV", "SIMPLE_CHEMICAL", 37, 41], ["FCoV", "SPECIES", 37, 41], ["an enveloped virus", "PROBLEM", 17, 35], ["FCoV", "PROBLEM", 37, 41], ["enveloped", "OBSERVATION_MODIFIER", 20, 29], ["virus", "OBSERVATION", 30, 35]]], ["However, the possibility of prolonged survival (up to 7 weeks) in the environment under certain conditions has been suggested.", [["prolonged survival", "PROBLEM", 28, 46], ["possibility of", "UNCERTAINTY", 13, 27], ["prolonged", "OBSERVATION_MODIFIER", 28, 37], ["survival", "OBSERVATION", 38, 46]]], ["15, 20 In this situation, fomites might play an important role in transmission.Etiology and EpidemiologyThe epidemiology and pathogenesis of FIP has both fascinated and confused veterinary virologists worldwide for decades.", [["FIP", "DISEASE", 141, 144], ["fomites", "CANCER", 26, 33], ["FIP", "PROBLEM", 141, 144], ["FIP", "OBSERVATION", 141, 144]]], ["The most widely accepted theory (the \"internal mutation hypothesis\") is that cats are initially infected with a low-pathogenicity coronavirus after oronasal exposure, which results either in no signs, or mild enteric disease.", [["oronasal", "ANATOMY", 148, 156], ["low-pathogenicity coronavirus", "DISEASE", 112, 141], ["enteric disease", "DISEASE", 209, 224], ["cats", "ORGANISM", 77, 81], ["coronavirus", "ORGANISM", 130, 141], ["oronasal", "ORGAN", 148, 156], ["cats", "SPECIES", 77, 81], ["the \"internal mutation hypothesis", "PROBLEM", 33, 66], ["a low-pathogenicity coronavirus", "PROBLEM", 110, 141], ["signs", "PROBLEM", 194, 199], ["mild enteric disease", "PROBLEM", 204, 224], ["most widely", "OBSERVATION_MODIFIER", 4, 15], ["low", "OBSERVATION_MODIFIER", 112, 115], ["no signs", "UNCERTAINTY", 191, 199], ["mild", "OBSERVATION_MODIFIER", 204, 208], ["enteric disease", "OBSERVATION", 209, 224]]], ["This low-pathogenicity virus has been referred to as feline enteric coronavirus in some publications in order to distinguish it from virulent FIP virus.", [["enteric coronavirus", "DISEASE", 60, 79], ["FIP", "DISEASE", 142, 145], ["feline enteric coronavirus", "ORGANISM", 53, 79], ["FIP virus", "ORGANISM", 142, 151], ["feline enteric coronavirus", "SPECIES", 53, 79], ["feline enteric coronavirus", "SPECIES", 53, 79], ["FIP virus", "SPECIES", 142, 151], ["This low-pathogenicity virus", "PROBLEM", 0, 28], ["feline enteric coronavirus", "PROBLEM", 53, 79], ["virulent FIP virus", "PROBLEM", 133, 151], ["pathogenicity virus", "OBSERVATION", 9, 28], ["coronavirus", "OBSERVATION", 68, 79], ["virulent", "OBSERVATION_MODIFIER", 133, 141], ["FIP virus", "OBSERVATION", 142, 151]]], ["The use of this name has been controversial, because although the virus is primarily confined to the gastrointestinal tract (and especially colonic epithelial cells), FCoV RNA can also be found in blood and tissue macrophages of cats that do not have FIP.", [["gastrointestinal tract", "ANATOMY", 101, 123], ["colonic epithelial cells", "ANATOMY", 140, 164], ["blood", "ANATOMY", 197, 202], ["tissue macrophages", "ANATOMY", 207, 225], ["FIP", "DISEASE", 251, 254], ["gastrointestinal tract", "ORGAN", 101, 123], ["colonic epithelial cells", "CELL", 140, 164], ["FCoV", "GENE_OR_GENE_PRODUCT", 167, 171], ["blood", "ORGANISM_SUBSTANCE", 197, 202], ["tissue macrophages", "CELL", 207, 225], ["cats", "ORGANISM", 229, 233], ["colonic epithelial cells", "CELL_TYPE", 140, 164], ["FCoV RNA", "RNA", 167, 175], ["blood and tissue macrophages", "CELL_TYPE", 197, 225], ["cats", "SPECIES", 229, 233], ["the virus", "PROBLEM", 62, 71], ["colonic epithelial cells", "PROBLEM", 140, 164], ["FCoV RNA", "PROBLEM", 167, 175], ["FIP", "PROBLEM", 251, 254], ["virus", "OBSERVATION", 66, 71], ["gastrointestinal tract", "ANATOMY", 101, 123], ["colonic", "ANATOMY", 140, 147], ["epithelial cells", "OBSERVATION", 148, 164], ["FCoV RNA", "OBSERVATION", 167, 175], ["FIP", "OBSERVATION", 251, 254]]], ["21, 22 In some infected cats, the low-pathogenicity virus is believed to mutate to a virulent strain that can multiply within macrophages without hindrance by the immune system and incite a systemic pyogranulomatous vasculitis.", [["macrophages", "ANATOMY", 126, 137], ["immune system", "ANATOMY", 163, 176], ["vasculitis", "DISEASE", 216, 226], ["cats", "ORGANISM", 24, 28], ["macrophages", "CELL", 126, 137], ["macrophages", "CELL_TYPE", 126, 137], ["cats", "SPECIES", 24, 28], ["some infected cats", "PROBLEM", 10, 28], ["the low-pathogenicity virus", "PROBLEM", 30, 57], ["a virulent strain", "PROBLEM", 83, 100], ["a systemic pyogranulomatous vasculitis", "PROBLEM", 188, 226], ["some", "OBSERVATION_MODIFIER", 10, 14], ["infected", "OBSERVATION_MODIFIER", 15, 23], ["cats", "OBSERVATION", 24, 28], ["low", "OBSERVATION_MODIFIER", 34, 37], ["pathogenicity virus", "OBSERVATION", 38, 57], ["virulent", "OBSERVATION_MODIFIER", 85, 93], ["macrophages", "OBSERVATION", 126, 137], ["systemic", "OBSERVATION_MODIFIER", 190, 198], ["pyogranulomatous vasculitis", "OBSERVATION", 199, 226]]], ["The mutation may occur shortly after initial infection, or years later, which may explain why some indoor cats from single-cat households develop FIP several years after they are acquired.", [["infection", "DISEASE", 45, 54], ["FIP", "DISEASE", 146, 149], ["cats", "ORGANISM", 106, 110], ["cat", "ORGANISM", 123, 126], ["cats", "SPECIES", 106, 110], ["The mutation", "PROBLEM", 0, 12], ["initial infection", "PROBLEM", 37, 54], ["infection", "OBSERVATION", 45, 54]]], ["Virulent strains may not be able to replicate effectively within the gut, 23 which may be the reason why cat-to-cat transmission of FIP does not occur, yet the disease can be transmitted effectively by inoculating na\u00efve cats with effusion from a cat with FIP.", [["gut", "ANATOMY", 69, 72], ["FIP", "DISEASE", 132, 135], ["effusion", "DISEASE", 230, 238], ["FIP", "DISEASE", 255, 258], ["gut", "ORGANISM_SUBDIVISION", 69, 72], ["cat", "ORGANISM", 105, 108], ["cat", "ORGANISM", 112, 115], ["FIP", "ORGANISM", 132, 135], ["cats", "ORGANISM", 220, 224], ["cat", "ORGANISM", 246, 249], ["cats", "SPECIES", 220, 224], ["Virulent strains", "PROBLEM", 0, 16], ["FIP", "PROBLEM", 132, 135], ["the disease", "PROBLEM", 156, 167], ["effusion", "PROBLEM", 230, 238], ["a cat with FIP", "TREATMENT", 244, 258], ["FIP", "OBSERVATION", 132, 135], ["disease", "OBSERVATION", 160, 167], ["effusion", "OBSERVATION", 230, 238]]], ["Factors that contribute to immunosuppression, such as concurrent viral infection, stress due to overcrowding, surgery, or transport, and especially genetic factors may allow viral replication and mutation to proceed unchecked.", [["viral infection", "DISEASE", 65, 80], ["immunosuppression", "TREATMENT", 27, 44], ["concurrent viral infection", "PROBLEM", 54, 80], ["stress", "PROBLEM", 82, 88], ["surgery", "TREATMENT", 110, 117], ["viral replication", "TREATMENT", 174, 191], ["mutation", "PROBLEM", 196, 204], ["immunosuppression", "OBSERVATION", 27, 44], ["viral", "OBSERVATION_MODIFIER", 65, 70], ["infection", "OBSERVATION", 71, 80]]], ["Simultaneous immune compromise of a large number of cats, such as in a shelter situation, may explain epidemics of FIP.", [["FIP", "DISEASE", 115, 118], ["cats", "ORGANISM", 52, 56], ["cats", "SPECIES", 52, 56], ["Simultaneous immune compromise", "PROBLEM", 0, 30], ["epidemics of FIP", "PROBLEM", 102, 118], ["immune compromise", "OBSERVATION", 13, 30], ["large", "OBSERVATION_MODIFIER", 36, 41], ["number", "OBSERVATION_MODIFIER", 42, 48], ["cats", "OBSERVATION", 52, 56], ["may explain", "UNCERTAINTY", 90, 101], ["FIP", "OBSERVATION", 115, 118]]], ["Other risk factors for FIP include regular introduction of new cats to a cattery and the proportion of cats in a cattery that shed coronavirus chronically.", [["FIP", "DISEASE", 23, 26], ["coronavirus", "DISEASE", 131, 142], ["cats", "ORGANISM", 63, 67], ["cats", "ORGANISM", 103, 107], ["coronavirus", "ORGANISM", 131, 142], ["cats", "SPECIES", 63, 67], ["cats", "SPECIES", 103, 107], ["coronavirus", "SPECIES", 131, 142], ["FIP", "PROBLEM", 23, 26], ["new cats", "TREATMENT", 59, 67]]], ["12 There is no distinct mutation that allows avirulent FCoV strains to be differentiated from virulent strains, and therefore no diagnostic test exists that distinguishes FIP from benign FCoV strains.", [["strains", "ANATOMY", 103, 110], ["FIP", "DISEASE", 171, 174], ["FCoV strains", "ORGANISM", 55, 67], ["FIP", "ORGANISM", 171, 174], ["FCoV", "SPECIES", 55, 59], ["distinct mutation", "PROBLEM", 15, 32], ["avirulent FCoV strains", "PROBLEM", 45, 67], ["virulent strains", "PROBLEM", 94, 110], ["diagnostic test", "TEST", 129, 144], ["FIP", "PROBLEM", 171, 174], ["benign FCoV strains", "PROBLEM", 180, 199], ["no", "UNCERTAINTY", 12, 14], ["distinct", "OBSERVATION_MODIFIER", 15, 23], ["mutation", "OBSERVATION", 24, 32], ["benign", "OBSERVATION_MODIFIER", 180, 186], ["FCoV strains", "OBSERVATION", 187, 199]]], ["However, mutations in the spike protein gene, 24, 25 membrane protein gene, 26 and the nonstructural 3c and 7b genes 23,27-29 may play a role.", [["25 membrane protein", "GENE_OR_GENE_PRODUCT", 50, 69], ["nonstructural 3c", "GENE_OR_GENE_PRODUCT", 87, 103], ["7b", "GENE_OR_GENE_PRODUCT", 108, 110], ["spike protein gene, 24, 25 membrane protein gene", "DNA", 26, 74], ["nonstructural 3c and 7b genes 23,27-29", "DNA", 87, 125], ["mutations", "PROBLEM", 9, 18], ["the spike protein gene", "TEST", 22, 44], ["membrane protein gene", "TEST", 53, 74], ["the nonstructural 3c", "TEST", 83, 103], ["7b genes", "TEST", 108, 116]]], ["In particular, the 3c gene appears to be disrupted in many (but not all) virulent FCoV strains.Etiology and EpidemiologyThe other hypothesis proposed to explain the pathogenesis of FIP is that distinct circulating virulent and avirulent FCoV strains exist, and the combination of infection with a virulent FCoV and an individual cat's genetic and environmental predispositions leads to FIP.", [["FIP", "DISEASE", 181, 184], ["infection", "DISEASE", 280, 289], ["FIP", "DISEASE", 386, 389], ["FCoV strains", "ORGANISM", 82, 94], ["FCoV strains", "ORGANISM", 237, 249], ["FCoV", "CANCER", 306, 310], ["cat", "ORGANISM", 329, 332], ["3c gene", "DNA", 19, 26], ["cat", "SPECIES", 329, 332], ["FCoV", "SPECIES", 82, 86], ["FCoV", "SPECIES", 237, 241], ["FCoV", "SPECIES", 306, 310], ["virulent FCoV strains", "PROBLEM", 73, 94], ["The other hypothesis", "PROBLEM", 120, 140], ["the pathogenesis of FIP", "PROBLEM", 161, 184], ["distinct circulating virulent and avirulent FCoV strains", "PROBLEM", 193, 249], ["infection", "PROBLEM", 280, 289], ["a virulent FCoV", "PROBLEM", 295, 310], ["FIP", "PROBLEM", 386, 389], ["appears to be", "UNCERTAINTY", 27, 40], ["disrupted", "OBSERVATION", 41, 50], ["FCoV strains", "OBSERVATION", 82, 94], ["FIP", "OBSERVATION", 181, 184], ["distinct", "OBSERVATION_MODIFIER", 193, 201], ["circulating", "OBSERVATION_MODIFIER", 202, 213], ["virulent", "OBSERVATION_MODIFIER", 214, 222], ["avirulent", "OBSERVATION_MODIFIER", 227, 236], ["FCoV strains", "OBSERVATION", 237, 249], ["infection", "OBSERVATION", 280, 289], ["virulent FCoV", "OBSERVATION", 297, 310]]], ["30Signs and Their PathogenesisCats are usually infected with FCoV by oronasal exposure to virus in feces or fomites contaminated with fecal material.", [["feces", "ANATOMY", 99, 104], ["FCoV", "CHEMICAL", 61, 65], ["FCoV", "GENE_OR_GENE_PRODUCT", 61, 65], ["oronasal", "ORGANISM_SUBDIVISION", 69, 77], ["feces", "ORGANISM_SUBSTANCE", 99, 104], ["fecal material", "MULTI-TISSUE_STRUCTURE", 134, 148], ["FCoV", "SPECIES", 61, 65], ["FCoV", "PROBLEM", 61, 65], ["oronasal exposure to virus in feces", "PROBLEM", 69, 104], ["fomites", "PROBLEM", 108, 115], ["fecal material", "PROBLEM", 134, 148], ["PathogenesisCats", "OBSERVATION", 18, 34], ["infected", "OBSERVATION", 47, 55], ["FCoV", "OBSERVATION", 61, 65], ["oronasal exposure", "OBSERVATION", 69, 86], ["fecal material", "OBSERVATION", 134, 148]]], ["Shared litter boxes are thought to play a major role in transmission.", [["litter boxes", "OBSERVATION", 7, 19], ["thought to play", "UNCERTAINTY", 24, 39], ["major", "OBSERVATION_MODIFIER", 42, 47]]], ["15 Replication of low-pathogenicity strains of FCoV in epithelial cells at the tips of intestinal villi may be associated with no signs, or acute or chronic, persistent or intermittent smallbowel diarrhea, and less commonly, vomiting and/or inappetence.", [["epithelial cells", "ANATOMY", 55, 71], ["intestinal villi", "ANATOMY", 87, 103], ["FCoV", "CHEMICAL", 47, 51], ["diarrhea", "DISEASE", 196, 204], ["vomiting", "DISEASE", 225, 233], ["inappetence", "DISEASE", 241, 252], ["FCoV", "CELL", 47, 51], ["epithelial cells", "CELL", 55, 71], ["intestinal villi", "MULTI-TISSUE_STRUCTURE", 87, 103], ["epithelial cells", "CELL_TYPE", 55, 71], ["FCoV", "SPECIES", 47, 51], ["FCoV", "PROBLEM", 47, 51], ["epithelial cells", "PROBLEM", 55, 71], ["signs", "PROBLEM", 130, 135], ["acute or chronic, persistent or intermittent smallbowel diarrhea", "PROBLEM", 140, 204], ["vomiting", "PROBLEM", 225, 233], ["inappetence", "PROBLEM", 241, 252], ["low", "OBSERVATION_MODIFIER", 18, 21], ["pathogenicity strains", "OBSERVATION_MODIFIER", 22, 43], ["FCoV", "OBSERVATION", 47, 51], ["epithelial cells", "OBSERVATION", 55, 71], ["tips", "ANATOMY_MODIFIER", 79, 83], ["intestinal villi", "ANATOMY", 87, 103], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["chronic", "OBSERVATION_MODIFIER", 149, 156], ["persistent", "OBSERVATION_MODIFIER", 158, 168], ["intermittent", "OBSERVATION_MODIFIER", 172, 184], ["smallbowel", "OBSERVATION_MODIFIER", 185, 195], ["diarrhea", "OBSERVATION", 196, 204], ["less commonly", "OBSERVATION_MODIFIER", 210, 223]]], ["Transient upper respiratory signs have been reported in some cats on initial infection with FCoV.", [["respiratory", "ANATOMY", 16, 27], ["infection", "DISEASE", 77, 86], ["cats", "ORGANISM", 61, 65], ["FCoV", "SPECIES", 92, 96], ["Transient upper respiratory signs", "PROBLEM", 0, 33], ["initial infection", "PROBLEM", 69, 86], ["FCoV", "PROBLEM", 92, 96], ["upper", "ANATOMY_MODIFIER", 10, 15], ["respiratory", "ANATOMY", 16, 27], ["signs", "OBSERVATION", 28, 33], ["infection", "OBSERVATION", 77, 86], ["FCoV", "OBSERVATION", 92, 96]]], ["15 Virus is shed in the feces from 1 week after infection.", [["feces", "ANATOMY", 24, 29], ["infection", "DISEASE", 48, 57], ["Virus", "ORGANISM", 3, 8], ["feces", "ORGANISM_SUBDIVISION", 24, 29], ["15 Virus", "PROBLEM", 0, 8], ["infection", "PROBLEM", 48, 57], ["Virus", "OBSERVATION", 3, 8], ["feces", "ANATOMY", 24, 29], ["infection", "OBSERVATION", 48, 57]]], ["Some cats then shed large quantities of virus continuously for life.", [["cats", "ORGANISM", 5, 9], ["cats", "SPECIES", 5, 9], ["Some cats", "PROBLEM", 0, 9], ["cats", "OBSERVATION", 5, 9], ["large", "OBSERVATION_MODIFIER", 20, 25], ["quantities", "OBSERVATION_MODIFIER", 26, 36], ["virus", "OBSERVATION", 40, 45]]], ["12, 22, [31] [32] [33] Both serotype I and serotype II strains appear to enter macrophages via a lectin receptor known as fDC-SIGN (feline dendritic cell-specific intercellular adhesion molecule grabbing non-integrin receptor).", [["macrophages", "ANATOMY", 79, 90], ["dendritic cell", "ANATOMY", 139, 153], ["serotype II strains", "ORGANISM", 43, 62], ["macrophages", "CELL", 79, 90], ["fDC-SIGN", "GENE_OR_GENE_PRODUCT", 122, 130], ["feline dendritic cell-specific intercellular adhesion molecule grabbing non-integrin receptor", "GENE_OR_GENE_PRODUCT", 132, 225], ["macrophages", "CELL_TYPE", 79, 90], ["lectin receptor", "PROTEIN", 97, 112], ["fDC", "PROTEIN", 122, 125], ["SIGN", "PROTEIN", 126, 130], ["feline dendritic cell-specific intercellular adhesion molecule", "PROTEIN", 132, 194], ["non-integrin receptor", "PROTEIN", 204, 225], ["Both serotype I", "PROBLEM", 23, 38], ["serotype II strains", "PROBLEM", 43, 62], ["a lectin receptor", "TEST", 95, 112], ["fDC", "TEST", 122, 125], ["SIGN (feline dendritic cell", "PROBLEM", 126, 153], ["specific intercellular adhesion molecule", "TREATMENT", 154, 194], ["dendritic cell", "OBSERVATION", 139, 153]]], ["3, 34 Replication of virulent FCoV strains within macrophages results in two forms of disease, which reflect the immune response mounted by the host.", [["macrophages", "ANATOMY", 50, 61], ["FCoV strains", "CELL", 30, 42], ["macrophages", "CELL", 50, 61], ["macrophages", "CELL_TYPE", 50, 61], ["FCoV", "SPECIES", 30, 34], ["virulent FCoV strains", "PROBLEM", 21, 42], ["disease", "PROBLEM", 86, 93], ["virulent", "OBSERVATION_MODIFIER", 21, 29], ["FCoV strains", "OBSERVATION", 30, 42], ["two forms", "OBSERVATION_MODIFIER", 73, 82], ["disease", "OBSERVATION", 86, 93], ["immune response", "OBSERVATION", 113, 128]]], ["FIP is an immune complex disease.", [["FIP", "DISEASE", 0, 3], ["FIP", "GENE_OR_GENE_PRODUCT", 0, 3], ["FIP", "PROBLEM", 0, 3], ["an immune complex disease", "PROBLEM", 7, 32], ["immune complex", "OBSERVATION", 10, 24]]], ["Noneffusive (\"dry\") FIP occurs in cats that mount a partial CMI response and is characterized by pyogranulomatous to granulomatous inflammation within a variety of organs, but especially the mesenteric lymph nodes, kidneys, liver, lungs, brain, and eye.", [["granulomatous", "ANATOMY", 117, 130], ["organs", "ANATOMY", 164, 170], ["mesenteric lymph nodes", "ANATOMY", 191, 213], ["kidneys", "ANATOMY", 215, 222], ["liver", "ANATOMY", 224, 229], ["lungs", "ANATOMY", 231, 236], ["brain", "ANATOMY", 238, 243], ["eye", "ANATOMY", 249, 252], ["FIP", "DISEASE", 20, 23], ["inflammation", "DISEASE", 131, 143], ["cats", "ORGANISM", 34, 38], ["organs", "ORGAN", 164, 170], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 191, 213], ["kidneys", "ORGAN", 215, 222], ["liver", "ORGAN", 224, 229], ["lungs", "ORGAN", 231, 236], ["brain", "ORGAN", 238, 243], ["eye", "ORGAN", 249, 252], ["cats", "SPECIES", 34, 38], ["Noneffusive (\"dry\")", "PROBLEM", 0, 19], ["FIP", "PROBLEM", 20, 23], ["a partial CMI response", "PROBLEM", 50, 72], ["pyogranulomatous to granulomatous inflammation", "PROBLEM", 97, 143], ["the mesenteric lymph nodes, kidneys, liver, lungs, brain, and eye", "PROBLEM", 187, 252], ["FIP", "OBSERVATION", 20, 23], ["partial", "OBSERVATION_MODIFIER", 52, 59], ["CMI response", "OBSERVATION", 60, 72], ["pyogranulomatous", "OBSERVATION_MODIFIER", 97, 113], ["granulomatous", "OBSERVATION_MODIFIER", 117, 130], ["inflammation", "OBSERVATION", 131, 143], ["variety", "OBSERVATION_MODIFIER", 153, 160], ["organs", "ANATOMY", 164, 170], ["mesenteric", "ANATOMY", 191, 201], ["lymph nodes", "OBSERVATION", 202, 213], ["kidneys", "ANATOMY", 215, 222], ["liver", "ANATOMY", 224, 229], ["lungs", "ANATOMY", 231, 236], ["brain", "ANATOMY", 238, 243], ["eye", "ANATOMY", 249, 252]]], ["Solitary or multifocal granulomas of the intestinal wall also occasionally develop, especially in the region of the ileocecal junction ( Figure 20 -3).", [["granulomas", "ANATOMY", 23, 33], ["intestinal wall", "ANATOMY", 41, 56], ["ileocecal junction", "ANATOMY", 116, 134], ["granulomas", "DISEASE", 23, 33], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 41, 56], ["ileocecal junction", "MULTI-TISSUE_STRUCTURE", 116, 134], ["Solitary or multifocal granulomas of the intestinal wall", "PROBLEM", 0, 56], ["multifocal", "OBSERVATION_MODIFIER", 12, 22], ["granulomas", "OBSERVATION", 23, 33], ["intestinal wall", "ANATOMY", 41, 56], ["region", "ANATOMY_MODIFIER", 102, 108], ["ileocecal junction", "ANATOMY", 116, 134]]], ["15 Effusive (\"wet\") FIP occurs in cats that are unable to mount an immune response and is characterized by accumulation of high protein exudates in the thorax and/or abdomen, which typically contain low numbers of cells.", [["thorax", "ANATOMY", 152, 158], ["abdomen", "ANATOMY", 166, 173], ["cells", "ANATOMY", 214, 219], ["FIP", "DISEASE", 20, 23], ["cats", "ORGANISM", 34, 38], ["thorax", "ORGAN", 152, 158], ["abdomen", "ORGAN", 166, 173], ["cells", "CELL", 214, 219], ["cats", "SPECIES", 34, 38], ["Effusive (\"wet\") FIP", "PROBLEM", 3, 23], ["high protein exudates in the thorax and/or abdomen", "PROBLEM", 123, 173], ["low numbers of cells", "PROBLEM", 199, 219], ["FIP", "OBSERVATION", 20, 23], ["high protein exudates", "OBSERVATION", 123, 144], ["thorax", "ANATOMY", 152, 158], ["abdomen", "ANATOMY", 166, 173], ["low numbers", "OBSERVATION_MODIFIER", 199, 210], ["of cells", "OBSERVATION", 211, 219]]], ["Production of vascular endothelial growth factor by infected monocytes may be lead to increased vascular permeability and contribute to cavitary effusion.", [["monocytes", "ANATOMY", 61, 70], ["vascular", "ANATOMY", 96, 104], ["cavitary effusion", "ANATOMY", 136, 153], ["cavitary effusion", "DISEASE", 136, 153], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 14, 48], ["monocytes", "CELL", 61, 70], ["vascular", "MULTI-TISSUE_STRUCTURE", 96, 104], ["vascular endothelial growth factor", "PROTEIN", 14, 48], ["infected monocytes", "CELL_TYPE", 52, 70], ["vascular endothelial growth factor", "PROBLEM", 14, 48], ["infected monocytes", "PROBLEM", 52, 70], ["increased vascular permeability", "PROBLEM", 86, 117], ["cavitary effusion", "PROBLEM", 136, 153], ["vascular endothelial", "ANATOMY", 14, 34], ["growth", "OBSERVATION_MODIFIER", 35, 41], ["infected monocytes", "OBSERVATION", 52, 70], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["vascular", "ANATOMY", 96, 104], ["permeability", "OBSERVATION", 105, 117], ["cavitary", "OBSERVATION_MODIFIER", 136, 144], ["effusion", "OBSERVATION", 145, 153]]], ["35 Many cats have a mixture of both forms of the disease, and noneffusive disease may progress to effusive disease.", [["noneffusive disease", "DISEASE", 62, 81], ["effusive disease", "DISEASE", 98, 114], ["cats", "ORGANISM", 8, 12], ["cats", "SPECIES", 8, 12], ["the disease", "PROBLEM", 45, 56], ["noneffusive disease", "PROBLEM", 62, 81], ["effusive disease", "PROBLEM", 98, 114], ["disease", "OBSERVATION", 49, 56]]], ["Infection itself results in immune dysregulation, with a profound, virus-induced depletion of CD4+ and CD8+ cells; production of TNF-\u03b1, granulocyte-macrophage colony stimulating factor (GM-CSF), and granulocyte colonystimulating factor (G-CSF) by infected macrophages; impaired IFN-\u03b3 production; and hypergammaglobulinemia.", [["CD4+ and CD8+ cells", "ANATOMY", 94, 113], ["macrophages", "ANATOMY", 256, 267], ["hypergammaglobulinemia", "DISEASE", 300, 322], ["CD4", "GENE_OR_GENE_PRODUCT", 94, 97], ["CD8", "GENE_OR_GENE_PRODUCT", 103, 106], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 129, 134], ["granulocyte-macrophage colony stimulating factor", "GENE_OR_GENE_PRODUCT", 136, 184], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 186, 192], ["granulocyte colonystimulating factor", "GENE_OR_GENE_PRODUCT", 199, 235], ["G-CSF", "GENE_OR_GENE_PRODUCT", 237, 242], ["macrophages", "CELL", 256, 267], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 278, 283], ["CD4", "PROTEIN", 94, 97], ["CD8", "PROTEIN", 103, 106], ["TNF-\u03b1", "PROTEIN", 129, 134], ["granulocyte-macrophage colony stimulating factor", "PROTEIN", 136, 184], ["GM", "PROTEIN", 186, 188], ["CSF", "PROTEIN", 189, 192], ["granulocyte colonystimulating factor", "PROTEIN", 199, 235], ["CSF", "PROTEIN", 239, 242], ["infected macrophages", "CELL_TYPE", 247, 267], ["IFN", "PROTEIN", 278, 281], ["\u03b3", "PROTEIN", 282, 283], ["Infection itself", "PROBLEM", 0, 16], ["immune dysregulation", "PROBLEM", 28, 48], ["a profound, virus", "PROBLEM", 55, 72], ["CD4", "TEST", 94, 97], ["CD8+ cells", "PROBLEM", 103, 113], ["TNF", "TEST", 129, 132], ["granulocyte", "TEST", 136, 147], ["macrophage colony stimulating factor", "TEST", 148, 184], ["GM-CSF", "TEST", 186, 192], ["granulocyte colonystimulating factor", "TEST", 199, 235], ["G-CSF", "TEST", 237, 242], ["infected macrophages", "PROBLEM", 247, 267], ["impaired IFN-\u03b3 production", "PROBLEM", 269, 294], ["hypergammaglobulinemia", "PROBLEM", 300, 322], ["immune dysregulation", "OBSERVATION", 28, 48], ["CD8+ cells", "OBSERVATION", 103, 113], ["granulocyte", "ANATOMY", 136, 147], ["macrophage", "ANATOMY", 148, 158], ["granulocyte", "ANATOMY", 199, 210], ["infected macrophages", "OBSERVATION", 247, 267], ["hypergammaglobulinemia", "OBSERVATION", 300, 322]]], ["[36] [37] [38] The mechanism of T-cell depletion is not clear, as the virus does not infect lymphocytes, only monocytes and macrophages.", [["T-cell", "ANATOMY", 32, 38], ["lymphocytes", "ANATOMY", 92, 103], ["monocytes", "ANATOMY", 110, 119], ["macrophages", "ANATOMY", 124, 135], ["[36] [37] [38]", "SIMPLE_CHEMICAL", 0, 14], ["T-cell", "CELL", 32, 38], ["lymphocytes", "CELL", 92, 103], ["monocytes", "CELL", 110, 119], ["macrophages", "CELL", 124, 135], ["lymphocytes", "CELL_TYPE", 92, 103], ["monocytes", "CELL_TYPE", 110, 119], ["macrophages", "CELL_TYPE", 124, 135], ["T-cell depletion", "PROBLEM", 32, 48], ["the virus", "PROBLEM", 66, 75], ["monocytes", "TEST", 110, 119], ["cell depletion", "OBSERVATION", 34, 48], ["macrophages", "OBSERVATION", 124, 135]]], ["Infection of antigen-presenting cells, specifically dendritic cells, has been hypothesized to lead to T-cell apoptosis.", [["antigen-presenting cells", "ANATOMY", 13, 37], ["dendritic cells", "ANATOMY", 52, 67], ["T-cell", "ANATOMY", 102, 108], ["cells", "CELL", 32, 37], ["dendritic cells", "CELL", 52, 67], ["T-cell", "CELL", 102, 108], ["antigen-presenting cells", "CELL_TYPE", 13, 37], ["dendritic cells", "CELL_TYPE", 52, 67], ["Infection of antigen", "PROBLEM", 0, 20], ["presenting cells", "PROBLEM", 21, 37], ["dendritic cells", "PROBLEM", 52, 67], ["T-cell apoptosis", "PROBLEM", 102, 118], ["dendritic cells", "OBSERVATION", 52, 67], ["cell apoptosis", "OBSERVATION", 104, 118]]], ["Progressive immune system failure may be associated with a conversion to predominantly effusive disease manifestations.", [["immune system", "ANATOMY", 12, 25], ["immune system failure", "DISEASE", 12, 33], ["Progressive immune system failure", "PROBLEM", 0, 33], ["predominantly effusive disease manifestations", "PROBLEM", 73, 118], ["immune system failure", "OBSERVATION", 12, 33], ["predominantly", "OBSERVATION_MODIFIER", 73, 86], ["effusive disease", "OBSERVATION", 87, 103]]], ["Despite the profound T-cell deficiency that accompanies FIP, opportunistic infections are rarely reported.", [["T-cell", "ANATOMY", 21, 27], ["T-cell deficiency", "DISEASE", 21, 38], ["FIP", "DISEASE", 56, 59], ["opportunistic infections", "DISEASE", 61, 85], ["T-cell", "CELL", 21, 27], ["the profound T-cell deficiency", "PROBLEM", 8, 38], ["FIP", "PROBLEM", 56, 59], ["opportunistic infections", "PROBLEM", 61, 85], ["profound", "OBSERVATION_MODIFIER", 12, 20], ["-cell deficiency", "OBSERVATION", 22, 38], ["FIP", "OBSERVATION_MODIFIER", 56, 59], ["opportunistic", "OBSERVATION_MODIFIER", 61, 74], ["infections", "OBSERVATION", 75, 85]]], ["Nevertheless, concurrent infections with retroviruses and Toxoplasma gondii and opportunistic bacterial infections can occur; 6 the author is aware of one cat that was co-infected with Sporothrix schenckii.", [["infections", "DISEASE", 25, 35], ["Toxoplasma gondii", "DISEASE", 58, 75], ["opportunistic bacterial infections", "DISEASE", 80, 114], ["Sporothrix schenckii", "DISEASE", 185, 205], ["retroviruses", "ORGANISM", 41, 53], ["Toxoplasma gondii", "ORGANISM", 58, 75], ["cat", "ORGANISM", 155, 158], ["Sporothrix schenckii", "ORGANISM", 185, 205], ["Toxoplasma gondii", "SPECIES", 58, 75], ["cat", "SPECIES", 155, 158], ["Sporothrix schenckii", "SPECIES", 185, 205], ["Toxoplasma gondii", "SPECIES", 58, 75], ["Sporothrix schenckii", "SPECIES", 185, 205], ["concurrent infections", "PROBLEM", 14, 35], ["retroviruses", "PROBLEM", 41, 53], ["Toxoplasma gondii", "PROBLEM", 58, 75], ["opportunistic bacterial infections", "PROBLEM", 80, 114], ["Sporothrix schenckii", "PROBLEM", 185, 205], ["infections", "OBSERVATION", 25, 35], ["Sporothrix schenckii", "OBSERVATION", 185, 205]]], ["The incubation period for FIP is highly variable.", [["FIP", "DISEASE", 26, 29], ["FIP", "PROBLEM", 26, 29], ["FIP", "OBSERVATION", 26, 29], ["highly", "OBSERVATION_MODIFIER", 33, 39], ["variable", "OBSERVATION_MODIFIER", 40, 48]]], ["Kittens usually become infected at 4 to 8 weeks of age, when maternal antibody begins to wane, but infections have been reported in kittens as young as 2 weeks of age.", [["infections", "DISEASE", 99, 109], ["maternal antibody", "PROTEIN", 61, 78], ["maternal antibody", "PROBLEM", 61, 78], ["infections", "PROBLEM", 99, 109], ["infected", "OBSERVATION", 23, 31]]], ["20 Disease may occur a few weeks after infection or years later, but most often it occurs 6 to 18 months after initial infection.", [["infection", "DISEASE", 39, 48], ["infection", "DISEASE", 119, 128], ["20 Disease", "PROBLEM", 0, 10], ["infection", "PROBLEM", 39, 48], ["initial infection", "PROBLEM", 111, 128], ["Disease", "OBSERVATION", 3, 10], ["infection", "OBSERVATION", 119, 128]]], ["19 Even after the onset of systemic pyogranulomatous inflammatory disease, clinical signs may not be apparent for months.", [["inflammatory disease", "DISEASE", 53, 73], ["systemic pyogranulomatous inflammatory disease", "PROBLEM", 27, 73], ["clinical signs", "PROBLEM", 75, 89], ["systemic", "OBSERVATION_MODIFIER", 27, 35], ["pyogranulomatous", "OBSERVATION_MODIFIER", 36, 52], ["inflammatory disease", "OBSERVATION", 53, 73], ["may not be apparent", "UNCERTAINTY", 90, 109]]], ["In support of this, lesions consistent with FIP have been found incidentally in cats during abdominal surgery such as ovariohysterectomy.", [["lesions", "ANATOMY", 20, 27], ["abdominal", "ANATOMY", 92, 101], ["FIP", "DISEASE", 44, 47], ["lesions", "PATHOLOGICAL_FORMATION", 20, 27], ["cats", "ORGANISM", 80, 84], ["abdominal", "ORGANISM_SUBDIVISION", 92, 101], ["cats", "SPECIES", 80, 84], ["lesions", "PROBLEM", 20, 27], ["FIP", "PROBLEM", 44, 47], ["abdominal surgery", "TREATMENT", 92, 109], ["ovariohysterectomy", "TREATMENT", 118, 136], ["lesions", "OBSERVATION", 20, 27], ["consistent with", "UNCERTAINTY", 28, 43], ["FIP", "OBSERVATION", 44, 47], ["abdominal", "ANATOMY", 92, 101], ["surgery", "OBSERVATION", 102, 109], ["ovariohysterectomy", "OBSERVATION", 118, 136]]], ["20 The clinical signs of FIP often change over time and depend on the organs affected and the relative predominance of inflammatory versus effusive disease manifestations.", [["organs", "ANATOMY", 70, 76], ["FIP", "DISEASE", 25, 28], ["organs", "ORGAN", 70, 76], ["FIP", "PROBLEM", 25, 28], ["inflammatory versus effusive disease manifestations", "PROBLEM", 119, 170], ["FIP", "OBSERVATION", 25, 28], ["organs", "ANATOMY", 70, 76], ["predominance", "OBSERVATION_MODIFIER", 103, 115], ["inflammatory", "OBSERVATION_MODIFIER", 119, 131]]], ["The most common signs are lethargy and inappetence, as well as a fluctuating fever that does not respond to antibacterial drug treatment.", [["lethargy", "DISEASE", 26, 34], ["inappetence", "DISEASE", 39, 50], ["fever", "DISEASE", 77, 82], ["lethargy", "PROBLEM", 26, 34], ["inappetence", "PROBLEM", 39, 50], ["a fluctuating fever", "PROBLEM", 63, 82], ["antibacterial drug treatment", "TREATMENT", 108, 136], ["lethargy", "OBSERVATION", 26, 34], ["inappetence", "OBSERVATION", 39, 50], ["fluctuating", "OBSERVATION_MODIFIER", 65, 76], ["fever", "OBSERVATION", 77, 82]]], ["Nevertheless, many cats are bright, appetent, and in good body condition early in the course of illness.", [["body", "ANATOMY", 58, 62], ["cats", "ORGANISM", 19, 23], ["body", "ORGANISM_SUBDIVISION", 58, 62], ["cats", "SPECIES", 19, 23], ["illness", "PROBLEM", 96, 103], ["good body", "OBSERVATION_MODIFIER", 53, 62]]], ["Some cats have increased thirst and urination, possibly secondary to pyrexia.", [["increased thirst and urination", "DISEASE", 15, 45], ["pyrexia", "DISEASE", 69, 76], ["cats", "ORGANISM", 5, 9], ["cats", "SPECIES", 5, 9], ["Some cats", "PROBLEM", 0, 9], ["increased thirst", "PROBLEM", 15, 31], ["urination", "PROBLEM", 36, 45], ["pyrexia", "PROBLEM", 69, 76], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["thirst", "OBSERVATION", 25, 31], ["possibly secondary to", "UNCERTAINTY", 47, 68], ["pyrexia", "OBSERVATION", 69, 76]]], ["Ultimately, weight loss develops, but owners of cats that develop abdominal distention may mistake the distention for weight gain or pregnancy.", [["abdominal", "ANATOMY", 66, 75], ["weight loss", "DISEASE", 12, 23], ["abdominal distention", "DISEASE", 66, 86], ["weight gain", "DISEASE", 118, 129], ["cats", "ORGANISM", 48, 52], ["abdominal", "ORGANISM_SUBDIVISION", 66, 75], ["cats", "SPECIES", 48, 52], ["weight loss", "PROBLEM", 12, 23], ["abdominal distention", "PROBLEM", 66, 86], ["the distention", "PROBLEM", 99, 113], ["weight gain", "PROBLEM", 118, 129], ["pregnancy", "PROBLEM", 133, 142], ["abdominal", "ANATOMY", 66, 75], ["distention", "OBSERVATION", 76, 86], ["distention", "OBSERVATION", 103, 113]]], ["Stunted growth may occur in affected kittens.", [["kittens", "ORGANISM", 37, 44], ["Stunted growth", "PROBLEM", 0, 14], ["affected kittens", "PROBLEM", 28, 44]]], ["Pleural effusion may be associated with tachypnea and respiratory distress.", [["Pleural", "ANATOMY", 0, 7], ["respiratory", "ANATOMY", 54, 65], ["Pleural effusion", "DISEASE", 0, 16], ["tachypnea", "DISEASE", 40, 49], ["respiratory distress", "DISEASE", 54, 74], ["Pleural effusion", "PROBLEM", 0, 16], ["tachypnea", "PROBLEM", 40, 49], ["respiratory distress", "PROBLEM", 54, 74], ["effusion", "OBSERVATION", 8, 16], ["tachypnea", "OBSERVATION", 40, 49], ["respiratory distress", "OBSERVATION", 54, 74]]], ["Testicular enlargement may occur in cats with serositis that involves the tunica vaginalis.", [["Testicular", "ANATOMY", 0, 10], ["tunica vaginalis", "ANATOMY", 74, 90], ["Testicular enlargement", "DISEASE", 0, 22], ["serositis", "DISEASE", 46, 55], ["Testicular", "ORGAN", 0, 10], ["cats", "ORGANISM", 36, 40], ["tunica vaginalis", "ORGANISM", 74, 90], ["cats", "SPECIES", 36, 40], ["tunica vaginalis", "SPECIES", 74, 90], ["Testicular enlargement", "PROBLEM", 0, 22], ["serositis", "PROBLEM", 46, 55], ["enlargement", "OBSERVATION", 11, 22], ["serositis", "OBSERVATION", 46, 55], ["tunica vaginalis", "ANATOMY", 74, 90]]], ["FIP is responsible for approximately 10% of pericardial effusions in cats, the third most common cause of pericardial effusion after cardiomyopathy and neoplasia.", [["pericardial effusions", "ANATOMY", 44, 65], ["pericardial", "ANATOMY", 106, 117], ["neoplasia", "ANATOMY", 152, 161], ["FIP", "DISEASE", 0, 3], ["pericardial effusions", "DISEASE", 44, 65], ["pericardial effusion", "DISEASE", 106, 126], ["cardiomyopathy", "DISEASE", 133, 147], ["neoplasia", "DISEASE", 152, 161], ["FIP", "GENE_OR_GENE_PRODUCT", 0, 3], ["pericardial effusions", "PATHOLOGICAL_FORMATION", 44, 65], ["cats", "ORGANISM", 69, 73], ["pericardial effusion", "PATHOLOGICAL_FORMATION", 106, 126], ["neoplasia", "CANCER", 152, 161], ["FIP", "PROBLEM", 0, 3], ["pericardial effusions in cats", "PROBLEM", 44, 73], ["pericardial effusion", "PROBLEM", 106, 126], ["cardiomyopathy", "PROBLEM", 133, 147], ["neoplasia", "PROBLEM", 152, 161], ["pericardial", "ANATOMY", 44, 55], ["effusions", "OBSERVATION", 56, 65], ["pericardial", "ANATOMY", 106, 117], ["effusion", "OBSERVATION", 118, 126], ["cardiomyopathy", "OBSERVATION", 133, 147], ["neoplasia", "OBSERVATION", 152, 161]]], ["39 Rarely, pericardial effusion results in cardiac tamponade.", [["pericardial effusion", "ANATOMY", 11, 31], ["cardiac", "ANATOMY", 43, 50], ["pericardial effusion", "DISEASE", 11, 31], ["cardiac tamponade", "DISEASE", 43, 60], ["cardiac", "ORGAN", 43, 50], ["pericardial effusion", "PROBLEM", 11, 31], ["cardiac tamponade", "PROBLEM", 43, 60], ["pericardial", "ANATOMY", 11, 22], ["effusion", "OBSERVATION", 23, 31], ["cardiac", "ANATOMY", 43, 50], ["tamponade", "OBSERVATION", 51, 60]]], ["Pyogranulomatous or granulomatous inflammation may lead to mesenteric lymphadenomegaly, irregular renomegaly, intestinal masses, hepatomegaly, icterus, pneumonia, uveitis, chorioretinitis, and, rarely, nodular skin lesions.", [["Pyogranulomatous", "ANATOMY", 0, 16], ["granulomatous", "ANATOMY", 20, 33], ["mesenteric", "ANATOMY", 59, 69], ["renomegaly", "ANATOMY", 98, 108], ["intestinal masses", "ANATOMY", 110, 127], ["nodular skin lesions", "ANATOMY", 202, 222], ["inflammation", "DISEASE", 34, 46], ["lymphadenomegaly", "DISEASE", 70, 86], ["renomegaly", "DISEASE", 98, 108], ["intestinal masses", "DISEASE", 110, 127], ["hepatomegaly", "DISEASE", 129, 141], ["icterus", "DISEASE", 143, 150], ["pneumonia", "DISEASE", 152, 161], ["uveitis", "DISEASE", 163, 170], ["chorioretinitis", "DISEASE", 172, 187], ["skin lesions", "DISEASE", 210, 222], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 59, 69], ["intestinal masses", "PATHOLOGICAL_FORMATION", 110, 127], ["nodular skin lesions", "CANCER", 202, 222], ["Pyogranulomatous or granulomatous inflammation", "PROBLEM", 0, 46], ["mesenteric lymphadenomegaly", "PROBLEM", 59, 86], ["irregular renomegaly", "PROBLEM", 88, 108], ["intestinal masses", "PROBLEM", 110, 127], ["hepatomegaly", "PROBLEM", 129, 141], ["icterus", "PROBLEM", 143, 150], ["pneumonia", "PROBLEM", 152, 161], ["uveitis", "PROBLEM", 163, 170], ["chorioretinitis", "PROBLEM", 172, 187], ["nodular skin lesions", "PROBLEM", 202, 222], ["granulomatous", "OBSERVATION", 20, 33], ["mesenteric", "ANATOMY", 59, 69], ["lymphadenomegaly", "OBSERVATION", 70, 86], ["irregular", "OBSERVATION_MODIFIER", 88, 97], ["renomegaly", "OBSERVATION", 98, 108], ["intestinal", "ANATOMY", 110, 120], ["masses", "OBSERVATION", 121, 127], ["hepatomegaly", "OBSERVATION", 129, 141], ["icterus", "OBSERVATION", 143, 150], ["pneumonia", "OBSERVATION", 152, 161], ["uveitis", "OBSERVATION", 163, 170], ["chorioretinitis", "OBSERVATION", 172, 187], ["nodular", "OBSERVATION_MODIFIER", 202, 209], ["skin", "ANATOMY", 210, 214], ["lesions", "OBSERVATION", 215, 222]]], ["Neurologic signs, which can include focal or generalized seizures, occur in at least 10% of cats with FIP and result primarily from meningoencephalitis, meningomyelitis, ependymitis, choroiditis, and obstructive hydrocephalus.", [["seizures", "DISEASE", 57, 65], ["FIP", "DISEASE", 102, 105], ["meningoencephalitis", "DISEASE", 132, 151], ["meningomyelitis", "DISEASE", 153, 168], ["ependymitis", "DISEASE", 170, 181], ["choroiditis", "DISEASE", 183, 194], ["obstructive hydrocephalus", "DISEASE", 200, 225], ["cats", "ORGANISM", 92, 96], ["Neurologic signs", "TEST", 0, 16], ["focal or generalized seizures", "PROBLEM", 36, 65], ["FIP", "PROBLEM", 102, 105], ["meningoencephalitis", "PROBLEM", 132, 151], ["meningomyelitis", "PROBLEM", 153, 168], ["ependymitis", "PROBLEM", 170, 181], ["choroiditis", "PROBLEM", 183, 194], ["obstructive hydrocephalus", "PROBLEM", 200, 225], ["focal", "OBSERVATION_MODIFIER", 36, 41], ["generalized", "OBSERVATION_MODIFIER", 45, 56], ["seizures", "OBSERVATION", 57, 65], ["meningoencephalitis", "OBSERVATION", 132, 151], ["choroiditis", "OBSERVATION", 183, 194], ["obstructive", "OBSERVATION_MODIFIER", 200, 211], ["hydrocephalus", "OBSERVATION", 212, 225]]], ["Obstructive hydrocephalus occurs secondary to choroiditis and ependymitis ( Figure 20-4) .", [["Obstructive hydrocephalus", "DISEASE", 0, 25], ["choroiditis", "DISEASE", 46, 57], ["ependymitis", "DISEASE", 62, 73], ["Obstructive hydrocephalus", "PROBLEM", 0, 25], ["choroiditis", "PROBLEM", 46, 57], ["ependymitis", "PROBLEM", 62, 73], ["hydrocephalus", "OBSERVATION", 12, 25], ["choroiditis", "OBSERVATION", 46, 57]]], ["In one study, FIP was responsible for almost half of all neurologic disease in 97 cats due to infectious or inflammatory causes.", [["neurologic", "ANATOMY", 57, 67], ["FIP", "DISEASE", 14, 17], ["neurologic disease", "DISEASE", 57, 75], ["FIP", "ORGANISM", 14, 17], ["cats", "ORGANISM", 82, 86], ["one study", "TEST", 3, 12], ["FIP", "PROBLEM", 14, 17], ["all neurologic disease", "PROBLEM", 53, 75], ["inflammatory causes", "PROBLEM", 108, 127], ["FIP", "OBSERVATION", 14, 17], ["neurologic disease", "OBSERVATION", 57, 75], ["infectious", "OBSERVATION", 94, 104], ["inflammatory", "OBSERVATION", 108, 120]]], ["40 Occasionally profound anemia occurs secondary to immunemediated hemolysis 13, 14 or possibly microangiopathic damage, whereby erythrocytes are lysed as they travel through inflamed blood vessels.", [["erythrocytes", "ANATOMY", 129, 141], ["blood vessels", "ANATOMY", 184, 197], ["anemia", "DISEASE", 25, 31], ["hemolysis", "DISEASE", 67, 76], ["microangiopathic damage", "DISEASE", 96, 119], ["erythrocytes", "CELL", 129, 141], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 184, 197], ["erythrocytes", "CELL_TYPE", 129, 141], ["Occasionally profound anemia", "PROBLEM", 3, 31], ["immunemediated hemolysis", "PROBLEM", 52, 76], ["microangiopathic damage", "PROBLEM", 96, 119], ["erythrocytes", "PROBLEM", 129, 141], ["profound", "OBSERVATION_MODIFIER", 16, 24], ["anemia", "OBSERVATION", 25, 31], ["hemolysis", "OBSERVATION", 67, 76], ["possibly", "UNCERTAINTY", 87, 95], ["microangiopathic", "OBSERVATION_MODIFIER", 96, 112], ["damage", "OBSERVATION", 113, 119], ["erythrocytes", "ANATOMY", 129, 141], ["vessels", "ANATOMY", 190, 197]]], ["Immune-mediated glomerulonephritis has also been reported, and FIP should always be considered in cats with protein-losing nephropathy, which is otherwise rare in cats.", [["glomerulonephritis", "DISEASE", 16, 34], ["FIP", "DISEASE", 63, 66], ["protein-losing nephropathy", "DISEASE", 108, 134], ["cats", "ORGANISM", 98, 102], ["cats", "ORGANISM", 163, 167], ["cats", "SPECIES", 163, 167], ["Immune-mediated glomerulonephritis", "PROBLEM", 0, 34], ["FIP", "PROBLEM", 63, 66], ["losing nephropathy", "PROBLEM", 116, 134], ["glomerulonephritis", "OBSERVATION", 16, 34], ["nephropathy", "OBSERVATION", 123, 134]]], ["41 Uncommonly, lameness occurs as a result of synovitis.", [["lameness", "DISEASE", 15, 23], ["synovitis", "DISEASE", 46, 55], ["synovitis", "PROBLEM", 46, 55], ["lameness", "OBSERVATION", 15, 23], ["synovitis", "OBSERVATION", 46, 55]]], ["6Physical Examination FindingsPhysical examination findings in cats with FIP reflect the type of disease present (effusive versus noneffusive) and the location where lesions occur.", [["lesions", "ANATOMY", 166, 173], ["FIP", "DISEASE", 73, 76], ["cats", "ORGANISM", 63, 67], ["lesions", "PATHOLOGICAL_FORMATION", 166, 173], ["cats", "SPECIES", 63, 67], ["6Physical Examination", "TEST", 0, 21], ["FindingsPhysical examination", "TEST", 22, 50], ["FIP", "PROBLEM", 73, 76], ["disease", "PROBLEM", 97, 104], ["lesions", "PROBLEM", 166, 173], ["disease", "OBSERVATION", 97, 104], ["lesions", "OBSERVATION", 166, 173]]], ["Cats with respiratory tract involvement may show tachypnea, and if there is pleural effusion, a rapid, shallow breathing pattern and muffled heart and lung sounds may be present.", [["respiratory tract", "ANATOMY", 10, 27], ["pleural effusion", "ANATOMY", 76, 92], ["heart", "ANATOMY", 141, 146], ["lung", "ANATOMY", 151, 155], ["respiratory tract involvement", "DISEASE", 10, 39], ["tachypnea", "DISEASE", 49, 58], ["pleural effusion", "DISEASE", 76, 92], ["respiratory tract", "ORGANISM_SUBDIVISION", 10, 27], ["pleural effusion", "PATHOLOGICAL_FORMATION", 76, 92], ["heart", "ORGAN", 141, 146], ["lung", "ORGAN", 151, 155], ["respiratory tract involvement", "PROBLEM", 10, 39], ["tachypnea", "PROBLEM", 49, 58], ["pleural effusion", "PROBLEM", 76, 92], ["a rapid, shallow breathing pattern", "PROBLEM", 94, 128], ["muffled heart and lung sounds", "PROBLEM", 133, 162], ["respiratory tract", "ANATOMY", 10, 27], ["tachypnea", "OBSERVATION", 49, 58], ["pleural", "ANATOMY", 76, 83], ["effusion", "OBSERVATION", 84, 92], ["rapid", "OBSERVATION_MODIFIER", 96, 101], ["shallow breathing", "OBSERVATION", 103, 120], ["heart", "ANATOMY", 141, 146], ["lung", "ANATOMY", 151, 155], ["sounds", "OBSERVATION", 156, 162]]], ["Other signs include pyrexia, dehydration, mucosal pallor or icterus, a thin body condition, and evidence of ascites.", [["mucosal", "ANATOMY", 42, 49], ["body", "ANATOMY", 76, 80], ["ascites", "ANATOMY", 108, 115], ["pyrexia", "DISEASE", 20, 27], ["dehydration", "DISEASE", 29, 40], ["mucosal pallor", "DISEASE", 42, 56], ["icterus", "DISEASE", 60, 67], ["ascites", "DISEASE", 108, 115], ["body", "ORGANISM_SUBDIVISION", 76, 80], ["Other signs", "TEST", 0, 11], ["pyrexia", "PROBLEM", 20, 27], ["dehydration", "PROBLEM", 29, 40], ["mucosal pallor", "PROBLEM", 42, 56], ["icterus", "PROBLEM", 60, 67], ["a thin body condition", "PROBLEM", 69, 90], ["ascites", "PROBLEM", 108, 115], ["pyrexia", "OBSERVATION", 20, 27], ["dehydration", "OBSERVATION", 29, 40], ["mucosal", "ANATOMY", 42, 49], ["pallor", "OBSERVATION", 50, 56], ["icterus", "OBSERVATION", 60, 67], ["thin body", "OBSERVATION_MODIFIER", 71, 80], ["ascites", "OBSERVATION", 108, 115]]], ["Abdominal palpation may reveal hepatomegaly, irregular renomegaly, and/or abdominal mass lesions that result from mesenteric lymphadenomegaly or intestinal pyogranulomas.", [["Abdominal", "ANATOMY", 0, 9], ["renomegaly", "ANATOMY", 55, 65], ["abdominal mass lesions", "ANATOMY", 74, 96], ["mesenteric lymphadenomegaly", "ANATOMY", 114, 141], ["intestinal pyogranulomas", "ANATOMY", 145, 169], ["hepatomegaly", "DISEASE", 31, 43], ["renomegaly", "DISEASE", 55, 65], ["abdominal mass lesions", "DISEASE", 74, 96], ["lymphadenomegaly", "DISEASE", 125, 141], ["intestinal pyogranulomas", "DISEASE", 145, 169], ["abdominal mass lesions", "PATHOLOGICAL_FORMATION", 74, 96], ["mesenteric lymphadenomegaly", "MULTI-TISSUE_STRUCTURE", 114, 141], ["intestinal pyogranulomas", "CANCER", 145, 169], ["Abdominal palpation", "TEST", 0, 19], ["hepatomegaly", "PROBLEM", 31, 43], ["irregular renomegaly", "PROBLEM", 45, 65], ["abdominal mass lesions", "PROBLEM", 74, 96], ["mesenteric lymphadenomegaly", "PROBLEM", 114, 141], ["intestinal pyogranulomas", "PROBLEM", 145, 169], ["palpation", "OBSERVATION", 10, 19], ["hepatomegaly", "OBSERVATION", 31, 43], ["irregular", "OBSERVATION_MODIFIER", 45, 54], ["renomegaly", "OBSERVATION", 55, 65], ["abdominal", "ANATOMY", 74, 83], ["mass", "OBSERVATION", 84, 88], ["mesenteric", "ANATOMY", 114, 124], ["lymphadenomegaly", "OBSERVATION", 125, 141], ["intestinal", "ANATOMY", 145, 155], ["pyogranulomas", "OBSERVATION", 156, 169]]], ["Sometimes pain is appreciated on abdominal palpation, which may reflect pancreatic involvement in some cats.", [["abdominal", "ANATOMY", 33, 42], ["pancreatic", "ANATOMY", 72, 82], ["pain", "DISEASE", 10, 14], ["abdominal", "ORGANISM_SUBDIVISION", 33, 42], ["pancreatic", "ORGAN", 72, 82], ["cats", "ORGANISM", 103, 107], ["Sometimes pain", "PROBLEM", 0, 14], ["abdominal palpation", "TEST", 33, 52], ["pancreatic involvement in some cats", "PROBLEM", 72, 107], ["pain", "OBSERVATION", 10, 14], ["abdominal", "ANATOMY", 33, 42], ["palpation", "OBSERVATION", 43, 52], ["may reflect", "UNCERTAINTY", 60, 71], ["pancreatic", "ANATOMY", 72, 82], ["involvement", "OBSERVATION", 83, 94]]], ["Testicular enlargement may be detected in intact male cats.", [["Testicular", "ANATOMY", 0, 10], ["Testicular enlargement", "DISEASE", 0, 22], ["Testicular", "ORGAN", 0, 10], ["cats", "ORGANISM", 54, 58], ["cats", "SPECIES", 54, 58], ["Testicular enlargement", "PROBLEM", 0, 22], ["enlargement", "OBSERVATION", 11, 22], ["may be", "UNCERTAINTY", 23, 29]]], ["A wide range of neurologic signs may be present, such as obtundation, twitching, tremors, behavioral changes, nystagmus, hyperesthesia, exaggerated segmental reflexes, ataxia, urinary incontinence, or cranial nerve defects.", [["neurologic", "ANATOMY", 16, 26], ["urinary", "ANATOMY", 176, 183], ["cranial nerve", "ANATOMY", 201, 214], ["tremors", "DISEASE", 81, 88], ["nystagmus", "DISEASE", 110, 119], ["hyperesthesia", "DISEASE", 121, 134], ["exaggerated segmental reflexes", "DISEASE", 136, 166], ["ataxia", "DISEASE", 168, 174], ["urinary incontinence", "DISEASE", 176, 196], ["cranial nerve defects", "DISEASE", 201, 222], ["urinary", "ORGANISM_SUBDIVISION", 176, 183], ["cranial nerve", "MULTI-TISSUE_STRUCTURE", 201, 214], ["A wide range of neurologic signs", "PROBLEM", 0, 32], ["obtundation", "PROBLEM", 57, 68], ["twitching", "PROBLEM", 70, 79], ["tremors", "PROBLEM", 81, 88], ["behavioral changes", "PROBLEM", 90, 108], ["nystagmus", "PROBLEM", 110, 119], ["hyperesthesia", "PROBLEM", 121, 134], ["exaggerated segmental reflexes", "PROBLEM", 136, 166], ["ataxia", "PROBLEM", 168, 174], ["urinary incontinence", "PROBLEM", 176, 196], ["cranial nerve defects", "PROBLEM", 201, 222], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["hyperesthesia", "OBSERVATION", 121, 134], ["segmental reflexes", "ANATOMY", 148, 166], ["urinary incontinence", "ANATOMY", 176, 196], ["cranial nerve", "ANATOMY", 201, 214], ["defects", "OBSERVATION", 215, 222]]], ["Ocular signs include conjunctivitis, mucopurulent ocular discharge, thickening and hyperemia of the nictitans, uveitis with dyscoria or anisocoria, aqueous flare, keratic precipitates, hypopyon, hyphema, chorioretinitis, perivascular infiltrates, retinal detachment, or blindness ( Figure 20DiagnosisCurrently, definitive diagnosis of FIP is made only by immunohistochemical staining for coronavirus antigen within lesions characterized by pyogranulomatous or granulomatous vasculitis.", [["Ocular", "ANATOMY", 0, 6], ["ocular", "ANATOMY", 50, 56], ["hypopyon", "ANATOMY", 185, 193], ["perivascular infiltrates", "ANATOMY", 221, 245], ["retinal", "ANATOMY", 247, 254], ["lesions", "ANATOMY", 415, 422], ["pyogranulomatous", "ANATOMY", 440, 456], ["conjunctivitis", "DISEASE", 21, 35], ["hyperemia", "DISEASE", 83, 92], ["uveitis", "DISEASE", 111, 118], ["dyscoria", "DISEASE", 124, 132], ["anisocoria", "DISEASE", 136, 146], ["hypopyon", "DISEASE", 185, 193], ["hyphema", "DISEASE", 195, 202], ["chorioretinitis", "DISEASE", 204, 219], ["retinal detachment", "DISEASE", 247, 265], ["blindness", "DISEASE", 270, 279], ["FIP", "DISEASE", 335, 338], ["vasculitis", "DISEASE", 474, 484], ["retinal", "MULTI-TISSUE_STRUCTURE", 247, 254], ["lesions", "PATHOLOGICAL_FORMATION", 415, 422], ["coronavirus antigen", "PROTEIN", 388, 407], ["Ocular signs", "PROBLEM", 0, 12], ["conjunctivitis", "PROBLEM", 21, 35], ["mucopurulent ocular discharge", "PROBLEM", 37, 66], ["thickening", "PROBLEM", 68, 78], ["hyperemia of the nictitans", "PROBLEM", 83, 109], ["uveitis", "PROBLEM", 111, 118], ["dyscoria", "PROBLEM", 124, 132], ["anisocoria", "PROBLEM", 136, 146], ["aqueous flare", "PROBLEM", 148, 161], ["keratic precipitates", "PROBLEM", 163, 183], ["hypopyon", "PROBLEM", 185, 193], ["hyphema", "PROBLEM", 195, 202], ["chorioretinitis", "PROBLEM", 204, 219], ["perivascular infiltrates", "PROBLEM", 221, 245], ["retinal detachment", "PROBLEM", 247, 265], ["blindness", "PROBLEM", 270, 279], ["FIP", "PROBLEM", 335, 338], ["immunohistochemical staining", "TEST", 355, 383], ["coronavirus antigen within lesions", "PROBLEM", 388, 422], ["pyogranulomatous or granulomatous vasculitis", "PROBLEM", 440, 484], ["conjunctivitis", "OBSERVATION", 21, 35], ["mucopurulent", "OBSERVATION_MODIFIER", 37, 49], ["ocular discharge", "OBSERVATION", 50, 66], ["thickening", "OBSERVATION", 68, 78], ["hyperemia", "OBSERVATION_MODIFIER", 83, 92], ["uveitis", "OBSERVATION", 111, 118], ["anisocoria", "OBSERVATION", 136, 146], ["aqueous flare", "OBSERVATION", 148, 161], ["hypopyon", "OBSERVATION", 185, 193], ["hyphema", "OBSERVATION", 195, 202], ["chorioretinitis", "OBSERVATION", 204, 219], ["perivascular", "ANATOMY_MODIFIER", 221, 233], ["infiltrates", "OBSERVATION", 234, 245], ["retinal", "ANATOMY", 247, 254], ["detachment", "OBSERVATION", 255, 265], ["blindness", "OBSERVATION", 270, 279], ["FIP", "OBSERVATION", 335, 338], ["pyogranulomatous", "OBSERVATION_MODIFIER", 440, 456], ["granulomatous", "OBSERVATION_MODIFIER", 460, 473], ["vasculitis", "OBSERVATION", 474, 484]]], ["Because it can be difficult or impossible to safely obtain biopsy specimens from cats with FIP, antemortem diagnosis is often only suspected on the basis of history, signalment, and clinical and laboratory findings, and by ruling out other causes of disease.", [["biopsy specimens", "ANATOMY", 59, 75], ["FIP", "DISEASE", 91, 94], ["biopsy specimens", "CANCER", 59, 75], ["cats", "ORGANISM", 81, 85], ["cats", "SPECIES", 81, 85], ["biopsy specimens", "TEST", 59, 75], ["antemortem diagnosis", "TEST", 96, 116], ["disease", "PROBLEM", 250, 257], ["disease", "OBSERVATION", 250, 257]]], ["Provided it is correctly performed and interpreted, immunocytochemistry may be helpful.", [["immunocytochemistry", "TEST", 52, 71]]], ["Because the presence of the characteristic effusion is most helpful for antemortem diagnosis, efforts should be always made to identify and analyze any fluid that is present in body cavities.", [["body cavities", "ANATOMY", 177, 190], ["effusion", "DISEASE", 43, 51], ["body cavities", "MULTI-TISSUE_STRUCTURE", 177, 190], ["the characteristic effusion", "PROBLEM", 24, 51], ["antemortem diagnosis", "TEST", 72, 92], ["any fluid", "PROBLEM", 148, 157], ["characteristic", "OBSERVATION_MODIFIER", 28, 42], ["effusion", "OBSERVATION", 43, 51], ["fluid", "OBSERVATION", 152, 157]]], ["When owner funds are limited, laboratory analysis of effusion, rather than blood, may be the most economic diagnostic approach.", [["effusion", "ANATOMY", 53, 61], ["blood", "ANATOMY", 75, 80], ["effusion", "DISEASE", 53, 61], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["laboratory analysis", "TEST", 30, 49], ["effusion", "PROBLEM", 53, 61], ["blood", "TEST", 75, 80], ["effusion", "OBSERVATION", 53, 61]]], ["Unfortunately, the lack of a definitive noninvasive diagnostic assay for FIP and the extremely poor prognosis sometimes leads clinicians to perform large numbers of diagnostic tests in the hope that an answer will appear.", [["FIP", "DISEASE", 73, 76], ["FIP", "PROBLEM", 73, 76], ["diagnostic tests", "TEST", 165, 181]]], ["In other situations, the diagnosis of FIP is made too hastily, and euthanasia is performed without sufficient clinical and laboratory justification.Laboratory Abnormalities Complete Blood CountA mild, nonregenerative anemia is often present in cats with FIP, and sometimes severe anemia occurs, which is usually poorly regenerative or nonregenerative (Table 20 -1).", [["Blood", "ANATOMY", 182, 187], ["FIP", "DISEASE", 38, 41], ["anemia", "DISEASE", 217, 223], ["FIP", "DISEASE", 254, 257], ["anemia", "DISEASE", 280, 286], ["Blood", "ORGANISM_SUBSTANCE", 182, 187], ["cats", "ORGANISM", 244, 248], ["cats", "SPECIES", 244, 248], ["FIP", "PROBLEM", 38, 41], ["Laboratory Abnormalities", "TEST", 148, 172], ["Blood CountA", "TEST", 182, 194], ["nonregenerative anemia", "PROBLEM", 201, 223], ["FIP", "PROBLEM", 254, 257], ["sometimes severe anemia", "PROBLEM", 263, 286], ["FIP", "OBSERVATION", 38, 41], ["mild", "OBSERVATION_MODIFIER", 195, 199], ["nonregenerative", "OBSERVATION_MODIFIER", 201, 216], ["anemia", "OBSERVATION", 217, 223], ["FIP", "OBSERVATION", 254, 257], ["severe", "OBSERVATION_MODIFIER", 273, 279], ["anemia", "OBSERVATION", 280, 286], ["poorly regenerative", "OBSERVATION_MODIFIER", 312, 331]]], ["Microcytosis may be present.", [["Microcytosis", "DISEASE", 0, 12], ["Microcytosis", "PROBLEM", 0, 12], ["may be", "UNCERTAINTY", 13, 19]]], ["Examination of erythrocyte morphology occasionally reveals schistocytosis, mild normoblastosis, or agglutination.", [["erythrocyte", "ANATOMY", 15, 26], ["schistocytosis", "DISEASE", 59, 73], ["normoblastosis", "DISEASE", 80, 94], ["erythrocyte", "CELL", 15, 26], ["Examination of erythrocyte morphology", "TEST", 0, 37], ["schistocytosis", "PROBLEM", 59, 73], ["mild normoblastosis", "PROBLEM", 75, 94], ["agglutination", "PROBLEM", 99, 112], ["schistocytosis", "OBSERVATION", 59, 73], ["mild", "OBSERVATION_MODIFIER", 75, 79], ["normoblastosis", "OBSERVATION", 80, 94], ["agglutination", "OBSERVATION_MODIFIER", 99, 112]]], ["There may be a leukocytosis due to a neutrophilia and monocytosis, or leukopenia.", [["leukocytosis", "DISEASE", 15, 27], ["neutrophilia", "DISEASE", 37, 49], ["monocytosis", "DISEASE", 54, 65], ["leukopenia", "DISEASE", 70, 80], ["a leukocytosis", "PROBLEM", 13, 27], ["a neutrophilia", "PROBLEM", 35, 49], ["monocytosis", "PROBLEM", 54, 65], ["leukopenia", "PROBLEM", 70, 80], ["may be", "UNCERTAINTY", 6, 12], ["leukocytosis", "OBSERVATION", 15, 27], ["neutrophilia", "OBSERVATION", 37, 49], ["monocytosis", "OBSERVATION", 54, 65], ["leukopenia", "OBSERVATION", 70, 80]]], ["Lymphopenia occurs in more than 50% of affected cats, and eosinopenia is also common.", [["Lymphopenia", "DISEASE", 0, 11], ["eosinopenia", "DISEASE", 58, 69], ["cats", "ORGANISM", 48, 52], ["cats", "SPECIES", 48, 52], ["Lymphopenia", "PROBLEM", 0, 11], ["affected cats", "PROBLEM", 39, 52], ["eosinopenia", "PROBLEM", 58, 69]]], ["In some cats, a left shift and evidence of toxic neutrophils are seen.", [["neutrophils", "ANATOMY", 49, 60], ["cats", "ORGANISM", 8, 12], ["neutrophils", "CELL", 49, 60], ["toxic neutrophils", "CELL_TYPE", 43, 60], ["cats", "SPECIES", 8, 12], ["a left shift", "PROBLEM", 14, 26], ["toxic neutrophils", "PROBLEM", 43, 60], ["some", "OBSERVATION_MODIFIER", 3, 7], ["cats", "OBSERVATION", 8, 12], ["left", "ANATOMY_MODIFIER", 16, 20], ["shift", "OBSERVATION", 21, 26], ["evidence of", "UNCERTAINTY", 31, 42], ["toxic", "OBSERVATION_MODIFIER", 43, 48], ["neutrophils", "OBSERVATION", 49, 60]]], ["Mild to moderate thrombocytopenia is common in cats with noneffusive disease and may reflect the presence of disseminated intravascular coagulation or immune-mediated platelet destruction.", [["intravascular", "ANATOMY", 122, 135], ["platelet", "ANATOMY", 167, 175], ["thrombocytopenia", "DISEASE", 17, 33], ["noneffusive disease", "DISEASE", 57, 76], ["intravascular coagulation", "DISEASE", 122, 147], ["platelet destruction", "DISEASE", 167, 187], ["cats", "ORGANISM", 47, 51], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 122, 135], ["platelet", "CELL", 167, 175], ["Mild to moderate thrombocytopenia", "PROBLEM", 0, 33], ["noneffusive disease", "PROBLEM", 57, 76], ["disseminated intravascular coagulation", "PROBLEM", 109, 147], ["immune-mediated platelet destruction", "PROBLEM", 151, 187], ["moderate", "OBSERVATION_MODIFIER", 8, 16], ["thrombocytopenia", "OBSERVATION", 17, 33], ["common", "OBSERVATION_MODIFIER", 37, 43], ["noneffusive disease", "OBSERVATION", 57, 76], ["may reflect the presence of", "UNCERTAINTY", 81, 108], ["disseminated", "OBSERVATION_MODIFIER", 109, 121], ["intravascular coagulation", "OBSERVATION", 122, 147], ["platelet destruction", "OBSERVATION", 167, 187]]], ["However, thrombocytosis can also occur.Serum Biochemical TestsMany cats with FIP have hyperproteinemia due to hyperglobulinemia, which results from a polyclonal gammopathy ( Figure 20-6 ).", [["Serum", "ANATOMY", 39, 44], ["thrombocytosis", "DISEASE", 9, 23], ["FIP", "DISEASE", 77, 80], ["hyperproteinemia", "DISEASE", 86, 102], ["hyperglobulinemia", "DISEASE", 110, 127], ["gammopathy", "DISEASE", 161, 171], ["Serum", "ORGANISM_SUBSTANCE", 39, 44], ["cats", "ORGANISM", 67, 71], ["cats", "SPECIES", 67, 71], ["thrombocytosis", "PROBLEM", 9, 23], ["Serum Biochemical TestsMany cats", "TEST", 39, 71], ["FIP", "PROBLEM", 77, 80], ["hyperproteinemia", "PROBLEM", 86, 102], ["hyperglobulinemia", "PROBLEM", 110, 127], ["a polyclonal gammopathy", "PROBLEM", 148, 171], ["thrombocytosis", "OBSERVATION", 9, 23], ["hyperglobulinemia", "OBSERVATION", 110, 127], ["polyclonal gammopathy", "OBSERVATION", 150, 171]]], ["Rarely, a monoclonal gammopathy can occur.", [["monoclonal gammopathy", "DISEASE", 10, 31], ["a monoclonal gammopathy", "PROBLEM", 8, 31], ["monoclonal", "OBSERVATION_MODIFIER", 10, 20], ["gammopathy", "OBSERVATION", 21, 31]]], ["42 Total protein concentrations may be as high as 12 g/ dL (Table 20 -2).", [["Total protein concentrations", "TEST", 3, 31]]], ["20 In one study, hyperglobulinemia was present in 50% of cats with effusion and 70% of cats without effusion.", [["hyperglobulinemia", "DISEASE", 17, 34], ["effusion", "DISEASE", 67, 75], ["effusion", "DISEASE", 100, 108], ["cats", "ORGANISM", 57, 61], ["cats", "ORGANISM", 87, 91], ["one study", "TEST", 6, 15], ["hyperglobulinemia", "PROBLEM", 17, 34], ["effusion", "PROBLEM", 67, 75], ["effusion", "PROBLEM", 100, 108], ["hyperglobulinemia", "OBSERVATION", 17, 34], ["effusion", "OBSERVATION", 67, 75], ["without", "UNCERTAINTY", 92, 99], ["effusion", "OBSERVATION", 100, 108]]], ["43 Globulin concentration may decrease terminally, so cats with advanced disease may have protein concentrations that are within the reference range.", [["Globulin", "CHEMICAL", 3, 11], ["Globulin", "GENE_OR_GENE_PRODUCT", 3, 11], ["cats", "ORGANISM", 54, 58], ["Globulin concentration", "TREATMENT", 3, 25], ["advanced disease", "PROBLEM", 64, 80], ["protein concentrations", "PROBLEM", 90, 112]]], ["14 Hypoalbuminemia is often present because of liver involvement, leakage from damaged vessels, urinary loss in cats with glomerulonephritis, or inflammation (albumin is a negative acute-phase reactant protein).", [["liver", "ANATOMY", 47, 52], ["vessels", "ANATOMY", 87, 94], ["urinary", "ANATOMY", 96, 103], ["Hypoalbuminemia", "DISEASE", 3, 18], ["urinary loss", "DISEASE", 96, 108], ["glomerulonephritis", "DISEASE", 122, 140], ["inflammation", "DISEASE", 145, 157], ["liver", "ORGAN", 47, 52], ["vessels", "MULTI-TISSUE_STRUCTURE", 87, 94], ["urinary", "ORGANISM_SUBSTANCE", 96, 103], ["albumin", "GENE_OR_GENE_PRODUCT", 159, 166], ["albumin", "PROTEIN", 159, 166], ["negative acute-phase reactant protein", "PROTEIN", 172, 209], ["Hypoalbuminemia", "PROBLEM", 3, 18], ["liver involvement", "PROBLEM", 47, 64], ["leakage from damaged vessels", "PROBLEM", 66, 94], ["urinary loss in cats", "PROBLEM", 96, 116], ["glomerulonephritis", "PROBLEM", 122, 140], ["inflammation", "PROBLEM", 145, 157], ["albumin", "TEST", 159, 166], ["Hypoalbuminemia", "OBSERVATION", 3, 18], ["liver", "ANATOMY", 47, 52], ["involvement", "OBSERVATION", 53, 64], ["leakage", "OBSERVATION", 66, 73], ["vessels", "ANATOMY", 87, 94], ["urinary", "ANATOMY", 96, 103], ["loss", "OBSERVATION", 104, 108], ["glomerulonephritis", "OBSERVATION", 122, 140], ["inflammation", "OBSERVATION", 145, 157]]], ["Thus, the serum albumin:globulin ratio may be more useful than the globulin alone for diagnosis; ratios less than 0.8 are uncommon (but not impossible) in cats with FIP, so they help to rule out (but not to rule in) a diagnosis of FIP.", [["serum", "ANATOMY", 10, 15], ["FIP", "DISEASE", 165, 168], ["FIP", "DISEASE", 231, 234], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["albumin", "GENE_OR_GENE_PRODUCT", 16, 23], ["globulin", "GENE_OR_GENE_PRODUCT", 24, 32], ["globulin", "GENE_OR_GENE_PRODUCT", 67, 75], ["cats", "ORGANISM", 155, 159], ["globulin", "PROTEIN", 67, 75], ["cats", "SPECIES", 155, 159], ["the serum albumin", "TEST", 6, 23], ["globulin ratio", "TEST", 24, 38], ["the globulin", "TEST", 63, 75], ["ratios", "TEST", 97, 103], ["FIP", "PROBLEM", 165, 168], ["FIP", "PROBLEM", 231, 234], ["FIP", "OBSERVATION", 165, 168], ["FIP", "OBSERVATION", 231, 234]]], ["44, 45 Other variable findings include hyponatremia, hypokalemia, hypochloremia, hyperglycemia, azotemia, increased liver enzyme activities, hypocholesterolemia, and hyperbilirubinemia.", [["liver", "ANATOMY", 116, 121], ["hyponatremia", "DISEASE", 39, 51], ["hypokalemia", "DISEASE", 53, 64], ["hypochloremia", "DISEASE", 66, 79], ["hyperglycemia", "DISEASE", 81, 94], ["azotemia", "DISEASE", 96, 104], ["hypocholesterolemia", "DISEASE", 141, 160], ["hyperbilirubinemia", "DISEASE", 166, 184], ["liver", "ORGAN", 116, 121], ["hyponatremia", "PROBLEM", 39, 51], ["hypokalemia", "PROBLEM", 53, 64], ["hypochloremia", "PROBLEM", 66, 79], ["hyperglycemia", "PROBLEM", 81, 94], ["azotemia", "PROBLEM", 96, 104], ["increased liver enzyme activities", "PROBLEM", 106, 139], ["hypocholesterolemia", "PROBLEM", 141, 160], ["hyperbilirubinemia", "PROBLEM", 166, 184], ["hyponatremia", "OBSERVATION", 39, 51], ["hypokalemia", "OBSERVATION", 53, 64], ["hyperglycemia", "OBSERVATION", 81, 94], ["azotemia", "OBSERVATION", 96, 104], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["liver", "ANATOMY", 116, 121], ["enzyme activities", "OBSERVATION", 122, 139], ["hypocholesterolemia", "OBSERVATION", 141, 160], ["hyperbilirubinemia", "OBSERVATION", 166, 184]]], ["The cause of hyperbilirubinemia is not clear, but it may result from hemolysis, hepatic necrosis, and/or cholestasis.", [["hepatic", "ANATOMY", 80, 87], ["hyperbilirubinemia", "DISEASE", 13, 31], ["hemolysis", "DISEASE", 69, 78], ["hepatic necrosis", "DISEASE", 80, 96], ["cholestasis", "DISEASE", 105, 116], ["hepatic", "ORGAN", 80, 87], ["hyperbilirubinemia", "PROBLEM", 13, 31], ["hemolysis", "PROBLEM", 69, 78], ["hepatic necrosis", "PROBLEM", 80, 96], ["cholestasis", "PROBLEM", 105, 116], ["hyperbilirubinemia", "OBSERVATION", 13, 31], ["hemolysis", "OBSERVATION", 69, 78], ["hepatic", "ANATOMY", 80, 87], ["necrosis", "OBSERVATION", 88, 96], ["cholestasis", "OBSERVATION", 105, 116]]], ["Measurement of \u03b1 1 -acid glycoprotein (an acute phase protein) has been suggested for diagnosis, because serum concentrations often exceed 1500 \u00b5g/mL in cats with FIP.", [["serum", "ANATOMY", 105, 110], ["\u03b1 1 -acid", "CHEMICAL", 15, 24], ["FIP", "DISEASE", 163, 166], ["\u03b1 1 -acid glycoprotein", "GENE_OR_GENE_PRODUCT", 15, 37], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["cats", "ORGANISM", 153, 157], ["\u03b1 1 -acid glycoprotein", "PROTEIN", 15, 37], ["acute phase protein", "PROTEIN", 42, 61], ["Measurement", "TEST", 0, 11], ["an acute phase protein", "TEST", 39, 61], ["serum concentrations", "PROBLEM", 105, 125], ["FIP", "OBSERVATION", 163, 166]]], ["20, 46, 47 However, \u03b1 1 -acid glycoprotein concentrations also increase with other inflammatory diseases.", [["\u03b1 1 -acid", "CHEMICAL", 20, 29], ["\u03b1 1 -acid glycoprotein", "GENE_OR_GENE_PRODUCT", 20, 42], ["\u03b1 1 -acid glycoprotein", "PROTEIN", 20, 42], ["acid glycoprotein concentrations", "PROBLEM", 25, 57], ["other inflammatory diseases", "PROBLEM", 77, 104], ["increase", "OBSERVATION_MODIFIER", 63, 71], ["inflammatory diseases", "OBSERVATION", 83, 104]]], ["20 A BUrinalysisThe urinalysis in cats with FIP may be unremarkable or contain protein due to glomerular or tubular damage.", [["glomerular", "ANATOMY", 94, 104], ["tubular", "ANATOMY", 108, 115], ["FIP", "DISEASE", 44, 47], ["cats", "ORGANISM", 34, 38], ["glomerular", "TISSUE", 94, 104], ["tubular", "TISSUE", 108, 115], ["cats", "SPECIES", 34, 38], ["A BUrinalysisThe urinalysis in cats", "TEST", 3, 38], ["FIP", "TEST", 44, 47], ["protein", "PROBLEM", 79, 86], ["glomerular", "PROBLEM", 94, 104], ["tubular damage", "PROBLEM", 108, 122], ["unremarkable", "OBSERVATION", 55, 67], ["glomerular", "OBSERVATION", 94, 104], ["tubular damage", "OBSERVATION", 108, 122]]], ["Hematuria and, less commonly, pyuria and cylindruria may be present.", [["Hematuria", "DISEASE", 0, 9], ["pyuria", "DISEASE", 30, 36], ["cylindruria", "DISEASE", 41, 52], ["cylindruria", "CANCER", 41, 52], ["Hematuria", "PROBLEM", 0, 9], ["pyuria", "PROBLEM", 30, 36], ["cylindruria", "PROBLEM", 41, 52], ["less commonly", "OBSERVATION_MODIFIER", 15, 28], ["pyuria", "OBSERVATION", 30, 36], ["cylindruria", "OBSERVATION", 41, 52], ["may be", "UNCERTAINTY", 53, 59]]], ["Bilirubinuria may be detected in cats with liver injury.Coagulation ProfileIn addition to thrombocytopenia, abnormalities of coagulation in cats with FIP include prolonged prothrombin time and partial thromboplastin time as a result of severe liver injury, and increased fibrin degradation product or D-dimer concentrations.", [["liver", "ANATOMY", 43, 48], ["liver", "ANATOMY", 243, 248], ["Bilirubinuria", "DISEASE", 0, 13], ["liver injury", "DISEASE", 43, 55], ["thrombocytopenia", "DISEASE", 90, 106], ["abnormalities of coagulation", "DISEASE", 108, 136], ["FIP", "DISEASE", 150, 153], ["liver injury", "DISEASE", 243, 255], ["D-dimer", "CHEMICAL", 301, 308], ["cats", "ORGANISM", 33, 37], ["liver", "ORGAN", 43, 48], ["cats", "ORGANISM", 140, 144], ["prothrombin", "GENE_OR_GENE_PRODUCT", 172, 183], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 201, 215], ["liver", "ORGAN", 243, 248], ["fibrin", "GENE_OR_GENE_PRODUCT", 271, 277], ["D-dimer", "SIMPLE_CHEMICAL", 301, 308], ["prothrombin", "PROTEIN", 172, 183], ["fibrin", "PROTEIN", 271, 277], ["cats", "SPECIES", 33, 37], ["cats", "SPECIES", 140, 144], ["Bilirubinuria", "TEST", 0, 13], ["liver injury", "PROBLEM", 43, 55], ["Coagulation ProfileIn", "TEST", 56, 77], ["thrombocytopenia", "PROBLEM", 90, 106], ["abnormalities of coagulation in cats", "PROBLEM", 108, 144], ["FIP", "PROBLEM", 150, 153], ["prolonged prothrombin time", "PROBLEM", 162, 188], ["partial thromboplastin time", "PROBLEM", 193, 220], ["severe liver injury", "PROBLEM", 236, 255], ["increased fibrin degradation product", "PROBLEM", 261, 297], ["D-dimer concentrations", "PROBLEM", 301, 323], ["may be detected", "UNCERTAINTY", 14, 29], ["liver", "ANATOMY", 43, 48], ["injury", "OBSERVATION", 49, 55], ["thrombocytopenia", "OBSERVATION", 90, 106], ["partial thromboplastin", "OBSERVATION", 193, 215], ["severe", "OBSERVATION_MODIFIER", 236, 242], ["liver", "ANATOMY", 243, 248], ["injury", "OBSERVATION", 249, 255], ["increased", "OBSERVATION_MODIFIER", 261, 270], ["fibrin degradation", "OBSERVATION", 271, 289]]], ["15Analysis of Effusion FluidThe \"classic\" FIP effusion fluid is a high-protein (greater than 3.5 g/dL) exudate that contains a low number of nucleated cells (<5000 cells/\u00b5L), usually nondegenerate to mildly degenerate neutrophils and macrophages (Table 20-3) .", [["effusion fluid", "ANATOMY", 46, 60], ["exudate", "ANATOMY", 103, 110], ["nucleated cells", "ANATOMY", 141, 156], ["cells", "ANATOMY", 164, 169], ["\u00b5L", "ANATOMY", 170, 172], ["neutrophils", "ANATOMY", 218, 229], ["macrophages", "ANATOMY", 234, 245], ["FIP effusion", "DISEASE", 42, 54], ["nucleated cells", "CELL", 141, 156], ["cells", "CELL", 164, 169], ["neutrophils", "CELL", 218, 229], ["macrophages", "CELL", 234, 245], ["nucleated cells", "CELL_TYPE", 141, 156], ["neutrophils", "CELL_TYPE", 218, 229], ["macrophages", "CELL_TYPE", 234, 245], ["Effusion Fluid", "PROBLEM", 14, 28], ["The \"classic\" FIP effusion fluid", "PROBLEM", 28, 60], ["exudate", "PROBLEM", 103, 110], ["a low number of nucleated cells", "PROBLEM", 125, 156], ["cells/\u00b5L", "TEST", 164, 172], ["mildly degenerate neutrophils", "PROBLEM", 200, 229], ["macrophages", "TEST", 234, 245], ["Effusion", "OBSERVATION", 14, 22], ["Fluid", "OBSERVATION_MODIFIER", 23, 28], ["FIP", "OBSERVATION_MODIFIER", 42, 45], ["effusion", "OBSERVATION", 46, 54], ["fluid", "OBSERVATION_MODIFIER", 55, 60], ["exudate", "OBSERVATION", 103, 110], ["low number", "OBSERVATION_MODIFIER", 127, 137], ["nucleated cells", "OBSERVATION", 141, 156], ["mildly", "OBSERVATION_MODIFIER", 200, 206], ["degenerate neutrophils", "OBSERVATION", 207, 229], ["macrophages", "OBSERVATION_MODIFIER", 234, 245]]], ["Erythrophagocytosis, leukophagia, and reactive mesothelial cells can be observed in the fluid from some cats.", [["mesothelial cells", "ANATOMY", 47, 64], ["fluid", "ANATOMY", 88, 93], ["Erythrophagocytosis", "DISEASE", 0, 19], ["leukophagia", "DISEASE", 21, 32], ["mesothelial cells", "CELL", 47, 64], ["cats", "ORGANISM", 104, 108], ["reactive mesothelial cells", "CELL_TYPE", 38, 64], ["cats", "SPECIES", 104, 108], ["Erythrophagocytosis", "PROBLEM", 0, 19], ["leukophagia", "PROBLEM", 21, 32], ["reactive mesothelial cells", "PROBLEM", 38, 64], ["reactive", "OBSERVATION_MODIFIER", 38, 46], ["mesothelial cells", "OBSERVATION", 47, 64], ["fluid", "OBSERVATION", 88, 93]]], ["Grossly, the fluid has a yellow appearance and may contain fibrin clots.", [["fluid", "ANATOMY", 13, 18], ["fibrin clots", "ANATOMY", 59, 71], ["fluid", "ORGANISM_SUBSTANCE", 13, 18], ["fibrin", "GENE_OR_GENE_PRODUCT", 59, 65], ["clots", "ORGANISM_SUBSTANCE", 66, 71], ["a yellow appearance", "PROBLEM", 23, 42], ["fibrin clots", "PROBLEM", 59, 71], ["fluid", "OBSERVATION", 13, 18], ["yellow", "OBSERVATION_MODIFIER", 25, 31], ["may contain", "UNCERTAINTY", 47, 58], ["fibrin clots", "OBSERVATION", 59, 71]]], ["However, the total protein content and cell counts of abdominal and pleural effusions vary considerably, which complicates the diagnosis for some cats with effusive disease.", [["cell", "ANATOMY", 39, 43], ["abdominal", "ANATOMY", 54, 63], ["pleural effusions", "ANATOMY", 68, 85], ["pleural effusions", "DISEASE", 68, 85], ["effusive disease", "DISEASE", 156, 172], ["cell", "CELL", 39, 43], ["abdominal", "ORGANISM_SUBDIVISION", 54, 63], ["pleural effusions", "PATHOLOGICAL_FORMATION", 68, 85], ["cats", "ORGANISM", 146, 150], ["the total protein content", "TEST", 9, 34], ["cell counts", "TEST", 39, 50], ["abdominal and pleural effusions", "PROBLEM", 54, 85], ["some cats", "PROBLEM", 141, 150], ["effusive disease", "PROBLEM", 156, 172], ["cell counts", "OBSERVATION", 39, 50], ["abdominal", "ANATOMY", 54, 63], ["pleural", "ANATOMY", 68, 75], ["effusions", "OBSERVATION", 76, 85], ["effusive disease", "OBSERVATION", 156, 172]]], ["Very rarely, chylous effusions occur.", [["chylous effusions", "ANATOMY", 13, 30], ["chylous effusions", "DISEASE", 13, 30], ["chylous effusions", "PATHOLOGICAL_FORMATION", 13, 30], ["chylous effusions", "PROBLEM", 13, 30], ["chylous", "OBSERVATION_MODIFIER", 13, 20], ["effusions", "OBSERVATION", 21, 30]]], ["48 An effusion albumin/globulin ratio below 0.4 is suggestive of FIP.", [["FIP", "DISEASE", 65, 68], ["albumin", "GENE_OR_GENE_PRODUCT", 15, 22], ["globulin", "GENE_OR_GENE_PRODUCT", 23, 31], ["globulin", "PROTEIN", 23, 31], ["An effusion albumin/globulin ratio", "TEST", 3, 37], ["FIP", "PROBLEM", 65, 68], ["effusion", "OBSERVATION", 6, 14], ["suggestive of", "UNCERTAINTY", 51, 64], ["FIP", "OBSERVATION", 65, 68]]], ["49 The Rivalta test is a simple test that can differentiate between transudates and exudates.", [["exudates", "ANATOMY", 84, 92], ["exudates", "TISSUE", 84, 92], ["The Rivalta test", "TEST", 3, 19], ["a simple test", "TEST", 23, 36], ["transudates", "PROBLEM", 68, 79], ["exudates", "PROBLEM", 84, 92], ["transudates", "OBSERVATION", 68, 79], ["exudates", "OBSERVATION_MODIFIER", 84, 92]]], ["In this test, a drop of 98% glacial acetic acid is mixed with 7 to 8 mL of distilled water in a transparent 10-mL tube.", [["glacial acetic acid", "CHEMICAL", 28, 47], ["acetic acid", "CHEMICAL", 36, 47], ["acetic acid", "SIMPLE_CHEMICAL", 36, 47], ["tube", "TISSUE", 114, 118], ["this test", "TEST", 3, 12], ["a drop", "TEST", 14, 20], ["glacial acetic acid", "TEST", 28, 47], ["a transparent 10-mL tube", "TREATMENT", 94, 118], ["drop", "OBSERVATION_MODIFIER", 16, 20], ["tube", "OBSERVATION", 114, 118]]], ["A drop of effusion is then added to the tube, and if it dissipates in the solution, the test is negative.", [["tube", "ANATOMY", 40, 44], ["effusion", "DISEASE", 10, 18], ["tube", "TISSUE", 40, 44], ["A drop of effusion", "PROBLEM", 0, 18], ["the tube", "TREATMENT", 36, 44], ["the test", "TEST", 84, 92], ["drop", "OBSERVATION_MODIFIER", 2, 6], ["effusion", "OBSERVATION", 10, 18], ["tube", "OBSERVATION", 40, 44], ["negative", "OBSERVATION", 96, 104]]], ["If it retains its shape, stays attached to the surface, or moves slowly down in the solution, then the test is positive.", [["surface", "ANATOMY", 47, 54], ["surface", "CELLULAR_COMPONENT", 47, 54], ["the test", "TEST", 99, 107], ["shape", "OBSERVATION_MODIFIER", 18, 23], ["surface", "OBSERVATION_MODIFIER", 47, 54], ["positive", "OBSERVATION", 111, 119]]], ["20 In a study of cats with effusion, 35% of which had FIP and a conclusive Rivalta test, the positive predictive value of this test for the diagnosis of FIP was 58% (58% chance that a cat that tests positive truly has FIP), and the negative predictive value was 93% (93% chance that a cat that tests negative does not have FIP).", [["effusion", "DISEASE", 27, 35], ["FIP", "DISEASE", 54, 57], ["FIP", "DISEASE", 153, 156], ["FIP", "DISEASE", 323, 326], ["cats", "ORGANISM", 17, 21], ["cat", "ORGANISM", 184, 187], ["cat", "ORGANISM", 285, 288], ["FIP", "PROTEIN", 323, 326], ["cats", "SPECIES", 17, 21], ["a study", "TEST", 6, 13], ["effusion", "PROBLEM", 27, 35], ["FIP", "PROBLEM", 54, 57], ["a conclusive Rivalta test", "TEST", 62, 87], ["this test", "TEST", 122, 131], ["FIP", "TEST", 153, 156], ["a cat that tests", "TEST", 182, 198], ["a cat that tests", "TEST", 283, 299], ["effusion", "OBSERVATION", 27, 35]]], ["50 In younger cats, the positive predictive value of the test is higher, because diseases such as lymphoma and bacterial peritonitis are less common.", [["lymphoma", "ANATOMY", 98, 106], ["lymphoma", "DISEASE", 98, 106], ["peritonitis", "DISEASE", 121, 132], ["cats", "ORGANISM", 14, 18], ["lymphoma", "CANCER", 98, 106], ["cats", "SPECIES", 14, 18], ["the test", "TEST", 53, 61], ["diseases", "PROBLEM", 81, 89], ["lymphoma", "PROBLEM", 98, 106], ["bacterial peritonitis", "PROBLEM", 111, 132], ["lymphoma", "OBSERVATION", 98, 106], ["bacterial", "OBSERVATION_MODIFIER", 111, 120], ["peritonitis", "OBSERVATION", 121, 132]]], ["Positive test results indicate only the presence of an exudate, so cytologic examination of the fluid must still be performed.Cerebrospinal Fluid AnalysisThe cerebrospinal fluid (CSF) of cats with neurologic FIP often has increased protein content (30 to more than 1000 mg/dL, reference range less than 25 mg/dL) and increased total nucleated cell count (20 to 10,000 cells/\u00b5L), usually consisting of a mixed but predominantly neutrophilic cellular pleocytosis (Table 20 -4).", [["exudate", "ANATOMY", 55, 62], ["fluid", "ANATOMY", 96, 101], ["Cerebrospinal", "ANATOMY", 126, 139], ["cerebrospinal fluid", "ANATOMY", 158, 177], ["neurologic", "ANATOMY", 197, 207], ["nucleated cell", "ANATOMY", 333, 347], ["cells", "ANATOMY", 368, 373], ["cellular", "ANATOMY", 440, 448], ["FIP", "DISEASE", 208, 211], ["pleocytosis", "DISEASE", 449, 460], ["fluid", "ORGANISM_SUBSTANCE", 96, 101], ["Cerebrospinal", "ORGANISM_SUBSTANCE", 126, 139], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 158, 177], ["CSF", "ORGANISM_SUBSTANCE", 179, 182], ["cats", "ORGANISM", 187, 191], ["nucleated cell", "CELL", 333, 347], ["cells", "CELL", 368, 373], ["cellular", "CELL", 440, 448], ["cats", "SPECIES", 187, 191], ["an exudate", "PROBLEM", 52, 62], ["cytologic examination of the fluid", "TEST", 67, 101], ["Cerebrospinal Fluid Analysis", "TEST", 126, 154], ["The cerebrospinal fluid (CSF", "TEST", 154, 182], ["neurologic FIP", "PROBLEM", 197, 211], ["increased protein content", "PROBLEM", 222, 247], ["increased total nucleated cell count", "TEST", 317, 353], ["cells/\u00b5L", "TEST", 368, 376], ["a mixed but predominantly neutrophilic cellular pleocytosis", "PROBLEM", 401, 460], ["exudate", "OBSERVATION", 55, 62], ["fluid", "OBSERVATION", 96, 101], ["Fluid", "OBSERVATION", 140, 145], ["cerebrospinal", "ANATOMY", 158, 171], ["fluid", "OBSERVATION", 172, 177], ["nucleated cell count", "OBSERVATION", 333, 353], ["mixed", "OBSERVATION_MODIFIER", 403, 408], ["predominantly", "OBSERVATION_MODIFIER", 413, 426], ["neutrophilic cellular pleocytosis", "OBSERVATION", 427, 460]]], ["In some cats, protein content and leukocyte counts are normal.", [["leukocyte", "ANATOMY", 34, 43], ["cats", "ORGANISM", 8, 12], ["leukocyte", "CELL", 34, 43], ["cats", "SPECIES", 8, 12], ["protein content", "TEST", 14, 29], ["leukocyte counts", "TEST", 34, 50], ["protein content", "OBSERVATION", 14, 29], ["leukocyte counts", "OBSERVATION", 34, 50], ["normal", "OBSERVATION", 55, 61]]], ["51, 52Diagnostic Imaging Plain RadiographyPlain thoracic radiography may reveal pleural effusion, enlargement of the cardiac silhouette in cats with pericardial effusion, and pulmonary nodular or peribronchial infiltrates in cats with pyogranulomatous pneumonia (Figure 20-7) .", [["thoracic", "ANATOMY", 48, 56], ["pleural", "ANATOMY", 80, 87], ["cardiac", "ANATOMY", 117, 124], ["pericardial", "ANATOMY", 149, 160], ["pulmonary nodular", "ANATOMY", 175, 192], ["peribronchial infiltrates", "ANATOMY", 196, 221], ["pleural effusion", "DISEASE", 80, 96], ["enlargement of the cardiac silhouette", "DISEASE", 98, 135], ["pericardial effusion", "DISEASE", 149, 169], ["pneumonia", "DISEASE", 252, 261], ["pleural effusion", "PATHOLOGICAL_FORMATION", 80, 96], ["cardiac", "ORGAN", 117, 124], ["cats", "ORGANISM", 139, 143], ["pericardial", "PATHOLOGICAL_FORMATION", 149, 160], ["pulmonary nodular", "PATHOLOGICAL_FORMATION", 175, 192], ["peribronchial infiltrates", "PATHOLOGICAL_FORMATION", 196, 221], ["cats", "ORGANISM", 225, 229], ["cats", "SPECIES", 225, 229], ["52Diagnostic Imaging", "TEST", 4, 24], ["Plain Radiography", "TEST", 25, 42], ["Plain thoracic radiography", "TEST", 42, 68], ["pleural effusion", "PROBLEM", 80, 96], ["enlargement of the cardiac silhouette in cats", "PROBLEM", 98, 143], ["pericardial effusion", "PROBLEM", 149, 169], ["pulmonary nodular", "PROBLEM", 175, 192], ["peribronchial infiltrates in cats", "PROBLEM", 196, 229], ["pyogranulomatous pneumonia", "PROBLEM", 235, 261], ["thoracic", "ANATOMY", 48, 56], ["pleural", "ANATOMY", 80, 87], ["effusion", "OBSERVATION", 88, 96], ["enlargement", "OBSERVATION", 98, 109], ["cardiac", "ANATOMY", 117, 124], ["silhouette", "ANATOMY_MODIFIER", 125, 135], ["cats", "OBSERVATION_MODIFIER", 139, 143], ["pericardial", "ANATOMY", 149, 160], ["effusion", "OBSERVATION", 161, 169], ["pulmonary", "ANATOMY", 175, 184], ["nodular", "OBSERVATION_MODIFIER", 185, 192], ["peribronchial", "ANATOMY", 196, 209], ["infiltrates", "OBSERVATION", 210, 221], ["pyogranulomatous", "OBSERVATION_MODIFIER", 235, 251], ["pneumonia", "OBSERVATION", 252, 261]]], ["Abdominal radiographs may show loss of peritoneal or retroperitoneal detail due to peritoneal effusion, hepatomegaly, splenomegaly, renomegaly, or mass lesions associated with the gastrointestinal tract or abdominal lymph nodes.Sonographic FindingsAbdominal ultrasound findings in FIP include the presence of anechoic or mildly echogenic peritoneal fluid; hyperechogenicity and \"clumping\" of the mesentery; enlarged and hypoechoic abdominal lymph nodes (Figure 20-8, A) ; enlargement and diffuse or focal hypoechogenicity of the liver and spleen; 53 renal asymmetry with increased cortical echogenicity, hypoechoic nodules, subcapsular fluid accumulation, or loss of corticomedullary distinction (see Figure 20-8, B) ; and/or thickening of all intestinal wall layers or intestinal mass lesions.", [["Abdominal", "ANATOMY", 0, 9], ["peritoneal", "ANATOMY", 39, 49], ["retroperitoneal", "ANATOMY", 53, 68], ["peritoneal", "ANATOMY", 83, 93], ["renomegaly", "ANATOMY", 132, 142], ["mass lesions", "ANATOMY", 147, 159], ["gastrointestinal tract", "ANATOMY", 180, 202], ["abdominal lymph nodes", "ANATOMY", 206, 227], ["Abdominal", "ANATOMY", 248, 257], ["peritoneal fluid", "ANATOMY", 338, 354], ["mesentery", "ANATOMY", 396, 405], ["hypoechoic abdominal lymph nodes", "ANATOMY", 420, 452], ["liver", "ANATOMY", 529, 534], ["spleen", "ANATOMY", 539, 545], ["renal", "ANATOMY", 550, 555], ["cortical", "ANATOMY", 581, 589], ["hypoechoic nodules", "ANATOMY", 604, 622], ["subcapsular fluid", "ANATOMY", 624, 641], ["corticomedullary", "ANATOMY", 667, 683], ["intestinal wall layers", "ANATOMY", 744, 766], ["intestinal mass lesions", "ANATOMY", 770, 793], ["loss of peritoneal or retroperitoneal detail", "DISEASE", 31, 75], ["peritoneal effusion", "DISEASE", 83, 102], ["hepatomegaly", "DISEASE", 104, 116], ["splenomegaly", "DISEASE", 118, 130], ["renomegaly", "DISEASE", 132, 142], ["FIP", "DISEASE", 281, 284], ["hyperechogenicity", "DISEASE", 356, 373], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 39, 49], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 83, 93], ["lesions", "PATHOLOGICAL_FORMATION", 152, 159], ["gastrointestinal tract", "ORGAN", 180, 202], ["abdominal lymph nodes", "MULTI-TISSUE_STRUCTURE", 206, 227], ["peritoneal fluid", "ORGANISM_SUBSTANCE", 338, 354], ["mesentery", "ORGAN", 396, 405], ["abdominal lymph nodes", "MULTI-TISSUE_STRUCTURE", 431, 452], ["liver", "ORGAN", 529, 534], ["spleen", "ORGAN", 539, 545], ["renal", "ORGAN", 550, 555], ["cortical echogenicity", "PATHOLOGICAL_FORMATION", 581, 602], ["hypoechoic nodules", "PATHOLOGICAL_FORMATION", 604, 622], ["intestinal wall layers", "TISSUE", 744, 766], ["intestinal mass lesions", "CANCER", 770, 793], ["Abdominal radiographs", "TEST", 0, 21], ["loss of peritoneal or retroperitoneal detail", "PROBLEM", 31, 75], ["peritoneal effusion", "PROBLEM", 83, 102], ["hepatomegaly", "PROBLEM", 104, 116], ["splenomegaly", "PROBLEM", 118, 130], ["renomegaly", "PROBLEM", 132, 142], ["mass lesions", "PROBLEM", 147, 159], ["the gastrointestinal tract", "PROBLEM", 176, 202], ["abdominal lymph nodes", "PROBLEM", 206, 227], ["Abdominal ultrasound", "TEST", 248, 268], ["FIP", "PROBLEM", 281, 284], ["anechoic or mildly echogenic peritoneal fluid", "PROBLEM", 309, 354], ["hyperechogenicity", "PROBLEM", 356, 373], ["\"clumping\" of the mesentery", "PROBLEM", 378, 405], ["enlarged and hypoechoic abdominal lymph nodes", "PROBLEM", 407, 452], ["Figure", "TEST", 454, 460], ["enlargement and diffuse or focal hypoechogenicity of the liver and spleen", "PROBLEM", 472, 545], ["53 renal asymmetry", "PROBLEM", 547, 565], ["increased cortical echogenicity", "PROBLEM", 571, 602], ["hypoechoic nodules", "PROBLEM", 604, 622], ["subcapsular fluid accumulation", "PROBLEM", 624, 654], ["loss of corticomedullary distinction", "PROBLEM", 659, 695], ["thickening of all intestinal wall layers", "PROBLEM", 726, 766], ["intestinal mass lesions", "PROBLEM", 770, 793], ["loss", "OBSERVATION_MODIFIER", 31, 35], ["peritoneal", "ANATOMY", 39, 49], ["retroperitoneal", "ANATOMY", 53, 68], ["peritoneal", "ANATOMY", 83, 93], ["effusion", "OBSERVATION", 94, 102], ["hepatomegaly", "OBSERVATION", 104, 116], ["splenomegaly", "OBSERVATION", 118, 130], ["mass", "OBSERVATION", 147, 151], ["gastrointestinal tract", "ANATOMY", 180, 202], ["abdominal", "ANATOMY", 206, 215], ["lymph nodes", "OBSERVATION", 216, 227], ["Abdominal", "ANATOMY", 248, 257], ["FIP", "OBSERVATION", 281, 284], ["anechoic", "OBSERVATION_MODIFIER", 309, 317], ["mildly", "OBSERVATION_MODIFIER", 321, 327], ["echogenic", "OBSERVATION_MODIFIER", 328, 337], ["peritoneal", "ANATOMY", 338, 348], ["fluid", "OBSERVATION", 349, 354], ["hyperechogenicity", "OBSERVATION", 356, 373], ["clumping", "OBSERVATION_MODIFIER", 379, 387], ["mesentery", "ANATOMY", 396, 405], ["enlarged", "OBSERVATION_MODIFIER", 407, 415], ["hypoechoic", "OBSERVATION_MODIFIER", 420, 430], ["abdominal", "ANATOMY", 431, 440], ["lymph nodes", "OBSERVATION", 441, 452], ["enlargement", "OBSERVATION", 472, 483], ["diffuse", "OBSERVATION_MODIFIER", 488, 495], ["focal", "OBSERVATION_MODIFIER", 499, 504], ["hypoechogenicity", "OBSERVATION", 505, 521], ["liver", "ANATOMY", 529, 534], ["spleen", "ANATOMY", 539, 545], ["renal", "ANATOMY", 550, 555], ["asymmetry", "OBSERVATION", 556, 565], ["increased", "OBSERVATION_MODIFIER", 571, 580], ["cortical", "OBSERVATION_MODIFIER", 581, 589], ["echogenicity", "OBSERVATION_MODIFIER", 590, 602], ["hypoechoic", "OBSERVATION_MODIFIER", 604, 614], ["nodules", "OBSERVATION", 615, 622], ["subcapsular", "ANATOMY_MODIFIER", 624, 635], ["fluid accumulation", "OBSERVATION", 636, 654], ["loss", "OBSERVATION_MODIFIER", 659, 663], ["corticomedullary distinction", "OBSERVATION", 667, 695], ["thickening", "OBSERVATION", 726, 736], ["all", "ANATOMY_MODIFIER", 740, 743], ["intestinal", "ANATOMY", 744, 754], ["wall", "ANATOMY_MODIFIER", 755, 759], ["layers", "ANATOMY_MODIFIER", 760, 766], ["intestinal", "ANATOMY", 770, 780], ["mass", "OBSERVATION", 781, 785]]], ["Pleural effusion or comet-tail artifacts (due to pulmonary infiltrates) may be seen through the diaphragm.Magnetic Resonance Imaging of the Central Nervous SystemFindings on MRI that suggest FIP consist of ventricular dilatation and variable contrast enhancement of the periventricular regions, choroid, and meninges.", [["Pleural", "ANATOMY", 0, 7], ["pulmonary infiltrates", "ANATOMY", 49, 70], ["diaphragm", "ANATOMY", 96, 105], ["ventricular", "ANATOMY", 206, 217], ["periventricular regions", "ANATOMY", 270, 293], ["choroid", "ANATOMY", 295, 302], ["meninges", "ANATOMY", 308, 316], ["Pleural effusion", "DISEASE", 0, 16], ["FIP", "DISEASE", 191, 194], ["ventricular dilatation", "DISEASE", 206, 228], ["Pleural", "PATHOLOGICAL_FORMATION", 0, 7], ["pulmonary", "ORGAN", 49, 58], ["diaphragm", "ORGAN", 96, 105], ["ventricular", "MULTI-TISSUE_STRUCTURE", 206, 217], ["periventricular regions", "MULTI-TISSUE_STRUCTURE", 270, 293], ["choroid", "MULTI-TISSUE_STRUCTURE", 295, 302], ["meninges", "ORGAN", 308, 316], ["Pleural effusion", "PROBLEM", 0, 16], ["comet-tail artifacts", "PROBLEM", 20, 40], ["pulmonary infiltrates", "PROBLEM", 49, 70], ["Magnetic Resonance Imaging", "TEST", 106, 132], ["MRI", "TEST", 174, 177], ["FIP", "PROBLEM", 191, 194], ["ventricular dilatation", "PROBLEM", 206, 228], ["variable contrast enhancement of the periventricular regions, choroid, and meninges", "PROBLEM", 233, 316], ["effusion", "OBSERVATION", 8, 16], ["comet", "OBSERVATION", 20, 25], ["tail artifacts", "OBSERVATION", 26, 40], ["pulmonary", "ANATOMY", 49, 58], ["infiltrates", "OBSERVATION", 59, 70], ["diaphragm", "ANATOMY", 96, 105], ["Central", "ANATOMY_MODIFIER", 140, 147], ["Nervous", "ANATOMY", 148, 155], ["FIP", "OBSERVATION", 191, 194], ["ventricular", "ANATOMY", 206, 217], ["dilatation", "OBSERVATION", 218, 228], ["variable", "OBSERVATION_MODIFIER", 233, 241], ["contrast enhancement", "OBSERVATION", 242, 262], ["periventricular", "ANATOMY_MODIFIER", 270, 285], ["regions", "ANATOMY_MODIFIER", 286, 293], ["choroid", "ANATOMY", 295, 302], ["meninges", "ANATOMY", 308, 316]]], ["In some cats, MRI findings are unremarkable.Microbiologic Tests Serologic DiagnosisDetection of antibodies to FCoV can be performed using immunofluorescent antibody testing, ELISA, or virus neutralization.", [["cats", "ORGANISM", 8, 12], ["antibodies", "PROTEIN", 96, 106], ["FCoV", "PROTEIN", 110, 114], ["cats", "SPECIES", 8, 12], ["FCoV", "SPECIES", 110, 114], ["MRI findings", "TEST", 14, 26], ["Microbiologic Tests", "TEST", 44, 63], ["Serologic DiagnosisDetection", "TEST", 64, 92], ["antibodies", "TEST", 96, 106], ["FCoV", "TEST", 110, 114], ["immunofluorescent antibody testing", "TEST", 138, 172], ["ELISA", "TEST", 174, 179], ["virus neutralization", "PROBLEM", 184, 204], ["unremarkable", "OBSERVATION", 31, 43]]], ["54 The methods used, as well as the titers themselves, vary considerably between laboratories.", [["The methods", "TREATMENT", 3, 14]]], ["For example, some laboratories use related coronaviruses as a source of antigen for the test, rather than FCoV.", [["coronaviruses", "ORGANISM", 43, 56], ["coronaviruses", "PROBLEM", 43, 56], ["the test", "TEST", 84, 92]]], ["15 Use of a reliable laboratory that reports quantitative titers (to the endpoint dilution, as well as down to 1:100) is critical.", [["quantitative titers", "TEST", 45, 64], ["the endpoint dilution", "TEST", 69, 90]]], ["Even when performed correctly, a positive FCoV antibody titer is not diagnostic for FIP, because cats that have been exposed to avirulent FCoV strains or even other related coronaviruses are also seropositive.", [["FIP", "DISEASE", 84, 87], ["FCoV", "GENE_OR_GENE_PRODUCT", 42, 46], ["cats", "ORGANISM", 97, 101], ["FCoV strains", "ORGANISM", 138, 150], ["coronaviruses", "ORGANISM", 173, 186], ["FCoV antibody", "PROTEIN", 42, 55], ["cats", "SPECIES", 97, 101], ["FCoV", "SPECIES", 42, 46], ["FCoV", "SPECIES", 138, 142], ["a positive FCoV antibody titer", "TEST", 31, 61], ["FIP", "PROBLEM", 84, 87], ["avirulent FCoV strains", "PROBLEM", 128, 150], ["other related coronaviruses", "PROBLEM", 159, 186], ["seropositive", "PROBLEM", 196, 208]]], ["Therefore, serology is a \"coronavirus antibody test\" and not an \"FIP test.\"", [["serology", "TEST", 11, 19], ["a \"coronavirus antibody test", "TEST", 23, 51], ["an \"FIP test", "TEST", 61, 73]]], ["It has been suggested that more cats have been killed as a result of misinterpretation of FCoV antibody tests than by the disease itself.", [["cats", "ORGANISM", 32, 36], ["FCoV antibody", "GENE_OR_GENE_PRODUCT", 90, 103], ["FCoV antibody", "PROTEIN", 90, 103], ["FCoV antibody tests", "TEST", 90, 109], ["the disease itself", "PROBLEM", 118, 136], ["disease", "OBSERVATION", 122, 129]]], ["20 Certainly a diagnosis of FIP should never be made based on the presence of nonspecific clinical or laboratory abnormalities such as fever or leukocytosis and a positive coronavirus antibody test.", [["FIP", "DISEASE", 28, 31], ["fever", "DISEASE", 135, 140], ["leukocytosis", "DISEASE", 144, 156], ["FIP", "ORGANISM", 28, 31], ["FIP", "PROBLEM", 28, 31], ["nonspecific clinical or laboratory abnormalities", "PROBLEM", 78, 126], ["fever", "PROBLEM", 135, 140], ["leukocytosis", "PROBLEM", 144, 156], ["a positive coronavirus antibody test", "PROBLEM", 161, 197], ["FIP", "OBSERVATION", 28, 31], ["leukocytosis", "OBSERVATION", 144, 156], ["coronavirus antibody", "OBSERVATION", 172, 192]]], ["Occasionally (up to 10% of the time), cats with advanced disease are seronegative, because of failure of antibody production with severe immunosuppression, or the complexing of antibody by the large quantities of virus present.", [["cats", "ORGANISM", 38, 42], ["cats", "SPECIES", 38, 42], ["advanced disease", "PROBLEM", 48, 64], ["seronegative", "PROBLEM", 69, 81], ["failure of antibody production", "PROBLEM", 94, 124], ["severe immunosuppression", "PROBLEM", 130, 154], ["the complexing of antibody", "PROBLEM", 159, 185], ["virus", "PROBLEM", 213, 218], ["severe", "OBSERVATION_MODIFIER", 130, 136], ["immunosuppression", "OBSERVATION", 137, 154], ["large", "OBSERVATION_MODIFIER", 193, 198], ["virus", "OBSERVATION", 213, 218]]], ["In one study, titers of 1:1600 or higher were highly suggestive (94% chance) of FIP in the presence of compatible clinical signs.", [["FIP", "DISEASE", 80, 83], ["one study", "TEST", 3, 12], ["titers", "TEST", 14, 20], ["FIP", "PROBLEM", 80, 83], ["FIP", "OBSERVATION", 80, 83]]], ["44 In addition, strong positive titers (e.g., \u2265 1:6400) in cats with consistent signs and laboratory abnormalities support a diagnosis of FIP if a cat resides in a household that contains only one or two cats, because cats often become seronegative within a few months once they are removed from households that contain large numbers of cats.Microbiologic Tests Serologic DiagnosisOther body fluids can also be analyzed for antibodies to FCoV.", [["body fluids", "ANATOMY", 387, 398], ["FIP", "DISEASE", 138, 141], ["cats", "ORGANISM", 59, 63], ["cat", "ORGANISM", 147, 150], ["cats", "ORGANISM", 204, 208], ["cats", "ORGANISM", 218, 222], ["cats", "ORGANISM", 337, 341], ["FCoV", "GENE_OR_GENE_PRODUCT", 438, 442], ["antibodies", "PROTEIN", 424, 434], ["FCoV", "PROTEIN", 438, 442], ["cats", "SPECIES", 59, 63], ["cats", "SPECIES", 204, 208], ["cats", "SPECIES", 218, 222], ["strong positive titers", "PROBLEM", 16, 38], ["laboratory abnormalities", "PROBLEM", 90, 114], ["FIP", "PROBLEM", 138, 141], ["Microbiologic Tests", "TEST", 342, 361], ["Serologic DiagnosisOther body fluids", "TREATMENT", 362, 398], ["FIP", "OBSERVATION", 138, 141], ["large", "OBSERVATION_MODIFIER", 320, 325], ["numbers", "OBSERVATION_MODIFIER", 326, 333]]], ["In one study, positive antibody titers in effusion had a positive predictive value of 90% and a negative predictive value of 79%, but the magnitude of the titer did not correlate with the diagnosis of FIP.", [["effusion", "DISEASE", 42, 50], ["FIP", "DISEASE", 201, 204], ["one study", "TEST", 3, 12], ["positive antibody titers in effusion", "PROBLEM", 14, 50], ["FIP", "PROBLEM", 201, 204], ["antibody titers", "OBSERVATION", 23, 38], ["effusion", "OBSERVATION", 42, 50], ["FIP", "OBSERVATION", 201, 204]]], ["44 The presence of anti-FCoV antibody in the CSF correlated well with a diagnosis of FIP in one study, 52 but not in another study.", [["FIP", "DISEASE", 85, 88], ["anti-FCoV antibody", "GENE_OR_GENE_PRODUCT", 19, 37], ["CSF", "GENE_OR_GENE_PRODUCT", 45, 48], ["anti-FCoV antibody", "PROTEIN", 19, 37], ["CSF", "PROTEIN", 45, 48], ["anti-FCoV antibody in the CSF", "PROBLEM", 19, 48], ["FIP", "PROBLEM", 85, 88], ["one study", "TEST", 92, 101], ["another study", "TEST", 117, 130], ["anti-FCoV antibody", "OBSERVATION", 19, 37], ["FIP", "OBSERVATION", 85, 88]]], ["51 In addition, the presence of sufficient quantities of CSF for serology are frequently not available.Molecular Diagnosis Using the Polymerase Chain ReactionReal-time reverse transcriptase-PCR (RT-PCR) assays have been developed for detection of FCoV, but these do not differentiate between virulent and avirulent strains.", [["CSF", "GENE_OR_GENE_PRODUCT", 57, 60], ["FCoV", "GENE_OR_GENE_PRODUCT", 247, 251], ["CSF", "PROTEIN", 57, 60], ["reverse transcriptase", "PROTEIN", 168, 189], ["FCoV", "SPECIES", 247, 251], ["CSF for serology", "TEST", 57, 73], ["the Polymerase Chain ReactionReal", "TREATMENT", 129, 162], ["transcriptase", "TEST", 176, 189], ["PCR (RT-PCR) assays", "TEST", 190, 209], ["FCoV", "PROBLEM", 247, 251], ["virulent and avirulent strains", "PROBLEM", 292, 322], ["sufficient", "OBSERVATION_MODIFIER", 32, 42], ["quantities", "OBSERVATION_MODIFIER", 43, 53], ["FCoV", "OBSERVATION", 247, 251], ["avirulent strains", "OBSERVATION", 305, 322]]], ["In addition, avirulent strains can be found in the blood and tissues of cats that do not have FIP, 21Immunostaining of FCoV AntigenFCoV antigen can be detected in macrophages with immunocytochemistry or immunohistochemistry (Figure 20Pathologic Findings Gross Pathologic FindingsAt necropsy, gross findings in cats with FIP include variable quantities of pleural, pericardial, and peritoneal effusion ( Figure 20-10, A) .", [["blood", "ANATOMY", 51, 56], ["tissues", "ANATOMY", 61, 68], ["macrophages", "ANATOMY", 163, 174], ["pleural", "ANATOMY", 355, 362], ["pericardial", "ANATOMY", 364, 375], ["peritoneal effusion", "ANATOMY", 381, 400], ["FIP", "DISEASE", 320, 323], ["pleural, pericardial, and peritoneal effusion", "DISEASE", 355, 400], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["tissues", "TISSUE", 61, 68], ["cats", "ORGANISM", 72, 76], ["FCoV AntigenFCoV antigen", "GENE_OR_GENE_PRODUCT", 119, 143], ["macrophages", "CELL", 163, 174], ["cats", "ORGANISM", 310, 314], ["pleural", "MULTI-TISSUE_STRUCTURE", 355, 362], ["pericardial", "MULTI-TISSUE_STRUCTURE", 364, 375], ["peritoneal effusion", "CANCER", 381, 400], ["FCoV AntigenFCoV antigen", "PROTEIN", 119, 143], ["macrophages", "CELL_TYPE", 163, 174], ["cats", "SPECIES", 72, 76], ["cats", "SPECIES", 310, 314], ["FCoV", "SPECIES", 119, 123], ["avirulent strains", "PROBLEM", 13, 30], ["the blood and tissues of cats", "PROBLEM", 47, 76], ["FIP", "PROBLEM", 94, 97], ["FCoV AntigenFCoV antigen", "TEST", 119, 143], ["immunocytochemistry", "TEST", 180, 199], ["immunohistochemistry", "TEST", 203, 223], ["FIP", "PROBLEM", 320, 323], ["pleural, pericardial, and peritoneal effusion", "PROBLEM", 355, 400], ["avirulent strains", "OBSERVATION", 13, 30], ["pleural", "ANATOMY", 355, 362], ["pericardial", "ANATOMY", 364, 375], ["peritoneal", "ANATOMY", 381, 391], ["effusion", "OBSERVATION", 392, 400]]], ["Fibrin adhesions may be present and the mesentery may be clumped.", [["mesentery", "ANATOMY", 40, 49], ["Fibrin", "GENE_OR_GENE_PRODUCT", 0, 6], ["mesentery", "ORGAN", 40, 49], ["Fibrin adhesions", "PROBLEM", 0, 16], ["adhesions", "OBSERVATION", 7, 16], ["may be", "UNCERTAINTY", 17, 23], ["mesentery", "ANATOMY", 40, 49], ["may be", "UNCERTAINTY", 50, 56], ["clumped", "OBSERVATION", 57, 64]]], ["Abdominal organs may be enlarged or irregular.", [["Abdominal organs", "ANATOMY", 0, 16], ["organs", "ORGAN", 10, 16], ["enlarged", "PROBLEM", 24, 32], ["irregular", "PROBLEM", 36, 45], ["organs", "ANATOMY", 10, 16], ["may be", "UNCERTAINTY", 17, 23], ["enlarged", "OBSERVATION", 24, 32], ["irregular", "OBSERVATION_MODIFIER", 36, 45]]], ["Granulomas appear as variably sized multifocal white, cream, tan, or yellow nodular lesions on serosal surfaces and within the parenchyma of organs such as the lungs, spleen, kidneys, pancreas, and liver (see Figure 20-10, B) .", [["Granulomas", "ANATOMY", 0, 10], ["tan", "ANATOMY", 61, 64], ["yellow nodular lesions", "ANATOMY", 69, 91], ["serosal surfaces", "ANATOMY", 95, 111], ["parenchyma", "ANATOMY", 127, 137], ["organs", "ANATOMY", 141, 147], ["lungs", "ANATOMY", 160, 165], ["spleen", "ANATOMY", 167, 173], ["kidneys", "ANATOMY", 175, 182], ["pancreas", "ANATOMY", 184, 192], ["liver", "ANATOMY", 198, 203], ["Granulomas", "DISEASE", 0, 10], ["nodular lesions", "PATHOLOGICAL_FORMATION", 76, 91], ["serosal surfaces", "TISSUE", 95, 111], ["parenchyma", "TISSUE", 127, 137], ["organs", "ORGAN", 141, 147], ["lungs", "ORGAN", 160, 165], ["spleen", "ORGAN", 167, 173], ["kidneys", "ORGAN", 175, 182], ["pancreas", "ORGAN", 184, 192], ["liver", "ORGAN", 198, 203], ["Granulomas", "PROBLEM", 0, 10], ["variably sized multifocal white, cream, tan, or yellow nodular lesions on serosal surfaces", "PROBLEM", 21, 111], ["variably", "OBSERVATION_MODIFIER", 21, 29], ["sized", "OBSERVATION_MODIFIER", 30, 35], ["multifocal", "OBSERVATION_MODIFIER", 36, 46], ["white", "OBSERVATION_MODIFIER", 47, 52], ["cream", "OBSERVATION_MODIFIER", 54, 59], ["tan", "OBSERVATION_MODIFIER", 61, 64], ["yellow", "OBSERVATION_MODIFIER", 69, 75], ["nodular", "OBSERVATION_MODIFIER", 76, 83], ["lesions", "OBSERVATION", 84, 91], ["serosal surfaces", "OBSERVATION_MODIFIER", 95, 111], ["parenchyma", "ANATOMY_MODIFIER", 127, 137], ["organs", "ANATOMY", 141, 147], ["lungs", "ANATOMY", 160, 165], ["spleen", "ANATOMY", 167, 173], ["kidneys", "ANATOMY", 175, 182], ["pancreas", "ANATOMY", 184, 192], ["liver", "ANATOMY", 198, 203]]], ["Lesions have also been described within the nasal cavity and sinuses.", [["nasal cavity", "ANATOMY", 44, 56], ["sinuses", "ANATOMY", 61, 68], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 44, 56], ["sinuses", "ORGAN", 61, 68], ["Lesions", "PROBLEM", 0, 7], ["nasal cavity", "ANATOMY", 44, 56], ["sinuses", "ANATOMY", 61, 68]]], ["Pyogranulomas may be visible grossly as miliary lesions, or they may be several centimeters in diameter.", [["Pyogranulomas", "ANATOMY", 0, 13], ["miliary lesions", "ANATOMY", 40, 55], ["Pyogranulomas", "DISEASE", 0, 13], ["miliary lesions", "PATHOLOGICAL_FORMATION", 40, 55], ["Pyogranulomas", "PROBLEM", 0, 13], ["miliary lesions", "PROBLEM", 40, 55], ["may be", "UNCERTAINTY", 14, 20], ["visible", "OBSERVATION_MODIFIER", 21, 28], ["grossly", "OBSERVATION_MODIFIER", 29, 36], ["miliary", "OBSERVATION_MODIFIER", 40, 47], ["lesions", "OBSERVATION", 48, 55], ["may be", "UNCERTAINTY", 65, 71], ["several", "OBSERVATION_MODIFIER", 72, 79], ["centimeters", "OBSERVATION_MODIFIER", 80, 91], ["diameter", "OBSERVATION_MODIFIER", 95, 103]]], ["Thoracic and/or abdominal lymphadenomegaly is a common finding.", [["Thoracic", "ANATOMY", 0, 8], ["abdominal", "ANATOMY", 16, 25], ["Thoracic and/or abdominal lymphadenomegaly", "DISEASE", 0, 42], ["Thoracic", "MULTI-TISSUE_STRUCTURE", 0, 8], ["Thoracic and/or abdominal lymphadenomegaly", "PROBLEM", 0, 42], ["abdominal", "ANATOMY", 16, 25], ["lymphadenomegaly", "OBSERVATION", 26, 42]]], ["Diffuse or focal thickening of the intestinal wall or intestinal mass lesions may be present.", [["intestinal wall", "ANATOMY", 35, 50], ["intestinal mass lesions", "ANATOMY", 54, 77], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 35, 50], ["intestinal mass lesions", "PATHOLOGICAL_FORMATION", 54, 77], ["Diffuse or focal thickening of the intestinal wall", "PROBLEM", 0, 50], ["intestinal mass lesions", "PROBLEM", 54, 77], ["focal", "OBSERVATION_MODIFIER", 11, 16], ["thickening", "OBSERVATION", 17, 27], ["intestinal", "ANATOMY", 35, 45], ["wall", "ANATOMY_MODIFIER", 46, 50], ["intestinal", "ANATOMY", 54, 64], ["mass", "OBSERVATION", 65, 69], ["may be", "UNCERTAINTY", 78, 84]]], ["Examination of the brain can reveal fibrinous exudate in association with the meninges, with or without ventricular dilation and hydrocephalus (see Figure 20-4) .", [["brain", "ANATOMY", 19, 24], ["fibrinous exudate", "ANATOMY", 36, 53], ["meninges", "ANATOMY", 78, 86], ["ventricular", "ANATOMY", 104, 115], ["ventricular dilation", "DISEASE", 104, 124], ["hydrocephalus", "DISEASE", 129, 142], ["brain", "ORGAN", 19, 24], ["exudate", "ORGANISM_SUBSTANCE", 46, 53], ["meninges", "ORGAN", 78, 86], ["ventricular", "MULTI-TISSUE_STRUCTURE", 104, 115], ["Examination of the brain", "TEST", 0, 24], ["fibrinous exudate", "PROBLEM", 36, 53], ["ventricular dilation", "PROBLEM", 104, 124], ["hydrocephalus", "PROBLEM", 129, 142], ["brain", "ANATOMY", 19, 24], ["fibrinous", "OBSERVATION_MODIFIER", 36, 45], ["exudate", "OBSERVATION", 46, 53], ["meninges", "ANATOMY", 78, 86], ["without", "UNCERTAINTY", 96, 103], ["ventricular", "ANATOMY", 104, 115], ["dilation", "OBSERVATION", 116, 124], ["hydrocephalus", "OBSERVATION", 129, 142]]], ["Thymic involution may also be present.Histopathologic FindingsThe characteristic histopathologic findings of FIP are systemic perivascular, multifocal to coalescing pyogranulomatous or granulomatous inflammatory lesions (Figure 20-11 ).", [["Thymic", "ANATOMY", 0, 6], ["perivascular", "ANATOMY", 126, 138], ["pyogranulomatous", "ANATOMY", 165, 181], ["granulomatous inflammatory lesions", "ANATOMY", 185, 219], ["FIP", "DISEASE", 109, 112], ["Thymic", "ORGAN", 0, 6], ["granulomatous inflammatory lesions", "PATHOLOGICAL_FORMATION", 185, 219], ["Thymic involution", "PROBLEM", 0, 17], ["FIP", "PROBLEM", 109, 112], ["systemic perivascular", "PROBLEM", 117, 138], ["multifocal to coalescing pyogranulomatous or granulomatous inflammatory lesions", "PROBLEM", 140, 219], ["involution", "OBSERVATION", 7, 17], ["may also be", "UNCERTAINTY", 18, 29], ["FIP", "OBSERVATION", 109, 112], ["systemic", "OBSERVATION_MODIFIER", 117, 125], ["perivascular", "ANATOMY", 126, 138], ["multifocal", "OBSERVATION_MODIFIER", 140, 150], ["coalescing", "OBSERVATION_MODIFIER", 154, 164], ["pyogranulomatous", "OBSERVATION_MODIFIER", 165, 181], ["granulomatous", "OBSERVATION_MODIFIER", 185, 198], ["inflammatory", "OBSERVATION_MODIFIER", 199, 211]]], ["Lesions predominantly contain macrophages and neutrophils, with lesser numbers of lymphocytes and plasma cells, although occasionally the histiocytic or the lymphoplasmacytic component of the inflammatory response is more florid.", [["Lesions", "ANATOMY", 0, 7], ["macrophages", "ANATOMY", 30, 41], ["neutrophils", "ANATOMY", 46, 57], ["lymphocytes", "ANATOMY", 82, 93], ["plasma cells", "ANATOMY", 98, 110], ["histiocytic", "ANATOMY", 138, 149], ["florid", "DISEASE", 222, 228], ["macrophages", "CELL", 30, 41], ["neutrophils", "CELL", 46, 57], ["lymphocytes", "CELL", 82, 93], ["plasma cells", "CELL", 98, 110], ["macrophages", "CELL_TYPE", 30, 41], ["neutrophils", "CELL_TYPE", 46, 57], ["lymphocytes", "CELL_TYPE", 82, 93], ["plasma cells", "CELL_TYPE", 98, 110], ["Lesions", "PROBLEM", 0, 7], ["macrophages", "PROBLEM", 30, 41], ["neutrophils", "TEST", 46, 57], ["plasma cells", "TEST", 98, 110], ["the histiocytic", "PROBLEM", 134, 149], ["the inflammatory response", "PROBLEM", 188, 213], ["macrophages", "OBSERVATION", 30, 41], ["neutrophils", "OBSERVATION_MODIFIER", 46, 57], ["lesser", "OBSERVATION_MODIFIER", 64, 70], ["numbers", "OBSERVATION_MODIFIER", 71, 78], ["lymphocytes", "ANATOMY", 82, 93], ["plasma cells", "OBSERVATION", 98, 110], ["histiocytic", "OBSERVATION", 138, 149], ["lymphoplasmacytic", "OBSERVATION_MODIFIER", 157, 174], ["component", "OBSERVATION_MODIFIER", 175, 184], ["inflammatory", "OBSERVATION_MODIFIER", 192, 204]]], ["Necrosis may be present within the lesions.", [["lesions", "ANATOMY", 35, 42], ["Necrosis", "DISEASE", 0, 8], ["lesions", "PATHOLOGICAL_FORMATION", 35, 42], ["Necrosis", "PROBLEM", 0, 8], ["the lesions", "PROBLEM", 31, 42], ["may be", "UNCERTAINTY", 9, 15], ["lesions", "OBSERVATION", 35, 42]]], ["Lesions in the central nervous system consist of pyogranulomatous meningoencephalomyelitis and choroiditis.", [["central nervous system", "ANATOMY", 15, 37], ["pyogranulomatous meningoencephalomyelitis", "ANATOMY", 49, 90], ["meningoencephalomyelitis", "DISEASE", 66, 90], ["choroiditis", "DISEASE", 95, 106], ["central nervous system", "ANATOMICAL_SYSTEM", 15, 37], ["Lesions in the central nervous system", "PROBLEM", 0, 37], ["pyogranulomatous meningoencephalomyelitis", "PROBLEM", 49, 90], ["choroiditis", "PROBLEM", 95, 106], ["central", "ANATOMY_MODIFIER", 15, 22], ["nervous", "ANATOMY", 23, 30], ["pyogranulomatous meningoencephalomyelitis", "OBSERVATION", 49, 90], ["choroiditis", "OBSERVATION", 95, 106]]], ["Other findings that may be identified include lymphoid depletion, which results from apoptosis, and membranous glomerulonephritis.Treatment and PrognosisCurrently, no cure for FIP exists; it is a progressive, invariably fatal disease.", [["lymphoid", "ANATOMY", 46, 54], ["glomerulonephritis", "DISEASE", 111, 129], ["FIP", "DISEASE", 176, 179], ["lymphoid", "CELL", 46, 54], ["lymphoid depletion", "PROBLEM", 46, 64], ["apoptosis", "PROBLEM", 85, 94], ["membranous glomerulonephritis", "PROBLEM", 100, 129], ["Treatment", "TREATMENT", 130, 139], ["FIP", "PROBLEM", 176, 179], ["a progressive, invariably fatal disease", "PROBLEM", 194, 233], ["may be", "UNCERTAINTY", 20, 26], ["lymphoid depletion", "OBSERVATION", 46, 64], ["apoptosis", "OBSERVATION_MODIFIER", 85, 94], ["membranous", "OBSERVATION_MODIFIER", 100, 110], ["glomerulonephritis", "OBSERVATION", 111, 129], ["progressive", "OBSERVATION_MODIFIER", 196, 207], ["invariably", "OBSERVATION_MODIFIER", 209, 219], ["fatal", "OBSERVATION_MODIFIER", 220, 225], ["disease", "OBSERVATION", 226, 233]]], ["The goal of treatment is to prolong life span and improve quality of life through reduction of inflammation and supportive care.", [["inflammation", "DISEASE", 95, 107], ["treatment", "TREATMENT", 12, 21], ["life span", "TREATMENT", 36, 45], ["inflammation", "PROBLEM", 95, 107], ["supportive care", "TREATMENT", 112, 127], ["inflammation", "OBSERVATION", 95, 107]]], ["The most effective treatment known is prednisolone, administration of which results in temporary remissions in some cats (Table 20-6).", [["prednisolone", "CHEMICAL", 38, 50], ["prednisolone", "CHEMICAL", 38, 50], ["prednisolone", "SIMPLE_CHEMICAL", 38, 50], ["cats", "ORGANISM", 116, 120], ["prednisolone", "TREATMENT", 38, 50], ["temporary remissions", "TREATMENT", 87, 107], ["most effective", "OBSERVATION_MODIFIER", 4, 18], ["temporary remissions", "OBSERVATION", 87, 107]]], ["Other immunosuppressive drugs, such as chlorambucil and cyclophosphamide, have been used in addition to prednisolone, but whether these drugs improve outcome is unknown, and they have the potential to be toxic.", [["chlorambucil", "CHEMICAL", 39, 51], ["cyclophosphamide", "CHEMICAL", 56, 72], ["prednisolone", "CHEMICAL", 104, 116], ["chlorambucil", "CHEMICAL", 39, 51], ["cyclophosphamide", "CHEMICAL", 56, 72], ["prednisolone", "CHEMICAL", 104, 116], ["chlorambucil", "SIMPLE_CHEMICAL", 39, 51], ["cyclophosphamide", "SIMPLE_CHEMICAL", 56, 72], ["prednisolone", "SIMPLE_CHEMICAL", 104, 116], ["Other immunosuppressive drugs", "TREATMENT", 0, 29], ["chlorambucil", "TREATMENT", 39, 51], ["cyclophosphamide", "TREATMENT", 56, 72], ["prednisolone", "TREATMENT", 104, 116], ["immunosuppressive drugs", "OBSERVATION", 6, 29]]], ["A variety of immunomodulators and antiviral drugs have been tried, such as ribavirin and oral and parenteral human recombinant IFN-\u03b1, but none have convincingly shown benefit in vivo.", [["oral", "ANATOMY", 89, 93], ["ribavirin", "CHEMICAL", 75, 84], ["ribavirin", "CHEMICAL", 75, 84], ["ribavirin", "SIMPLE_CHEMICAL", 75, 84], ["oral", "ORGANISM_SUBDIVISION", 89, 93], ["human", "ORGANISM", 109, 114], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 127, 132], ["IFN", "PROTEIN", 127, 130], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["immunomodulators", "TREATMENT", 13, 29], ["antiviral drugs", "TREATMENT", 34, 49], ["ribavirin", "TREATMENT", 75, 84], ["oral and parenteral human recombinant IFN", "TREATMENT", 89, 130], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["immunomodulators", "OBSERVATION", 13, 29]]], ["Prolonged remissions were reported in several cats treated with a combination of glucocorticoids and feline IFN\u03c9, 56 but a randomized, placebo-controlled clinical trial reported no effect of feline IFN-\u03c9.", [["glucocorticoids", "CHEMICAL", 81, 96], ["IFN", "CHEMICAL", 198, 201], ["cats", "ORGANISM", 46, 50], ["feline", "ORGANISM", 101, 107], ["feline", "ORGANISM", 191, 197], ["IFN", "PROTEIN", 198, 201], ["Prolonged remissions", "PROBLEM", 0, 20], ["glucocorticoids", "TREATMENT", 81, 96], ["placebo", "TREATMENT", 135, 142], ["remissions", "OBSERVATION", 10, 20]]], ["57 Other drugs used to treat cats with FIP include the immunomodulatory drugs pentoxifylline and Polyprenyl Immunostimulant (see Chapter 7) 58 ; ozagrel hydrochloride, a thromboxane synthetase inhibitor 59 ; and the antiviral drug nelfinavir.", [["FIP", "DISEASE", 39, 42], ["pentoxifylline", "CHEMICAL", 78, 92], ["Polyprenyl", "CHEMICAL", 97, 107], ["ozagrel hydrochloride", "CHEMICAL", 145, 166], ["thromboxane", "CHEMICAL", 170, 181], ["nelfinavir", "CHEMICAL", 231, 241], ["pentoxifylline", "CHEMICAL", 78, 92], ["Polyprenyl", "CHEMICAL", 97, 107], ["ozagrel hydrochloride", "CHEMICAL", 145, 166], ["thromboxane", "CHEMICAL", 170, 181], ["nelfinavir", "CHEMICAL", 231, 241], ["cats", "ORGANISM", 29, 33], ["pentoxifylline", "SIMPLE_CHEMICAL", 78, 92], ["Polyprenyl", "SIMPLE_CHEMICAL", 97, 107], ["ozagrel hydrochloride", "SIMPLE_CHEMICAL", 145, 166], ["thromboxane", "SIMPLE_CHEMICAL", 170, 181], ["nelfinavir", "SIMPLE_CHEMICAL", 231, 241], ["cats", "SPECIES", 29, 33], ["Other drugs", "TREATMENT", 3, 14], ["FIP", "TREATMENT", 39, 42], ["the immunomodulatory drugs pentoxifylline", "TREATMENT", 51, 92], ["Polyprenyl Immunostimulant", "TREATMENT", 97, 123], ["ozagrel hydrochloride", "TREATMENT", 145, 166], ["a thromboxane synthetase inhibitor", "TREATMENT", 168, 202], ["the antiviral drug nelfinavir", "TREATMENT", 212, 241]]], ["14, 60 Controlled clinical trials are required to assess the efficacy and safety of these treatments.", [["these treatments", "TREATMENT", 84, 100]]], ["Because FIP is an immune-mediated disease, nonspecific immune stimulation has the potential to cause harm.", [["FIP", "DISEASE", 8, 11], ["FIP", "GENE_OR_GENE_PRODUCT", 8, 11], ["FIP", "PROBLEM", 8, 11], ["an immune-mediated disease", "PROBLEM", 15, 41], ["nonspecific immune stimulation", "TREATMENT", 43, 73], ["harm", "PROBLEM", 101, 105], ["disease", "OBSERVATION", 34, 41], ["nonspecific", "OBSERVATION_MODIFIER", 43, 54], ["immune stimulation", "OBSERVATION", 55, 73]]], ["The use of small interfering RNA molecules, which bind viral RNA and prevent viral replication, has recently shown promising results in vitro.", [["small interfering RNA molecules", "RNA", 11, 42], ["viral RNA", "RNA", 55, 64], ["small interfering RNA molecules", "PROBLEM", 11, 42], ["bind viral RNA", "PROBLEM", 50, 64], ["viral replication", "TREATMENT", 77, 94], ["small", "OBSERVATION_MODIFIER", 11, 16], ["interfering", "OBSERVATION_MODIFIER", 17, 28], ["RNA molecules", "OBSERVATION", 29, 42], ["viral replication", "OBSERVATION", 77, 94]]], ["61 Cyclosporin inhibits FIPV replication in vitro; 62 studies are required to determine if cyclosporin treatment benefits infected cats or whether harm results from immunosuppression.Treatment and PrognosisSupportive treatments that may be required include subcutaneous fluid therapy and nutritional support.", [["subcutaneous fluid", "ANATOMY", 257, 275], ["Cyclosporin", "CHEMICAL", 3, 14], ["cyclosporin", "CHEMICAL", 91, 102], ["Cyclosporin", "CHEMICAL", 3, 14], ["cyclosporin", "CHEMICAL", 91, 102], ["Cyclosporin", "SIMPLE_CHEMICAL", 3, 14], ["FIPV", "SIMPLE_CHEMICAL", 24, 28], ["cyclosporin", "SIMPLE_CHEMICAL", 91, 102], ["cats", "ORGANISM", 131, 135], ["cats", "SPECIES", 131, 135], ["FIPV", "SPECIES", 24, 28], ["Cyclosporin", "TREATMENT", 3, 14], ["FIPV replication", "TREATMENT", 24, 40], ["cyclosporin treatment", "TREATMENT", 91, 112], ["infected cats", "PROBLEM", 122, 135], ["immunosuppression", "TREATMENT", 165, 182], ["Treatment", "TREATMENT", 183, 192], ["PrognosisSupportive treatments", "TREATMENT", 197, 227], ["subcutaneous fluid therapy", "TREATMENT", 257, 283], ["nutritional support", "TREATMENT", 288, 307], ["FIPV replication", "OBSERVATION", 24, 40]]], ["Inappetent cats can benefit from enteral nutrition through a feeding tube.", [["cats", "ORGANISM", 11, 15], ["tube", "TISSUE", 69, 73], ["cats", "SPECIES", 11, 15], ["enteral nutrition", "TREATMENT", 33, 50], ["a feeding tube", "TREATMENT", 59, 73], ["feeding tube", "OBSERVATION", 61, 73]]], ["The use of broad-spectrum antimicrobial drugs to treat cats with FIP is controversial; it may only promote opportunistic infections with resistant bacteria.Treatment and PrognosisThe prognosis for cats with FIP is generally grave.", [["FIP", "DISEASE", 65, 68], ["infections", "DISEASE", 121, 131], ["FIP", "DISEASE", 207, 210], ["cats", "ORGANISM", 55, 59], ["cats", "ORGANISM", 197, 201], ["cats", "SPECIES", 55, 59], ["cats", "SPECIES", 197, 201], ["broad-spectrum antimicrobial drugs", "TREATMENT", 11, 45], ["FIP", "PROBLEM", 65, 68], ["opportunistic infections", "PROBLEM", 107, 131], ["resistant bacteria", "PROBLEM", 137, 155], ["Treatment", "TREATMENT", 156, 165], ["FIP", "PROBLEM", 207, 210]]], ["Almost all cats with effusion at the time of diagnosis die within weeks.", [["effusion", "DISEASE", 21, 29], ["cats", "ORGANISM", 11, 15], ["cats", "SPECIES", 11, 15], ["effusion", "PROBLEM", 21, 29], ["effusion", "OBSERVATION", 21, 29]]], ["Very rarely, more prolonged survival times (1 to 2 years) have been documented after glucocorticoid treatment (see Case Example).", [["glucocorticoid", "SIMPLE_CHEMICAL", 85, 99], ["glucocorticoid treatment", "TREATMENT", 85, 109]]], ["Biopsy is often not feasible antemortem as a result of critical illness and coagulopathies.Treatment and PrognosisFCoV, feline coronavirus; FIP, feline infectious peritonitis; RT-PCR, reverse transcriptase-polymerase chain reaction.Treatment and PrognosisThe median survival time in one study of 37 cats was 9 days (range, 3 to 200 days).", [["coagulopathies", "DISEASE", 76, 90], ["feline coronavirus", "DISEASE", 120, 138], ["FIP", "DISEASE", 140, 143], ["feline infectious peritonitis", "DISEASE", 145, 174], ["feline coronavirus", "ORGANISM", 120, 138], ["feline", "ORGANISM", 145, 151], ["cats", "ORGANISM", 299, 303], ["reverse transcriptase", "PROTEIN", 184, 205], ["feline coronavirus", "SPECIES", 120, 138], ["feline", "SPECIES", 145, 151], ["feline coronavirus", "SPECIES", 120, 138], ["Biopsy", "TEST", 0, 6], ["critical illness", "PROBLEM", 55, 71], ["coagulopathies", "PROBLEM", 76, 90], ["Treatment", "TREATMENT", 91, 100], ["PrognosisFCoV", "TREATMENT", 105, 118], ["feline coronavirus", "PROBLEM", 120, 138], ["FIP", "PROBLEM", 140, 143], ["feline infectious peritonitis", "PROBLEM", 145, 174], ["RT-PCR", "TEST", 176, 182], ["reverse transcriptase-polymerase chain reaction", "PROBLEM", 184, 231], ["coagulopathies", "OBSERVATION", 76, 90], ["infectious", "OBSERVATION_MODIFIER", 152, 162], ["peritonitis", "OBSERVATION", 163, 174]]], ["57 In another it was 21 days (range, 1 to 99 days) for 30 cats with effusive disease, 38 days (range, 1 to 171 days) for 12 cats with noneffusive disease, and 111 days (range, 7 to 477 days) for 9 cats with mixed effusive and noneffusive disease.", [["effusive disease", "DISEASE", 68, 84], ["noneffusive disease", "DISEASE", 134, 153], ["effusive and noneffusive disease", "DISEASE", 213, 245], ["cats", "ORGANISM", 58, 62], ["cats", "ORGANISM", 124, 128], ["cats", "ORGANISM", 197, 201], ["effusive disease", "PROBLEM", 68, 84], ["noneffusive disease", "PROBLEM", 134, 153], ["mixed effusive and noneffusive disease", "PROBLEM", 207, 245], ["noneffusive disease", "OBSERVATION", 226, 245]]], ["14 Hyperbilirubinemia, the presence of effusion, and lymphopenia are negative prognostic factors 20 ; in one study, the hematocrit, lymphocyte count, and serum albumin, potassium, sodium, and globulin concentrations decreased as disease progressed, and total bilirubin concentration and serum liver enzyme activities increased.", [["lymphocyte", "ANATOMY", 132, 142], ["serum", "ANATOMY", 154, 159], ["serum liver", "ANATOMY", 287, 298], ["Hyperbilirubinemia", "DISEASE", 3, 21], ["effusion", "DISEASE", 39, 47], ["lymphopenia", "DISEASE", 53, 64], ["potassium", "CHEMICAL", 169, 178], ["sodium", "CHEMICAL", 180, 186], ["globulin", "CHEMICAL", 192, 200], ["bilirubin", "CHEMICAL", 259, 268], ["potassium", "CHEMICAL", 169, 178], ["sodium", "CHEMICAL", 180, 186], ["bilirubin", "CHEMICAL", 259, 268], ["lymphocyte", "CELL", 132, 142], ["serum", "ORGANISM_SUBSTANCE", 154, 159], ["albumin", "GENE_OR_GENE_PRODUCT", 160, 167], ["potassium", "SIMPLE_CHEMICAL", 169, 178], ["sodium", "SIMPLE_CHEMICAL", 180, 186], ["globulin", "GENE_OR_GENE_PRODUCT", 192, 200], ["bilirubin", "GENE_OR_GENE_PRODUCT", 259, 268], ["serum", "ORGANISM_SUBSTANCE", 287, 292], ["liver", "ORGAN", 293, 298], ["serum albumin", "PROTEIN", 154, 167], ["serum liver enzyme", "PROTEIN", 287, 305], ["Hyperbilirubinemia", "PROBLEM", 3, 21], ["effusion", "PROBLEM", 39, 47], ["lymphopenia", "PROBLEM", 53, 64], ["one study", "TEST", 105, 114], ["the hematocrit", "TEST", 116, 130], ["lymphocyte count", "TEST", 132, 148], ["serum albumin", "TEST", 154, 167], ["potassium", "TEST", 169, 178], ["sodium", "TEST", 180, 186], ["globulin concentrations", "TEST", 192, 215], ["disease", "PROBLEM", 229, 236], ["total bilirubin concentration", "TEST", 253, 282], ["serum liver enzyme activities", "TEST", 287, 316], ["Hyperbilirubinemia", "OBSERVATION", 3, 21], ["effusion", "OBSERVATION", 39, 47], ["lymphopenia", "OBSERVATION", 53, 64], ["lymphocyte count", "OBSERVATION", 132, 148], ["liver", "ANATOMY", 293, 298]]], ["14 Euthanasia should be considered for cats with severe illness that fail to respond to treatment within a 3-day period.", [["cats", "ORGANISM", 39, 43], ["cats", "SPECIES", 39, 43], ["severe illness", "PROBLEM", 49, 63], ["treatment", "TREATMENT", 88, 97]]], ["20Immunity and VaccinationAlthough antibodies to the spike protein can neutralize virus, antibodies are required for FIP to occur, because FIP is an immune complex disease.", [["FIP", "DISEASE", 117, 120], ["FIP", "DISEASE", 139, 142], ["FIP", "GENE_OR_GENE_PRODUCT", 117, 120], ["VaccinationAlthough antibodies", "PROTEIN", 15, 45], ["spike protein", "PROTEIN", 53, 66], ["antibodies", "PROTEIN", 89, 99], ["20Immunity", "TREATMENT", 0, 10], ["VaccinationAlthough antibodies", "TEST", 15, 45], ["the spike protein", "TEST", 49, 66], ["neutralize virus", "PROBLEM", 71, 87], ["antibodies", "PROBLEM", 89, 99], ["FIP", "PROBLEM", 117, 120], ["FIP", "PROBLEM", 139, 142], ["an immune complex disease", "PROBLEM", 146, 171]]], ["Cell-mediated immunity is important for protection, 6 but if immunity is incomplete, granulomatous or pyogranulomatous disease results.", [["Cell", "ANATOMY", 0, 4], ["granulomatous", "ANATOMY", 85, 98], ["pyogranulomatous", "ANATOMY", 102, 118], ["Cell", "CELL", 0, 4], ["granulomatous or pyogranulomatous disease results", "PROBLEM", 85, 134], ["granulomatous", "OBSERVATION", 85, 98], ["pyogranulomatous disease", "OBSERVATION", 102, 126]]], ["The development of vaccines for FIP has been complicated by the fact that stimulation of antibody production against FCoV can accelerate the disease, should FIP develop after vaccination has been performed.", [["FIP", "DISEASE", 32, 35], ["FCoV", "CHEMICAL", 117, 121], ["FIP", "DISEASE", 157, 160], ["FIP", "ORGANISM", 32, 35], ["FCoV", "GENE_OR_GENE_PRODUCT", 117, 121], ["FCoV", "PROTEIN", 117, 121], ["FCoV", "SPECIES", 117, 121], ["vaccines", "TREATMENT", 19, 27], ["FIP", "PROBLEM", 32, 35], ["antibody production", "PROBLEM", 89, 108], ["FCoV", "PROBLEM", 117, 121], ["the disease", "PROBLEM", 137, 148], ["FIP", "PROBLEM", 157, 160], ["vaccination", "TREATMENT", 175, 186]]], ["Antibodies may bind to Fc receptors on macrophages and accelerate virus uptake in a phenomenon known as antibody-dependent disease enhancement (ADDE).", [["macrophages", "ANATOMY", 39, 50], ["Fc receptors", "GENE_OR_GENE_PRODUCT", 23, 35], ["macrophages", "CELL", 39, 50], ["Fc receptors", "PROTEIN", 23, 35], ["macrophages", "CELL_TYPE", 39, 50], ["Antibodies", "TREATMENT", 0, 10], ["Fc receptors", "TEST", 23, 35], ["macrophages", "TEST", 39, 50], ["accelerate virus uptake", "PROBLEM", 55, 78], ["a phenomenon", "PROBLEM", 82, 94], ["antibody-dependent disease enhancement", "PROBLEM", 104, 142], ["macrophages", "ANATOMY", 39, 50], ["virus uptake", "OBSERVATION", 66, 78], ["dependent", "OBSERVATION_MODIFIER", 113, 122], ["disease", "OBSERVATION", 123, 130]]], ["Currently, an intranasal, temperature-sensitive mutant serotype II FIP virus vaccine is available on the market, but its use has been controversial.", [["mutant serotype II FIP virus", "ORGANISM", 48, 76], ["serotype II FIP virus", "SPECIES", 55, 76], ["an intranasal", "TEST", 11, 24], ["temperature", "TEST", 26, 37], ["mutant serotype II FIP virus vaccine", "TREATMENT", 48, 84]]], ["The vaccine virus replicates in the lower temperatures found in the respiratory tract.", [["respiratory tract", "ANATOMY", 68, 85], ["respiratory tract", "ORGANISM_SUBDIVISION", 68, 85], ["The vaccine virus", "TREATMENT", 0, 17], ["lower temperatures", "OBSERVATION_MODIFIER", 36, 54], ["respiratory tract", "ANATOMY", 68, 85]]], ["It is licensed for administration from 16 weeks of age, by which time most kittens have already been exposed to FCoV.", [["FCoV", "CHEMICAL", 112, 116], ["kittens", "ORGANISM", 75, 82], ["FCoV", "OBSERVATION", 112, 116]]], ["The vaccine does not appear to cause ADDE, 63 immunity against heterologous strains is controversial.", [["ADDE", "DISEASE", 37, 41], ["The vaccine", "TREATMENT", 0, 11], ["ADDE", "TEST", 37, 41], ["heterologous strains", "PROBLEM", 63, 83]]], ["In a study of 138 cats that belonged to 15 different cat breeders, virtually all of which were seropositive, there was no difference in prevalence of FIP in vaccinated versus placebo-treated cats.", [["FIP", "DISEASE", 150, 153], ["cats", "ORGANISM", 18, 22], ["cat", "ORGANISM", 53, 56], ["cats", "ORGANISM", 191, 195], ["cats", "SPECIES", 18, 22], ["cats", "SPECIES", 191, 195], ["a study", "TEST", 3, 10], ["FIP", "PROBLEM", 150, 153], ["placebo", "TREATMENT", 175, 182], ["FIP", "OBSERVATION", 150, 153]]], ["63 A slight reduction in the prevalence of FIP occurred when the vaccine was used in cats that had not been exposed to FCoV before vaccination, but protection was not convincing based on the small numbers of cats that developed the disease in each group.", [["FIP", "DISEASE", 43, 46], ["FCoV", "CHEMICAL", 119, 123], ["FCoV", "CHEMICAL", 119, 123], ["FIP", "PATHOLOGICAL_FORMATION", 43, 46], ["cats", "ORGANISM", 85, 89], ["cats", "ORGANISM", 208, 212], ["cats", "SPECIES", 85, 89], ["cats", "SPECIES", 208, 212], ["FCoV", "SPECIES", 119, 123], ["A slight reduction", "TREATMENT", 3, 21], ["FIP", "PROBLEM", 43, 46], ["the vaccine", "TREATMENT", 61, 72], ["vaccination", "TREATMENT", 131, 142], ["protection", "TREATMENT", 148, 158], ["the disease in each group", "PROBLEM", 228, 253], ["slight", "OBSERVATION_MODIFIER", 5, 11], ["reduction", "OBSERVATION_MODIFIER", 12, 21], ["FIP", "OBSERVATION", 43, 46], ["small", "OBSERVATION_MODIFIER", 191, 196], ["disease", "OBSERVATION", 232, 239]]], ["6, 65 PreventionImmunity and VaccinationIn households that contain only one or a few cats, young cats that develop FIP likely become infected with FCoV before they are acquired.", [["FIP", "DISEASE", 115, 118], ["cats", "ORGANISM", 85, 89], ["cats", "ORGANISM", 97, 101], ["cats", "SPECIES", 85, 89], ["cats", "SPECIES", 97, 101], ["FCoV", "SPECIES", 147, 151], ["Vaccination", "TREATMENT", 29, 40], ["FIP", "PROBLEM", 115, 118], ["infected", "OBSERVATION", 133, 141]]], ["They may or may not have FIP at the time of acquisition.", [["FIP", "DISEASE", 25, 28], ["FIP", "PROBLEM", 25, 28]]], ["When a cat from a single-cat household dies with FIP, it is suggested that the owner wait at least 2 months before a new cat is obtained, so that any virus in the environment becomes inactivated.", [["FIP", "DISEASE", 49, 52], ["cat", "ORGANISM", 7, 10], ["cat", "ORGANISM", 25, 28], ["cat", "ORGANISM", 121, 124], ["a new cat", "TEST", 115, 124], ["any virus", "PROBLEM", 146, 155]]], ["20 Selection of a new cat from a different genetic background than the previous cat should be considered, and if possible, the breeder should be informed if a purebred cat develops FIP.", [["FIP", "DISEASE", 181, 184], ["cat", "ORGANISM", 22, 25], ["cat", "ORGANISM", 80, 83], ["cat", "ORGANISM", 168, 171], ["a new cat", "PROBLEM", 16, 25], ["FIP", "PROBLEM", 181, 184], ["new", "OBSERVATION_MODIFIER", 18, 21]]], ["If a low number of other cats remain in the household, they may or may not continue to shed virus.", [["cats", "ORGANISM", 25, 29], ["low number", "OBSERVATION_MODIFIER", 5, 15]]], ["These cats often have a positive antibody titer, but this in no way predicts that they will develop FIP.", [["FIP", "DISEASE", 100, 103], ["cats", "ORGANISM", 6, 10], ["cats", "SPECIES", 6, 10], ["a positive antibody titer", "PROBLEM", 22, 47], ["FIP", "PROBLEM", 100, 103], ["positive", "OBSERVATION_MODIFIER", 24, 32], ["antibody titer", "OBSERVATION", 33, 47], ["FIP", "OBSERVATION", 100, 103]]], ["Before a new cat is introduced to a household that has a history of FIP, factors that could reduce stress and overcrowding should be identified and addressed.", [["FIP", "DISEASE", 68, 71], ["cat", "ORGANISM", 13, 16], ["FIP", "PROBLEM", 68, 71], ["stress", "PROBLEM", 99, 105], ["FIP", "OBSERVATION", 68, 71]]], ["The risk of transmission and disease can be reduced through attention to hygiene, prevention of overcrowding, maintenance of a larger ratio of adult to juvenile cats, and ensuring that cats are in stable groups of three or fewer per room.", [["cats", "ORGANISM", 161, 165], ["cats", "ORGANISM", 185, 189], ["cats", "SPECIES", 161, 165], ["disease", "PROBLEM", 29, 36], ["overcrowding", "PROBLEM", 96, 108], ["stable", "OBSERVATION_MODIFIER", 197, 203]]], ["Cats should have sufficient numbers of regularly cleaned litter trays located in a different area from where they are fed.", [["regularly cleaned litter trays", "TREATMENT", 39, 69], ["sufficient", "OBSERVATION_MODIFIER", 17, 27], ["numbers", "OBSERVATION_MODIFIER", 28, 35]]], ["Methods to control FIP in cattery situations, such as identification and removal of chronic shedders with serial fecal RT-PCR assays and removal of kittens from the queen followed by isolation at 5 to 6 weeks of age (before maternal antibody has declined), have limitations and are difficult to achieve properly in large catteries.", [["FIP", "DISEASE", 19, 22], ["Methods", "TREATMENT", 0, 7], ["removal", "TREATMENT", 73, 80], ["chronic shedders", "TREATMENT", 84, 100], ["serial fecal RT-PCR assays", "TREATMENT", 106, 132], ["removal of kittens", "TREATMENT", 137, 155], ["maternal antibody", "TEST", 224, 241], ["FIP", "OBSERVATION", 19, 22], ["large", "OBSERVATION_MODIFIER", 315, 320], ["catteries", "OBSERVATION", 321, 330]]], ["20 For example, cats that do not shed FCoV may still be infected with avirulent FCoV strains, and shedding may recommence at a later date.", [["cats", "ORGANISM", 16, 20], ["FCoV", "GENE_OR_GENE_PRODUCT", 38, 42], ["FCoV strains", "ORGANISM", 80, 92], ["cats", "SPECIES", 16, 20], ["FCoV", "SPECIES", 80, 84], ["avirulent FCoV strains", "PROBLEM", 70, 92], ["infected", "OBSERVATION", 56, 64], ["FCoV strains", "OBSERVATION", 80, 92]]], ["22 Isolation of kittens may be useful if reexposure is prevented until after they are 16 weeks of age, when their immune system is more mature.", [["immune system", "ANATOMY", 114, 127], ["kittens", "ORGANISM", 16, 23]]], ["6 In shelter situations, FIP may be reduced when overcrowding and prolonged stays are minimized, especially during kitten season.", [["FIP", "DISEASE", 25, 28], ["FIP", "PROBLEM", 25, 28], ["FIP", "OBSERVATION", 25, 28], ["may be", "UNCERTAINTY", 29, 35], ["reduced", "OBSERVATION_MODIFIER", 36, 43]]], ["6 If possible, owners that adopt cats from shelter environments should be provided with a handout that provides basic information on the disease (and other major infectious diseases of shelter cats such as retrovirus infections, bartonellosis, and feline upper respiratory tract disease) and the ubiquitous nature of infection.Immunity and VaccinationFurther understanding of genetic factors that contribute to FIP is required, because selective breeding may reduce the risk of the disease.", [["upper respiratory tract", "ANATOMY", 255, 278], ["retrovirus infections", "DISEASE", 206, 227], ["bartonellosis", "DISEASE", 229, 242], ["feline upper respiratory tract disease", "DISEASE", 248, 286], ["infection", "DISEASE", 317, 326], ["FIP", "DISEASE", 411, 414], ["cats", "ORGANISM", 33, 37], ["cats", "ORGANISM", 193, 197], ["retrovirus", "ORGANISM", 206, 216], ["feline", "ORGANISM", 248, 254], ["upper", "ORGANISM_SUBDIVISION", 255, 260], ["respiratory tract", "ORGANISM_SUBDIVISION", 261, 278], ["cats", "SPECIES", 193, 197], ["feline", "SPECIES", 248, 254], ["the disease", "PROBLEM", 133, 144], ["shelter cats", "TREATMENT", 185, 197], ["retrovirus infections", "PROBLEM", 206, 227], ["bartonellosis", "PROBLEM", 229, 242], ["feline upper respiratory tract disease", "PROBLEM", 248, 286], ["infection", "PROBLEM", 317, 326], ["genetic factors", "PROBLEM", 376, 391], ["FIP", "PROBLEM", 411, 414], ["selective breeding", "TREATMENT", 436, 454], ["the disease", "PROBLEM", 478, 489], ["respiratory tract", "ANATOMY", 261, 278], ["infection", "OBSERVATION", 317, 326], ["disease", "OBSERVATION", 482, 489]]], ["In the meantime, the breeding of cats that produce litters that succumb to FIP should be avoided.", [["FIP", "DISEASE", 75, 78], ["cats", "ORGANISM", 33, 37], ["cats", "SPECIES", 33, 37]]], ["This is especially true for male cats, because a single male cat can have an effect on far more kittens and litters than a single queen.", [["cats", "ORGANISM", 33, 37], ["cat", "ORGANISM", 61, 64], ["kittens", "ORGANISM_SUBDIVISION", 96, 103], ["cats", "SPECIES", 33, 37], ["cat", "SPECIES", 61, 64]]], ["6Public Health AspectsThere is no evidence that humans can become infected with FCoV.", [["humans", "ORGANISM", 48, 54], ["FCoV", "CANCER", 80, 84], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 48, 54], ["FCoV", "SPECIES", 80, 84], ["no evidence", "UNCERTAINTY", 31, 42], ["infected", "OBSERVATION", 66, 74]]], ["The closest human coronavirus relative is the severe acute respiratory syndrome (SARS) coronavirus.", [["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 53, 98], ["human", "ORGANISM", 12, 17], ["human", "SPECIES", 12, 17], ["coronavirus", "SPECIES", 18, 29], ["human coronavirus", "SPECIES", 12, 29], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 46, 98], ["The closest human coronavirus", "PROBLEM", 0, 29], ["the severe acute respiratory syndrome", "PROBLEM", 42, 79], ["SARS) coronavirus", "PROBLEM", 81, 98], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["respiratory syndrome", "OBSERVATION", 59, 79]]], ["Other coronaviruses cause FIP-like disease in nonfelids such as ferrets and mice.", [["FIP-like disease", "DISEASE", 26, 42], ["coronaviruses", "ORGANISM", 6, 19], ["ferrets", "ORGANISM", 64, 71], ["mice", "ORGANISM", 76, 80], ["ferrets", "SPECIES", 64, 71], ["mice", "SPECIES", 76, 80], ["ferrets", "SPECIES", 64, 71], ["mice", "SPECIES", 76, 80], ["Other coronaviruses", "PROBLEM", 0, 19], ["FIP", "PROBLEM", 26, 29], ["like disease in nonfelids", "PROBLEM", 30, 55], ["FIP", "OBSERVATION", 26, 29]]], ["If a coronavirus emerged that could cause similar clinical manifestations and outcomes in humans as FIPV can in cats, it would represent a major threat to humans and would be the subject of intense research.CASE EXAMPLESignalment: \"Ricky\", a 9-month-old male castrated domestic shorthair from Sacramento, CA History: Ricky was brought to a local veterinary clinic because of increased thirst and urination.", [["coronavirus", "DISEASE", 5, 16], ["FIPV", "CHEMICAL", 100, 104], ["coronavirus", "ORGANISM", 5, 16], ["humans", "ORGANISM", 90, 96], ["cats", "ORGANISM", 112, 116], ["humans", "ORGANISM", 155, 161], ["humans", "SPECIES", 90, 96], ["cats", "SPECIES", 112, 116], ["humans", "SPECIES", 155, 161], ["humans", "SPECIES", 90, 96], ["FIPV", "SPECIES", 100, 104], ["humans", "SPECIES", 155, 161], ["a coronavirus", "PROBLEM", 3, 16], ["similar clinical manifestations", "PROBLEM", 42, 73], ["increased thirst and urination", "PROBLEM", 375, 405]]], ["A serum chemistry panel showed hyperglobulinemia (7.7 mg/dL), and urinalysis showed a specific gravity (SGr) of 1.025 with an inactive sediment; aerobic bacterial urine culture was negative.", [["serum", "ANATOMY", 2, 7], ["urine", "ANATOMY", 163, 168], ["hyperglobulinemia", "DISEASE", 31, 48], ["serum", "ORGANISM_SUBSTANCE", 2, 7], ["urine", "ORGANISM_SUBSTANCE", 163, 168], ["A serum chemistry panel", "TEST", 0, 23], ["hyperglobulinemia", "TEST", 31, 48], ["urinalysis", "TEST", 66, 76], ["a specific gravity (SGr", "TEST", 84, 107], ["an inactive sediment", "PROBLEM", 123, 143], ["aerobic bacterial urine culture", "TEST", 145, 176], ["inactive", "OBSERVATION_MODIFIER", 126, 134], ["sediment", "OBSERVATION", 135, 143]]], ["Laboratory abnormalities included mature neutrophilia (11,904 cells/\u00b5L), lymphocytosis (5104 cells/\u00b5L), eosinophilia (1536 cells/\u00b5L), hyperglobulinemia (6.9 mg/dL), and hypoalbuminemia (2.4 mg/dL).", [["cells", "ANATOMY", 62, 67], ["cells", "ANATOMY", 93, 98], ["cells", "ANATOMY", 123, 128], ["mature neutrophilia", "DISEASE", 34, 53], ["lymphocytosis", "DISEASE", 73, 86], ["eosinophilia", "DISEASE", 104, 116], ["hyperglobulinemia", "DISEASE", 134, 151], ["hypoalbuminemia", "DISEASE", 169, 184], ["Laboratory abnormalities", "TEST", 0, 24], ["mature neutrophilia", "PROBLEM", 34, 53], ["cells", "TEST", 62, 67], ["lymphocytosis", "PROBLEM", 73, 86], ["cells", "TEST", 93, 98], ["\u00b5L", "TEST", 99, 101], ["eosinophilia", "TEST", 104, 116], ["cells", "TEST", 123, 128], ["\u00b5L", "TEST", 129, 131], ["hyperglobulinemia", "TEST", 134, 151], ["hypoalbuminemia", "PROBLEM", 169, 184], ["mature", "OBSERVATION_MODIFIER", 34, 40], ["neutrophilia", "OBSERVATION", 41, 53], ["lymphocytosis", "OBSERVATION", 73, 86], ["eosinophilia", "OBSERVATION", 104, 116], ["hypoalbuminemia", "OBSERVATION", 169, 184]]], ["A feline coronavirus antibody titer was 1:400.", [["feline", "ORGANISM", 2, 8], ["coronavirus", "ORGANISM", 9, 20], ["feline", "SPECIES", 2, 8], ["coronavirus", "SPECIES", 9, 20], ["feline coronavirus", "SPECIES", 2, 20], ["A feline coronavirus antibody titer", "TEST", 0, 35]]], ["Serology for Toxoplasma gondii was negative.", [["Toxoplasma gondii", "DISEASE", 13, 30], ["Toxoplasma gondii", "ORGANISM", 13, 30], ["Toxoplasma gondii", "SPECIES", 13, 30], ["Toxoplasma gondii", "SPECIES", 13, 30], ["Serology", "TEST", 0, 8], ["Toxoplasma gondii", "TEST", 13, 30]]], ["Plain thoracic radiographs showed a mild interstitial pattern.", [["thoracic", "ANATOMY", 6, 14], ["interstitial", "ANATOMY", 41, 53], ["Plain thoracic radiographs", "TEST", 0, 26], ["a mild interstitial pattern", "PROBLEM", 34, 61], ["thoracic", "ANATOMY", 6, 14], ["mild", "OBSERVATION_MODIFIER", 36, 40], ["interstitial pattern", "OBSERVATION", 41, 61]]], ["Abdominal ultrasound showed mesenteric lymphadenomegaly, and an aspirate of the lymph nodes showed lymphoid reactivity.", [["Abdominal", "ANATOMY", 0, 9], ["mesenteric", "ANATOMY", 28, 38], ["aspirate", "ANATOMY", 64, 72], ["lymph nodes", "ANATOMY", 80, 91], ["lymphoid", "ANATOMY", 99, 107], ["mesenteric lymphadenomegaly", "CANCER", 28, 55], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 80, 91], ["lymphoid", "ORGAN", 99, 107], ["Abdominal ultrasound", "TEST", 0, 20], ["mesenteric lymphadenomegaly", "PROBLEM", 28, 55], ["an aspirate of the lymph nodes", "PROBLEM", 61, 91], ["lymphoid reactivity", "PROBLEM", 99, 118], ["mesenteric", "ANATOMY", 28, 38], ["lymphadenomegaly", "OBSERVATION", 39, 55], ["aspirate", "OBSERVATION", 64, 72], ["lymph nodes", "OBSERVATION", 80, 91], ["lymphoid reactivity", "OBSERVATION", 99, 118]]], ["Treatment with cyproheptadine was initiated, and Ricky's appetite recovered, after which treatment was discontinued.", [["cyproheptadine", "CHEMICAL", 15, 29], ["cyproheptadine", "CHEMICAL", 15, 29], ["cyproheptadine", "SIMPLE_CHEMICAL", 15, 29], ["cyproheptadine", "TREATMENT", 15, 29], ["treatment", "TREATMENT", 89, 98]]], ["For the 3 weeks that followed, the cat had been appetent and energetic, but occasional soft feces had been noticed in the litter box.", [["soft feces", "ANATOMY", 87, 97], ["cat", "ORGANISM", 35, 38], ["feces", "ORGAN", 92, 97], ["occasional soft feces", "PROBLEM", 76, 97], ["energetic", "OBSERVATION_MODIFIER", 61, 70], ["soft feces", "OBSERVATION_MODIFIER", 87, 97]]], ["The owners were concerned about the possibility of FIP.", [["FIP", "DISEASE", 51, 54], ["FIP", "PROBLEM", 51, 54], ["FIP", "OBSERVATION", 51, 54]]], ["As a kitten he had multiple upper respiratory tract infections, but since adoption he had been healthy and shared a household with one other cat.", [["upper respiratory tract", "ANATOMY", 28, 51], ["respiratory tract infections", "DISEASE", 34, 62], ["upper respiratory", "ORGANISM_SUBDIVISION", 28, 45], ["tract", "ORGANISM_SUBDIVISION", 46, 51], ["cat", "ORGANISM", 141, 144], ["multiple upper respiratory tract infections", "PROBLEM", 19, 62], ["multiple", "OBSERVATION_MODIFIER", 19, 27], ["upper", "ANATOMY_MODIFIER", 28, 33], ["respiratory tract", "ANATOMY", 34, 51], ["infections", "OBSERVATION", 52, 62]]], ["He was an indoor cat that was sometimes walked briefly outdoors.", [["He", "ORGANISM", 0, 2], ["cat", "ORGANISM", 17, 20]]], ["He was fed commercial dry and wet cat food.CASE EXAMPLEImaging Findings: Abdominal ultrasound: The spleen was moderately enlarged.", [["Abdominal", "ANATOMY", 73, 82], ["spleen", "ANATOMY", 99, 105], ["He", "ORGANISM", 0, 2], ["cat", "ORGANISM", 34, 37], ["Abdominal", "ORGAN", 73, 82], ["spleen", "ORGAN", 99, 105], ["Abdominal ultrasound", "TEST", 73, 93], ["moderately enlarged", "PROBLEM", 110, 129], ["Abdominal", "ANATOMY", 73, 82], ["spleen", "ANATOMY", 99, 105], ["moderately", "OBSERVATION_MODIFIER", 110, 120], ["enlarged", "OBSERVATION", 121, 129]]], ["There was diffuse mesenteric lymphadenopathy (see Figure 20-8, B) .", [["diffuse mesenteric", "ANATOMY", 10, 28], ["mesenteric lymphadenopathy", "DISEASE", 18, 44], ["mesenteric", "ORGAN", 18, 28], ["diffuse mesenteric lymphadenopathy", "PROBLEM", 10, 44], ["diffuse", "OBSERVATION_MODIFIER", 10, 17], ["mesenteric", "ANATOMY", 18, 28], ["lymphadenopathy", "OBSERVATION", 29, 44]]], ["Treatment and Outcome: Biopsy of the enlarged mesenteric node was offered, but the owners declined.", [["mesenteric node", "ANATOMY", 46, 61], ["mesenteric node", "MULTI-TISSUE_STRUCTURE", 46, 61], ["Biopsy", "TEST", 23, 29], ["the enlarged mesenteric node", "PROBLEM", 33, 61], ["enlarged", "OBSERVATION_MODIFIER", 37, 45], ["mesenteric", "ANATOMY", 46, 56], ["node", "OBSERVATION", 57, 61]]], ["Ricky was treated with prednisolone (5 mg PO q12h for 7 days, followed by 5 mg PO q24h thereafter), chlorambucil (2 mg PO every 3 days), and pentoxifylline (50 mg PO q8h).", [["prednisolone", "CHEMICAL", 23, 35], ["chlorambucil", "CHEMICAL", 100, 112], ["pentoxifylline", "CHEMICAL", 141, 155], ["prednisolone", "CHEMICAL", 23, 35], ["chlorambucil", "CHEMICAL", 100, 112], ["pentoxifylline", "CHEMICAL", 141, 155], ["prednisolone", "SIMPLE_CHEMICAL", 23, 35], ["chlorambucil", "SIMPLE_CHEMICAL", 100, 112], ["pentoxifylline", "SIMPLE_CHEMICAL", 141, 155], ["prednisolone", "TREATMENT", 23, 35], ["chlorambucil", "TREATMENT", 100, 112], ["pentoxifylline", "TREATMENT", 141, 155]]], ["Six weeks later, the cat was well and CBC variables within reference ranges.", [["cat", "ORGANISM", 21, 24], ["CBC variables", "TEST", 38, 51]]], ["Serum total protein concentration was 8.5 g/dL, with a globulin concentration of 4.5 g/dL.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["globulin", "GENE_OR_GENE_PRODUCT", 55, 63], ["Serum total protein concentration", "TEST", 0, 33], ["a globulin concentration", "TEST", 53, 77]]], ["Abdominal ultrasound examination showed persistent but mild mesenteric lymphadenomegaly (0.5 to 0.75 cm in diameter).", [["Abdominal", "ANATOMY", 0, 9], ["mesenteric", "ANATOMY", 60, 70], ["lymphadenomegaly", "DISEASE", 71, 87], ["mesenteric lymphadenomegaly", "CANCER", 60, 87], ["Abdominal ultrasound examination", "TEST", 0, 32], ["persistent but mild mesenteric lymphadenomegaly", "PROBLEM", 40, 87], ["persistent", "OBSERVATION_MODIFIER", 40, 50], ["mild", "OBSERVATION_MODIFIER", 55, 59], ["mesenteric", "ANATOMY", 60, 70], ["lymphadenomegaly", "OBSERVATION", 71, 87], ["0.5 to 0.75 cm", "OBSERVATION_MODIFIER", 89, 103]]], ["A feline coronavirus titer was 1:25,600.", [["feline", "ORGANISM", 2, 8], ["coronavirus", "ORGANISM", 9, 20], ["feline coronavirus", "SPECIES", 2, 20], ["feline coronavirus", "SPECIES", 2, 20], ["A feline coronavirus titer", "TEST", 0, 26], ["coronavirus titer", "OBSERVATION", 9, 26]]], ["Treatment with feline interferon-\u03c9 was commenced (4.5 million units SC once weekly).", [["feline interferon-\u03c9", "CHEMICAL", 15, 34], ["feline", "ORGANISM", 15, 21], ["interferon-\u03c9", "SIMPLE_CHEMICAL", 22, 34], ["feline interferon", "TREATMENT", 15, 32]]], ["Ricky was seen again 3 months later, at which time he continued to be playful and appetent, with a stable body weight of 4.5 kg.", [["body", "ANATOMY", 106, 110], ["body", "ORGANISM_SUBDIVISION", 106, 110]]], ["A CBC showed mild anemia (HCT 29%), a neutrophil count of 4439 cells/\u00b5L, and lymphopenia (468 cells/\u00b5L).", [["neutrophil", "ANATOMY", 38, 48], ["cells", "ANATOMY", 63, 68], ["cells", "ANATOMY", 94, 99], ["anemia", "DISEASE", 18, 24], ["lymphopenia", "DISEASE", 77, 88], ["neutrophil", "CELL", 38, 48], ["A CBC", "TEST", 0, 5], ["mild anemia", "PROBLEM", 13, 24], ["HCT", "TEST", 26, 29], ["a neutrophil count", "TEST", 36, 54], ["cells", "TEST", 63, 68], ["\u00b5L", "TEST", 69, 71], ["lymphopenia", "PROBLEM", 77, 88], ["cells", "TEST", 94, 99], ["mild", "OBSERVATION_MODIFIER", 13, 17], ["anemia", "OBSERVATION", 18, 24], ["lymphopenia", "OBSERVATION", 77, 88]]], ["A chemistry panel and abdominal ultrasound showed no abnormalities.", [["abdominal", "ANATOMY", 22, 31], ["abdominal", "ORGANISM_SUBDIVISION", 22, 31], ["A chemistry panel", "TEST", 0, 17], ["abdominal ultrasound", "TEST", 22, 42], ["abnormalities", "PROBLEM", 53, 66], ["abdominal", "ANATOMY", 22, 31], ["no", "UNCERTAINTY", 50, 52], ["abnormalities", "OBSERVATION", 53, 66]]], ["Chlorambucil and interferon-\u03c9 were discontinued.", [["Chlorambucil", "CHEMICAL", 0, 12], ["interferon-\u03c9", "CHEMICAL", 17, 29], ["Chlorambucil", "CHEMICAL", 0, 12], ["Chlorambucil", "SIMPLE_CHEMICAL", 0, 12], ["interferon-\u03c9", "GENE_OR_GENE_PRODUCT", 17, 29], ["interferon", "PROTEIN", 17, 27], ["Chlorambucil", "TREATMENT", 0, 12], ["interferon", "TREATMENT", 17, 27]]], ["The next time the cat was reexamined was 12 months after the onset of illness, at which time he continued to be apparently healthy.", [["illness", "DISEASE", 70, 77], ["cat", "ORGANISM", 18, 21], ["illness", "PROBLEM", 70, 77]]], ["CBC findings were unchanged, and the serum globulin concentration was 4.7 g/dL.", [["serum", "ANATOMY", 37, 42], ["CBC", "CELL", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["globulin", "GENE_OR_GENE_PRODUCT", 43, 51], ["CBC findings", "TEST", 0, 12], ["the serum globulin concentration", "TEST", 33, 65], ["unchanged", "OBSERVATION_MODIFIER", 18, 27]]], ["The prednisolone dose was decreased to 5 mg q48h and pentoxifylline treatment was discontinued.", [["prednisolone", "CHEMICAL", 4, 16], ["pentoxifylline", "CHEMICAL", 53, 67], ["prednisolone", "CHEMICAL", 4, 16], ["pentoxifylline", "CHEMICAL", 53, 67], ["prednisolone", "SIMPLE_CHEMICAL", 4, 16], ["pentoxifylline", "SIMPLE_CHEMICAL", 53, 67], ["The prednisolone dose", "TREATMENT", 0, 21], ["pentoxifylline treatment", "TREATMENT", 53, 77]]], ["One month later, albumin and globulin concentrations were 3.3 and 5.1 g/dL, respectively, and the prednisolone dose was reduced to 2.5 mg q48h.", [["prednisolone", "CHEMICAL", 98, 110], ["prednisolone", "CHEMICAL", 98, 110], ["albumin", "GENE_OR_GENE_PRODUCT", 17, 24], ["globulin", "GENE_OR_GENE_PRODUCT", 29, 37], ["prednisolone", "SIMPLE_CHEMICAL", 98, 110], ["albumin", "PROTEIN", 17, 24], ["albumin and globulin concentrations", "TEST", 17, 52], ["the prednisolone dose", "TREATMENT", 94, 115]]], ["At the next 1-month recheck, a CBC was unremarkable but globulin was 5.7 g/dL.", [["globulin", "GENE_OR_GENE_PRODUCT", 56, 64], ["a CBC", "TEST", 29, 34], ["globulin", "TEST", 56, 64]]], ["Abdominal ultrasound showed mildly enlarged mesenteric lymph nodes, and the serum coronavirus antibody titer was 1:409,600.", [["Abdominal", "ANATOMY", 0, 9], ["mesenteric lymph nodes", "ANATOMY", 44, 66], ["serum", "ANATOMY", 76, 81], ["mesenteric lymph nodes", "MULTI-TISSUE_STRUCTURE", 44, 66], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["coronavirus", "SPECIES", 82, 93], ["Abdominal ultrasound", "TEST", 0, 20], ["mildly enlarged mesenteric lymph nodes", "PROBLEM", 28, 66], ["the serum coronavirus antibody titer", "TEST", 72, 108], ["mildly", "OBSERVATION_MODIFIER", 28, 34], ["enlarged", "OBSERVATION_MODIFIER", 35, 43], ["mesenteric", "ANATOMY", 44, 54], ["lymph nodes", "OBSERVATION", 55, 66]]], ["The prednisolone dose was increased to 5 mg PO q24h; 1 month later, the serum globulin concentration was 4.9 g/dL.", [["serum", "ANATOMY", 72, 77], ["prednisolone", "CHEMICAL", 4, 16], ["globulin", "CHEMICAL", 78, 86], ["prednisolone", "CHEMICAL", 4, 16], ["prednisolone", "SIMPLE_CHEMICAL", 4, 16], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["globulin", "GENE_OR_GENE_PRODUCT", 78, 86], ["The prednisolone dose", "TREATMENT", 0, 21], ["the serum globulin concentration", "TEST", 68, 100]]], ["One and a half years after the onset of illness, Ricky was still apparently healthy according to the owner, but a midabdominal mass was palpated on physical examination, and the serum globulin concentration had increased again (5.6 g/dL).", [["midabdominal mass", "ANATOMY", 114, 131], ["serum", "ANATOMY", 178, 183], ["serum", "ORGANISM_SUBSTANCE", 178, 183], ["globulin", "GENE_OR_GENE_PRODUCT", 184, 192], ["serum globulin", "PROTEIN", 178, 192], ["illness", "PROBLEM", 40, 47], ["a midabdominal mass", "PROBLEM", 112, 131], ["physical examination", "TEST", 148, 168], ["the serum globulin concentration", "TEST", 174, 206], ["mass", "OBSERVATION", 127, 131]]], ["Abdominal ultrasound showed several moderately enlarged and hypoechoic lymph nodes in the ileocolic region, the largest of which was 0.9 cm in diameter.", [["Abdominal", "ANATOMY", 0, 9], ["hypoechoic lymph nodes", "ANATOMY", 60, 82], ["ileocolic region", "ANATOMY", 90, 106], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 71, 82], ["ileocolic region", "MULTI-TISSUE_STRUCTURE", 90, 106], ["Abdominal ultrasound", "TEST", 0, 20], ["several moderately enlarged and hypoechoic lymph nodes in the ileocolic region", "PROBLEM", 28, 106], ["several", "OBSERVATION_MODIFIER", 28, 35], ["moderately", "OBSERVATION_MODIFIER", 36, 46], ["enlarged", "OBSERVATION_MODIFIER", 47, 55], ["hypoechoic", "OBSERVATION_MODIFIER", 60, 70], ["lymph nodes", "OBSERVATION", 71, 82], ["ileocolic", "ANATOMY", 90, 99], ["region", "ANATOMY_MODIFIER", 100, 106], ["largest", "OBSERVATION_MODIFIER", 112, 119], ["0.9 cm", "OBSERVATION_MODIFIER", 133, 139], ["diameter", "OBSERVATION_MODIFIER", 143, 151]]], ["The surrounding mesentery was focally hyperechoic.", [["mesentery", "ANATOMY", 16, 25], ["mesentery", "ORGAN", 16, 25], ["focally hyperechoic", "PROBLEM", 30, 49], ["surrounding", "ANATOMY_MODIFIER", 4, 15], ["mesentery", "ANATOMY", 16, 25], ["focally", "OBSERVATION_MODIFIER", 30, 37], ["hyperechoic", "OBSERVATION", 38, 49]]], ["There was also focal hyperechoic retroperitoneal tissue surrounding the right kidney with scant retroperitoneal fluid.", [["focal hyperechoic retroperitoneal tissue", "ANATOMY", 15, 55], ["right kidney", "ANATOMY", 72, 84], ["retroperitoneal fluid", "ANATOMY", 96, 117], ["focal hyperechoic retroperitoneal tissue", "TISSUE", 15, 55], ["kidney", "ORGAN", 78, 84], ["retroperitoneal fluid", "ORGANISM_SUBSTANCE", 96, 117], ["focal hyperechoic retroperitoneal tissue", "PROBLEM", 15, 55], ["scant retroperitoneal fluid", "PROBLEM", 90, 117], ["focal", "OBSERVATION_MODIFIER", 15, 20], ["hyperechoic", "OBSERVATION_MODIFIER", 21, 32], ["retroperitoneal", "ANATOMY", 33, 48], ["tissue", "OBSERVATION", 49, 55], ["right", "ANATOMY_MODIFIER", 72, 77], ["kidney", "ANATOMY", 78, 84], ["scant", "OBSERVATION_MODIFIER", 90, 95], ["retroperitoneal", "ANATOMY", 96, 111], ["fluid", "OBSERVATION", 112, 117]]], ["Attempts to obtain aspirates from the lymph nodes were unsuccessful.", [["aspirates", "ANATOMY", 19, 28], ["lymph nodes", "ANATOMY", 38, 49], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 38, 49], ["aspirates from the lymph nodes", "PROBLEM", 19, 49], ["lymph nodes", "OBSERVATION", 38, 49]]], ["The prednisolone dose was increased to 5mg PO q12h, and treatment with chlorambucil and pentoxifylline was reinstituted.", [["prednisolone", "CHEMICAL", 4, 16], ["chlorambucil", "CHEMICAL", 71, 83], ["pentoxifylline", "CHEMICAL", 88, 102], ["prednisolone", "CHEMICAL", 4, 16], ["chlorambucil", "CHEMICAL", 71, 83], ["pentoxifylline", "CHEMICAL", 88, 102], ["prednisolone", "SIMPLE_CHEMICAL", 4, 16], ["chlorambucil", "SIMPLE_CHEMICAL", 71, 83], ["pentoxifylline", "SIMPLE_CHEMICAL", 88, 102], ["The prednisolone dose", "TREATMENT", 0, 21], ["chlorambucil", "TREATMENT", 71, 83], ["pentoxifylline", "TREATMENT", 88, 102]]], ["One week later, Ricky developed lethargy and inappetence.", [["lethargy", "DISEASE", 32, 40], ["inappetence", "DISEASE", 45, 56], ["lethargy", "PROBLEM", 32, 40], ["inappetence", "PROBLEM", 45, 56], ["lethargy", "OBSERVATION", 32, 40], ["inappetence", "OBSERVATION", 45, 56]]], ["A CBC showed macrocytic anemia (HCT 24.3%, MCV 57.2 fL) and lymphopenia (782 cells/\u00b5L).", [["CBC", "ANATOMY", 2, 5], ["cells", "ANATOMY", 77, 82], ["macrocytic anemia", "DISEASE", 13, 30], ["lymphopenia", "DISEASE", 60, 71], ["CBC", "CELL", 2, 5], ["A CBC", "TEST", 0, 5], ["macrocytic anemia", "PROBLEM", 13, 30], ["HCT", "TEST", 32, 35], ["MCV", "TEST", 43, 46], ["fL", "TEST", 52, 54], ["lymphopenia", "PROBLEM", 60, 71], ["cells", "TEST", 77, 82], ["macrocytic anemia", "OBSERVATION", 13, 30], ["lymphopenia", "OBSERVATION", 60, 71]]], ["A serum chemistry panel showed only hyperglobulinemia (5.8 g/dL).", [["serum", "ANATOMY", 2, 7], ["hyperglobulinemia", "DISEASE", 36, 53], ["serum", "ORGANISM_SUBSTANCE", 2, 7], ["A serum chemistry panel", "TEST", 0, 23], ["hyperglobulinemia", "TEST", 36, 53]]], ["FeLV and FIV serology was repeated and was again negative, and the coronavirus antibody titer was 1:25,600.", [["FeLV", "ORGANISM", 0, 4], ["FIV", "ORGANISM", 9, 12], ["coronavirus", "ORGANISM", 67, 78], ["coronavirus", "SPECIES", 67, 78], ["FeLV", "SPECIES", 0, 4], ["FIV", "SPECIES", 9, 12], ["FeLV", "PROBLEM", 0, 4], ["FIV serology", "TEST", 9, 21], ["the coronavirus antibody titer", "TEST", 63, 93]]], ["Treatment with cyproheptadine was initiated and the chlorambucil and pentoxifylline discontinued.", [["cyproheptadine", "CHEMICAL", 15, 29], ["chlorambucil", "CHEMICAL", 52, 64], ["pentoxifylline", "CHEMICAL", 69, 83], ["cyproheptadine", "CHEMICAL", 15, 29], ["chlorambucil", "CHEMICAL", 52, 64], ["pentoxifylline", "CHEMICAL", 69, 83], ["cyproheptadine", "SIMPLE_CHEMICAL", 15, 29], ["chlorambucil", "SIMPLE_CHEMICAL", 52, 64], ["pentoxifylline", "SIMPLE_CHEMICAL", 69, 83], ["cyproheptadine", "TREATMENT", 15, 29], ["the chlorambucil", "TREATMENT", 48, 64], ["pentoxifylline", "TREATMENT", 69, 83]]], ["However, inappetence continued, and persistent pyrexia (103.4\u00b0 to 104\u00b0F), hematochezia, and tachypnea developed over the next few days.", [["inappetence", "DISEASE", 9, 20], ["pyrexia", "DISEASE", 47, 54], ["hematochezia", "DISEASE", 74, 86], ["tachypnea", "DISEASE", 92, 101], ["inappetence", "PROBLEM", 9, 20], ["persistent pyrexia", "PROBLEM", 36, 54], ["hematochezia", "PROBLEM", 74, 86], ["tachypnea", "PROBLEM", 92, 101], ["persistent", "OBSERVATION_MODIFIER", 36, 46], ["pyrexia", "OBSERVATION", 47, 54], ["hematochezia", "OBSERVATION", 74, 86], ["tachypnea", "OBSERVATION", 92, 101]]], ["The hematocrit dropped to 16.5%, and hypokalemia, hyponatremia, and hypochloremia were identified.", [["hypokalemia", "DISEASE", 37, 48], ["hyponatremia", "DISEASE", 50, 62], ["hypochloremia", "DISEASE", 68, 81], ["The hematocrit", "TEST", 0, 14], ["hypokalemia", "PROBLEM", 37, 48], ["hyponatremia", "PROBLEM", 50, 62], ["hypochloremia", "PROBLEM", 68, 81], ["hypokalemia", "OBSERVATION", 37, 48], ["hyponatremia", "OBSERVATION", 50, 62]]], ["Ricky was hospitalized and treated with 1 unit of packed RBC, IV crystalloids, and parenteral antimicrobial drugs.", [["RBC", "ANATOMY", 57, 60], ["RBC", "CELL", 57, 60], ["parenteral antimicrobial drugs", "SIMPLE_CHEMICAL", 83, 113], ["packed RBC", "CELL_TYPE", 50, 60], ["packed RBC", "TREATMENT", 50, 60], ["IV crystalloids", "TREATMENT", 62, 77], ["parenteral antimicrobial drugs", "TREATMENT", 83, 113]]], ["Thoracic radiographs showed a severe, diffuse, patchy alveolar and nodular interstitial pattern with thickening of the bronchial walls and mild pleural effusion (see Figure 20-7) .", [["alveolar", "ANATOMY", 54, 62], ["nodular interstitial", "ANATOMY", 67, 87], ["bronchial walls", "ANATOMY", 119, 134], ["pleural", "ANATOMY", 144, 151], ["pleural effusion", "DISEASE", 144, 160], ["alveolar", "TISSUE", 54, 62], ["pleural effusion", "PATHOLOGICAL_FORMATION", 144, 160], ["Thoracic radiographs", "TEST", 0, 20], ["a severe, diffuse, patchy alveolar and nodular interstitial pattern", "PROBLEM", 28, 95], ["thickening of the bronchial walls", "PROBLEM", 101, 134], ["mild pleural effusion", "PROBLEM", 139, 160], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["diffuse", "OBSERVATION_MODIFIER", 38, 45], ["patchy", "OBSERVATION_MODIFIER", 47, 53], ["alveolar", "ANATOMY_MODIFIER", 54, 62], ["nodular", "OBSERVATION_MODIFIER", 67, 74], ["interstitial", "ANATOMY_MODIFIER", 75, 87], ["thickening", "OBSERVATION", 101, 111], ["bronchial walls", "ANATOMY", 119, 134], ["mild", "OBSERVATION_MODIFIER", 139, 143], ["pleural", "ANATOMY", 144, 151], ["effusion", "OBSERVATION", 152, 160]]], ["A tracheobronchial lavage showed marked mixed, predominantly pyogranulomatous inflammation with moderate epithelial hyperplasia and some degenerate neutrophils (see Figure 20 -9).", [["tracheobronchial lavage", "ANATOMY", 2, 25], ["pyogranulomatous", "ANATOMY", 61, 77], ["epithelial", "ANATOMY", 105, 115], ["neutrophils", "ANATOMY", 148, 159], ["inflammation", "DISEASE", 78, 90], ["epithelial", "TISSUE", 105, 115], ["neutrophils", "CELL", 148, 159], ["degenerate neutrophils", "CELL_TYPE", 137, 159], ["A tracheobronchial lavage", "TEST", 0, 25], ["marked mixed, predominantly pyogranulomatous inflammation", "PROBLEM", 33, 90], ["moderate epithelial hyperplasia", "PROBLEM", 96, 127], ["some degenerate neutrophils", "PROBLEM", 132, 159], ["tracheobronchial", "ANATOMY", 2, 18], ["lavage", "OBSERVATION", 19, 25], ["marked", "OBSERVATION_MODIFIER", 33, 39], ["mixed", "OBSERVATION_MODIFIER", 40, 45], ["predominantly", "OBSERVATION_MODIFIER", 47, 60], ["pyogranulomatous inflammation", "OBSERVATION", 61, 90], ["moderate", "OBSERVATION_MODIFIER", 96, 104], ["epithelial", "ANATOMY_MODIFIER", 105, 115], ["hyperplasia", "OBSERVATION", 116, 127], ["some", "OBSERVATION_MODIFIER", 132, 136], ["degenerate neutrophils", "OBSERVATION", 137, 159]]], ["Immunocytochemistry with an anti-FCoV antibody was strongly positive in macrophages.", [["macrophages", "ANATOMY", 72, 83], ["anti-FCoV", "GENE_OR_GENE_PRODUCT", 28, 37], ["macrophages", "CELL", 72, 83], ["anti-FCoV antibody", "PROTEIN", 28, 46], ["macrophages", "CELL_TYPE", 72, 83], ["Immunocytochemistry", "TEST", 0, 19], ["an anti-FCoV antibody", "TEST", 25, 46], ["macrophages", "OBSERVATION", 72, 83]]], ["Aerobic and anaerobic bacterial cultures of the wash specimen were negative.", [["specimen", "ANATOMY", 53, 61], ["Aerobic and anaerobic bacterial cultures", "TEST", 0, 40], ["the wash specimen", "TEST", 44, 61]]], ["The cat subsequently seizured and was euthanized.Mesenteric Lymph NodeNecropsy Findings: Necropsy showed moderate to severe, multifocal to coalescing pyogranulomatous capsulitis and serositis that involved the spleen, liver, kidney, intestines, diaphragm, thoracic and abdominal walls, and pericardium.", [["spleen", "ANATOMY", 210, 216], ["liver", "ANATOMY", 218, 223], ["kidney", "ANATOMY", 225, 231], ["intestines", "ANATOMY", 233, 243], ["diaphragm", "ANATOMY", 245, 254], ["thoracic", "ANATOMY", 256, 264], ["abdominal walls", "ANATOMY", 269, 284], ["pericardium", "ANATOMY", 290, 301], ["pyogranulomatous capsulitis", "DISEASE", 150, 177], ["serositis", "DISEASE", 182, 191], ["cat", "ORGANISM", 4, 7], ["Mesenteric Lymph", "MULTI-TISSUE_STRUCTURE", 49, 65], ["spleen", "ORGAN", 210, 216], ["liver", "ORGAN", 218, 223], ["kidney", "ORGAN", 225, 231], ["intestines", "ORGAN", 233, 243], ["diaphragm", "ORGAN", 245, 254], ["thoracic", "MULTI-TISSUE_STRUCTURE", 256, 264], ["abdominal walls", "MULTI-TISSUE_STRUCTURE", 269, 284], ["pericardium", "ORGAN", 290, 301], ["Necropsy", "TEST", 89, 97], ["moderate to severe, multifocal to coalescing pyogranulomatous capsulitis", "PROBLEM", 105, 177], ["serositis", "PROBLEM", 182, 191], ["the spleen, liver, kidney, intestines, diaphragm, thoracic and abdominal walls, and pericardium", "PROBLEM", 206, 301], ["Lymph NodeNecropsy", "OBSERVATION", 60, 78], ["moderate", "OBSERVATION_MODIFIER", 105, 113], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["multifocal", "OBSERVATION_MODIFIER", 125, 135], ["coalescing", "OBSERVATION_MODIFIER", 139, 149], ["pyogranulomatous capsulitis", "OBSERVATION", 150, 177], ["serositis", "OBSERVATION", 182, 191], ["spleen", "ANATOMY", 210, 216], ["liver", "ANATOMY", 218, 223], ["kidney", "ANATOMY", 225, 231], ["intestines", "ANATOMY", 233, 243], ["diaphragm", "ANATOMY", 245, 254], ["thoracic", "ANATOMY", 256, 264], ["abdominal", "ANATOMY", 269, 278], ["walls", "ANATOMY_MODIFIER", 279, 284], ["pericardium", "ANATOMY", 290, 301]]], ["There was also multifocal pyogranulomatous splenitis, hepatitis, nephritis, meningoencephalitis, and pneumonia with necrosis.", [["pyogranulomatous", "ANATOMY", 26, 42], ["splenitis", "DISEASE", 43, 52], ["hepatitis", "DISEASE", 54, 63], ["nephritis", "DISEASE", 65, 74], ["meningoencephalitis", "DISEASE", 76, 95], ["pneumonia", "DISEASE", 101, 110], ["necrosis", "DISEASE", 116, 124], ["multifocal pyogranulomatous splenitis", "PROBLEM", 15, 52], ["hepatitis", "PROBLEM", 54, 63], ["nephritis", "PROBLEM", 65, 74], ["meningoencephalitis", "PROBLEM", 76, 95], ["pneumonia", "PROBLEM", 101, 110], ["necrosis", "PROBLEM", 116, 124], ["multifocal", "OBSERVATION_MODIFIER", 15, 25], ["pyogranulomatous splenitis", "OBSERVATION", 26, 52], ["hepatitis", "OBSERVATION", 54, 63], ["nephritis", "OBSERVATION", 65, 74], ["meningoencephalitis", "OBSERVATION", 76, 95], ["pneumonia", "OBSERVATION", 101, 110], ["necrosis", "OBSERVATION", 116, 124]]], ["Straw-colored effusion was present in the abdominal cavity, thoracic cavity, and pleural space.", [["abdominal cavity", "ANATOMY", 42, 58], ["thoracic cavity", "ANATOMY", 60, 75], ["pleural space", "ANATOMY", 81, 94], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 42, 58], ["thoracic cavity", "MULTI-TISSUE_STRUCTURE", 60, 75], ["pleural space", "MULTI-TISSUE_STRUCTURE", 81, 94], ["Straw-colored effusion", "PROBLEM", 0, 22], ["thoracic cavity, and pleural space", "PROBLEM", 60, 94], ["colored", "OBSERVATION_MODIFIER", 6, 13], ["effusion", "OBSERVATION", 14, 22], ["abdominal cavity", "ANATOMY", 42, 58], ["thoracic cavity", "ANATOMY", 60, 75], ["pleural", "ANATOMY", 81, 88]]], ["Immunohistochemistry was strongly positive for FCoV antigen (see Figure 20 -11).Mesenteric Lymph NodeComments: The course of disease and survival time (587 days) in this cat was unusually prolonged for FIP, and on many occasions the diagnosis was questioned.", [["FIP", "DISEASE", 202, 205], ["FCoV antigen", "GENE_OR_GENE_PRODUCT", 47, 59], ["Mesenteric Lymph", "MULTI-TISSUE_STRUCTURE", 80, 96], ["cat", "ORGANISM", 170, 173], ["FCoV antigen", "PROTEIN", 47, 59], ["Immunohistochemistry", "TEST", 0, 20], ["FCoV antigen", "TEST", 47, 59], ["disease", "PROBLEM", 125, 132], ["FIP", "PROBLEM", 202, 205], ["Lymph NodeComments", "OBSERVATION", 91, 109], ["disease", "OBSERVATION", 125, 132]]], ["However, the persistently increased FCoV antibody titer in a cat that lived with only one other cat raised suspicion for the disease.", [["FCoV antibody", "GENE_OR_GENE_PRODUCT", 36, 49], ["cat", "ORGANISM", 61, 64], ["cat", "ORGANISM", 96, 99], ["FCoV antibody", "PROTEIN", 36, 49], ["cat", "SPECIES", 61, 64], ["the persistently increased FCoV antibody titer", "PROBLEM", 9, 55], ["the disease", "PROBLEM", 121, 132], ["persistently", "OBSERVATION_MODIFIER", 13, 25], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["FCoV antibody titer", "OBSERVATION", 36, 55], ["disease", "OBSERVATION", 125, 132]]], ["Chronic, smoldering FIP may be more common than recognized.", [["FIP", "DISEASE", 20, 23], ["Chronic, smoldering FIP", "PROBLEM", 0, 23], ["smoldering FIP", "OBSERVATION", 9, 23], ["may be", "UNCERTAINTY", 24, 30], ["more common", "OBSERVATION_MODIFIER", 31, 42]]], ["6 The initial clinical signs in this cat were mild and may have been overlooked by some owners.", [["cat", "ORGANISM", 37, 40], ["The initial clinical signs", "TEST", 2, 28], ["mild", "OBSERVATION_MODIFIER", 46, 50]]], ["Although the cat appeared to respond to prednisolone treatment, it was not known whether the other medications used had any effect.", [["prednisolone", "CHEMICAL", 40, 52], ["prednisolone", "CHEMICAL", 40, 52], ["cat", "ORGANISM", 13, 16], ["prednisolone", "SIMPLE_CHEMICAL", 40, 52], ["prednisolone treatment", "TREATMENT", 40, 62], ["the other medications", "TREATMENT", 89, 110]]], ["Ultimately, disease progressed, and a diagnosis of FIP was confirmed with immunocytochemistry on the tracheobronchial lavage specimen.", [["tracheobronchial lavage specimen", "ANATOMY", 101, 133], ["FIP", "DISEASE", 51, 54], ["FIP", "ORGANISM", 51, 54], ["tracheobronchial lavage specimen", "MULTI-TISSUE_STRUCTURE", 101, 133], ["disease", "PROBLEM", 12, 19], ["FIP", "PROBLEM", 51, 54], ["immunocytochemistry", "TEST", 74, 93], ["the tracheobronchial lavage specimen", "TEST", 97, 133], ["disease", "OBSERVATION", 12, 19], ["FIP", "OBSERVATION", 51, 54], ["tracheobronchial", "ANATOMY", 101, 117], ["lavage", "OBSERVATION", 118, 124]]], ["Although effusion developed, the amount was too low to permit collection of the fluid for analysis.", [["fluid", "ANATOMY", 80, 85], ["effusion", "DISEASE", 9, 17], ["effusion", "PROBLEM", 9, 17], ["the fluid for analysis", "TEST", 76, 98], ["effusion", "OBSERVATION", 9, 17], ["amount", "OBSERVATION_MODIFIER", 33, 39], ["fluid", "OBSERVATION", 80, 85]]], ["The initial negative PCR and immunocytochemistry results may have reflected the presence of low quantities of virus.", [["The initial negative PCR", "TEST", 0, 24], ["immunocytochemistry", "TEST", 29, 48], ["low quantities of virus", "PROBLEM", 92, 115], ["low quantities", "OBSERVATION_MODIFIER", 92, 106], ["virus", "OBSERVATION", 110, 115]]]], "238031f3c3c29e1c3e95271521cd81d41c65d45f": [["IntroductionCoronavirus disease 2019 (COVID-19), which is caused by infection with the novel coronavirus SARS-Coronavirus-2 (SARS-CoV-2), was first described in Wuhan, China, at the .", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["infection", "DISEASE", 68, 77], ["coronavirus SARS", "DISEASE", 93, 109], ["COVID-19", "CELL", 38, 46], ["coronavirus SARS-Coronavirus-2", "ORGANISM", 93, 123], ["SARS-CoV-2", "ORGANISM", 125, 135], ["coronavirus", "SPECIES", 93, 104], ["IntroductionCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["SARS-CoV-2", "SPECIES", 125, 135], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["infection", "PROBLEM", 68, 77], ["the novel coronavirus SARS", "PROBLEM", 83, 109], ["Coronavirus", "TEST", 110, 121], ["infection", "OBSERVATION", 68, 77]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintIntroductionThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["COVID-19 and SARS-CoV-2 infections rapidly spread, and COVID-19 was declared a pandemic by the World Health Organization in March of 2020.IntroductionThe response to the COVID-19 pandemic by the scientific community has resulted in a concentrated effort of historical proportions, including widespread data sharing in the hopes of understanding every aspect of SARS-CoV-2 and COVID-19.", [["infections", "DISEASE", 24, 34], ["SARS", "DISEASE", 361, 365], ["SARS-CoV-2", "ORGANISM", 13, 23], ["SARS-CoV", "SPECIES", 13, 21], ["COVID", "TEST", 0, 5], ["SARS", "PROBLEM", 13, 17], ["CoV", "TEST", 18, 21], ["infections", "PROBLEM", 24, 34], ["COVID", "TEST", 55, 60], ["SARS", "TEST", 361, 365], ["CoV", "TEST", 366, 369], ["COVID", "TEST", 376, 381]]], ["Symptoms of SARS-CoV-2 infection are varied, as some patients are asymptomatic, whereas others suffer from cough, dyspnea, respiratory failure, cytokine storm, and, in many cases, death (1) .", [["respiratory", "ANATOMY", 123, 134], ["SARS", "DISEASE", 12, 16], ["infection", "DISEASE", 23, 32], ["cough", "DISEASE", 107, 112], ["dyspnea", "DISEASE", 114, 121], ["respiratory failure", "DISEASE", 123, 142], ["death", "DISEASE", 180, 185], ["SARS-CoV-2", "ORGANISM", 12, 22], ["patients", "ORGANISM", 53, 61], ["cytokine", "PROTEIN", 144, 152], ["CoV-", "SPECIES", 17, 21], ["patients", "SPECIES", 53, 61], ["SARS-CoV-2", "SPECIES", 12, 22], ["Symptoms", "PROBLEM", 0, 8], ["SARS", "PROBLEM", 12, 16], ["CoV", "PROBLEM", 17, 20], ["2 infection", "PROBLEM", 21, 32], ["asymptomatic", "PROBLEM", 66, 78], ["cough", "PROBLEM", 107, 112], ["dyspnea", "PROBLEM", 114, 121], ["respiratory failure", "PROBLEM", 123, 142], ["cytokine storm", "PROBLEM", 144, 158], ["SARS", "OBSERVATION", 12, 16], ["CoV", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 23, 32], ["cough", "OBSERVATION", 107, 112], ["respiratory", "ANATOMY", 123, 134], ["failure", "OBSERVATION", 135, 142], ["cytokine storm", "OBSERVATION", 144, 158]]], ["Furthermore, our understanding of COVID-19 symptoms continues to evolve as unexpected consequences of SARS-CoV-2 infection come to light, e.g., potential increased risk of thrombotic events in COVID-19 patients (2) (3) (4) (5) (6) .", [["SARS", "DISEASE", 102, 106], ["infection", "DISEASE", 113, 122], ["thrombotic", "DISEASE", 172, 182], ["SARS-CoV-2", "ORGANISM", 102, 112], ["patients", "ORGANISM", 202, 210], ["2) (3) (4) (5) (6)", "SIMPLE_CHEMICAL", 212, 230], ["patients", "SPECIES", 202, 210], ["SARS-CoV", "SPECIES", 102, 110], ["COVID-19 symptoms", "PROBLEM", 34, 51], ["SARS", "PROBLEM", 102, 106], ["CoV", "TEST", 107, 110], ["2 infection", "PROBLEM", 111, 122], ["thrombotic events", "PROBLEM", 172, 189], ["COVID", "TEST", 193, 198], ["increased", "OBSERVATION_MODIFIER", 154, 163], ["thrombotic", "OBSERVATION", 172, 182]]], ["SARS-CoV-2 infections spread through contact with symptomatic, as well as pre-symptomatic and asymptomatic, cases (7) .", [["SARS", "DISEASE", 0, 4], ["infections", "DISEASE", 11, 21], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 5, 8], ["2 infections", "PROBLEM", 9, 21]]], ["A detailed characterization of immune responses to SARS-CoV-2 infection in pre-symptomatic, mild, and, asymptomatic cases is warranted and imperative for the identification of predictive biomarkers and effective vaccination programs.IntroductionOur goal was to apply statistical comparisons to the three clinical case subjects from Wuhan, China, presented by Ong et al., as the original paper was not subjected to statistical analysis (8) .", [["SARS", "DISEASE", 51, 55], ["infection", "DISEASE", 62, 71], ["SARS-CoV-2", "ORGANISM", 51, 61], ["CoV-2", "SPECIES", 56, 61], ["SARS-CoV-2", "SPECIES", 51, 61], ["A detailed characterization", "TEST", 0, 27], ["immune responses", "PROBLEM", 31, 47], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59], ["2 infection", "PROBLEM", 60, 71], ["predictive biomarkers", "TEST", 176, 197], ["effective vaccination programs", "TREATMENT", 202, 232], ["statistical analysis", "TEST", 414, 434], ["infection", "OBSERVATION", 62, 71], ["mild", "OBSERVATION_MODIFIER", 92, 96]]], ["These data are unique because cases 1 and 2 are father and son with starkly different clinical courses of COVID-19 infection.", [["COVID-19", "CHEMICAL", 106, 114], ["infection", "DISEASE", 115, 124], ["COVID-19 infection", "PROBLEM", 106, 124], ["infection", "OBSERVATION", 115, 124]]], ["These two cases represent a dataset with reduced genetic diversity and offer the ability to compare a severe to a mild case temporally, as Ong et al.Introductioncharacterized whole blood mRNA ranging from early in the clinical course to as late as 19 days from symptom onset (DSO) (8) .IntroductionCase 1, a 66-year-old male, presented with fever (38.1 oC), cough, and, as defined by Ong et al., \"bilateral, patchy, ill-defined lung infiltrates\" (8) .", [["blood", "ANATOMY", 181, 186], ["lung", "ANATOMY", 428, 432], ["fever", "DISEASE", 341, 346], ["cough", "DISEASE", 358, 363], ["ill", "DISEASE", 416, 419], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["lung", "ORGAN", 428, 432], ["whole blood mRNA", "RNA", 175, 191], ["reduced genetic diversity", "PROBLEM", 41, 66], ["a mild case temporally", "PROBLEM", 112, 134], ["whole blood mRNA", "TEST", 175, 191], ["fever", "PROBLEM", 341, 346], ["cough", "PROBLEM", 358, 363], ["bilateral, patchy, ill-defined lung infiltrates\"", "PROBLEM", 397, 445], ["mild", "OBSERVATION_MODIFIER", 114, 118], ["cough", "OBSERVATION", 358, 363], ["bilateral", "ANATOMY_MODIFIER", 397, 406], ["patchy", "OBSERVATION_MODIFIER", 408, 414], ["ill", "OBSERVATION_MODIFIER", 416, 419], ["lung", "ANATOMY", 428, 432], ["infiltrates", "OBSERVATION", 433, 444]]], ["For the purposes of our study, we .", [["our study", "TEST", 20, 29]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintIntroductionThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Throat swabs from case 3 tested positive for SARS-CoV-2 consistently until 17 DSO and intermittently until 23 DSO.", [["Throat swabs", "ANATOMY", 0, 12], ["SARS", "DISEASE", 45, 49], ["Throat swabs", "ORGANISM_SUBSTANCE", 0, 12], ["SARS-CoV", "SPECIES", 45, 53], ["Throat swabs from case", "TEST", 0, 22], ["SARS", "PROBLEM", 45, 49], ["CoV", "TEST", 50, 53]]], ["We deemed his case to be moderate as he did not require any supplemental oxygen.IntroductionIn a related study, Hadjadi et al. characterized whole blood mRNA from 32 COVID-19 patients separated into groups by disease severity, mild/moderate, severe, and critical (10) , and herein we provide comparisons to these data.", [["whole blood", "ANATOMY", 141, 152], ["oxygen", "CHEMICAL", 73, 79], ["oxygen", "CHEMICAL", 73, 79], ["oxygen", "SIMPLE_CHEMICAL", 73, 79], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["patients", "ORGANISM", 175, 183], ["whole blood mRNA", "RNA", 141, 157], ["patients", "SPECIES", 175, 183], ["any supplemental oxygen", "TREATMENT", 56, 79], ["a related study", "TEST", 95, 110], ["whole blood mRNA", "TEST", 141, 157], ["COVID", "TEST", 166, 171], ["disease severity", "PROBLEM", 209, 225], ["mild/moderate, severe", "PROBLEM", 227, 248], ["these data", "TEST", 307, 317], ["disease", "OBSERVATION", 209, 216], ["mild", "OBSERVATION_MODIFIER", 227, 231], ["moderate", "OBSERVATION_MODIFIER", 232, 240], ["severe", "OBSERVATION_MODIFIER", 242, 248]]], ["We also compare our findings to those of Shen et al. that performed a full proteomics and metabolomic analysis of COVID-19 patient serum (11) .IntroductionBy applying unbiased sample grouping and statistical methods, this dataset may provide a window into the temporal dynamics of COVID-19-related immune responses in afebrile patients with mild symptoms.Hierarchical Clustering and PCA analysisData were generated by Ong et al. using the Human Immunology V2 multiplex panel available from NanoString Technologies, Inc (8) .", [["serum", "ANATOMY", 131, 136], ["patient", "ORGANISM", 123, 130], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["COVID-19", "CELL", 281, 289], ["patients", "ORGANISM", 327, 335], ["Human", "ORGANISM", 439, 444], ["patient", "SPECIES", 123, 130], ["patients", "SPECIES", 327, 335], ["Human", "SPECIES", 439, 444], ["a full proteomics", "TEST", 68, 85], ["metabolomic analysis", "TEST", 90, 110], ["COVID", "TEST", 114, 119], ["patient serum", "TEST", 123, 136], ["unbiased sample grouping", "TREATMENT", 167, 191], ["COVID", "TEST", 281, 286], ["afebrile", "PROBLEM", 318, 326], ["mild symptoms", "PROBLEM", 341, 354], ["Hierarchical Clustering and PCA analysisData", "TREATMENT", 355, 399], ["multiplex panel", "TEST", 459, 474], ["NanoString Technologies", "TEST", 490, 513], ["mild", "OBSERVATION_MODIFIER", 341, 345]]], ["Raw data were obtained from Array Express, accession number E-MTAB-8871, and uploaded into the nSolver Analysis software (NanoString Technologies, Inc.) for further analysis.", [["further analysis", "TEST", 157, 173]]], ["All data, analysis software, and patient information used in this study are freely available to the public.", [["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["All data", "TEST", 0, 8], ["analysis software", "TEST", 10, 27], ["this study", "TEST", 61, 71]]], ["These data were not generated from patients at any of our facilities, and thus, institutional review board oversight was not necessary.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43]]], ["Only case 1 day 4 was run in technical duplicates, and as no other sample was run in replicate, we removed the second replicate for this sample from any further analysis.", [["this sample", "TEST", 132, 143], ["any further analysis", "TEST", 149, 169]]], ["Data were subjected to the Advanced Analysis Module of the nSolver software and were normalized using default settings ( Figure 1 ).", [["the nSolver software", "TEST", 55, 75]]], ["For heatmap generation, each line represents a single gene, each column is a separate .", [["heatmap generation", "TREATMENT", 4, 22], ["each line", "TREATMENT", 24, 33], ["a single gene, each column", "TREATMENT", 45, 71]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintHierarchical Clustering and PCA analysisThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.", [["CC", "CHEMICAL", 0, 2], ["PCA analysis", "TEST", 236, 248], ["med", "ANATOMY", 102, 105]]], ["16.20115972 doi: medRxiv preprint 6 sample, and means were scaled (z-score) to give all genes equal variance.", [["means", "TEST", 48, 53], ["z-score", "TEST", 67, 74]]], ["Orange corresponds to higher expression, and blue corresponds to lower expression.", [["higher expression", "OBSERVATION_MODIFIER", 22, 39]]], ["Principal component analysis (PCA) plots were auto generated by nSolver Advanced Analysis software, NanoString, Technologies Inc.Pathway AnalysisnSolver software condensed each covariate's gene expression profiles into pathway scores.Pathway AnalysisPathway scores were fit using the first principal component of the data for each gene set ( Figure 1 ).", [["Principal component analysis", "TEST", 0, 28], ["Analysis software", "TEST", 81, 98], ["the data", "TEST", 313, 321]]], ["A positive score indicates that at least half of the genes in that pathway's set have positive weights, and vice versa for negative scores.", [["A positive score", "PROBLEM", 0, 16], ["positive weights", "PROBLEM", 86, 102]]], ["Pathway scores were subjected to gaussian statistical analysis t-tests with homogeneous variances.Differential Gene Expression AnalysisDifferential gene expression analysis was performed with nSolver software using \"groups\" as the covariate ( Figure 2 ).", [["Pathway scores", "PROBLEM", 0, 14], ["gaussian statistical analysis", "TEST", 33, 62], ["gene expression analysis", "TEST", 148, 172]]], ["The Benjamini-Yekutieli method of FDR calculations was selected, and all other analyses were performed with the default settings.Differential Gene Expression AnalysisTo compare our findings to the related study by Hadjadi et al. we obtained the normalized, logtransformed values from the authors (10) .", [["The Benjamini", "TREATMENT", 0, 13], ["FDR calculations", "TEST", 34, 50], ["all other analyses", "TEST", 69, 87], ["the related study", "TEST", 193, 210]]], ["For differential gene expression, we calculated pvalues and FDR values by Student's two-tailed, heteroscedastic t-test, adjusting for false discovery using the Benjamini-Yekutieli method.", [["FDR values", "TEST", 60, 70], ["the Benjamini", "TREATMENT", 156, 169], ["Yekutieli method", "TREATMENT", 170, 186]]], ["We maintained COVID-19 severity groups as outlined in the original manuscript (10) .", [["COVID", "TEST", 14, 19]]], ["Data and R statistical analysis methods generated by Shen et al. were downloaded from https://github.com/guomics-lab/CVDSBA and run in accordance with the original paper (11) .Differential Gene Expression Analysis.", [["Expression Analysis", "TEST", 194, 213]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintDifferential Gene Expression AnalysisThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.", [["CC", "CHEMICAL", 0, 2], ["Expression Analysis", "TEST", 226, 245], ["med", "ANATOMY", 102, 105]]], ["16.20115972 doi: medRxiv preprintIngenuity Pathway AnalysisDifferential gene expression values from the advanced analysis performed by the nSolver software, NanoString Technologies, Inc. were loaded into the Ingenuity Pathway Analysis (IPA) software, Qiagen Digital Insights ( Figure 2 ).", [["the advanced analysis", "TEST", 100, 121]]], ["Log2 transformed and Benjamini-Yekutieli calculated FDR values were used as input for further analyses.", [["Benjamini", "TEST", 21, 30], ["further analyses", "TEST", 86, 102]]], ["The \"Antigen Presentation Pathway\" in IPA was loaded and expanded using the grow function.", [["IPA", "CHEMICAL", 38, 41], ["IPA", "CANCER", 38, 41]]], ["All upstream regulators of CIITA and PAX5 were loaded onto the pathway.", [["CIITA", "GENE_OR_GENE_PRODUCT", 27, 32], ["PAX5", "GENE_OR_GENE_PRODUCT", 37, 41], ["upstream regulators", "PROTEIN", 4, 23], ["CIITA", "PROTEIN", 27, 32], ["PAX5", "PROTEIN", 37, 41], ["CIITA and PAX5", "TREATMENT", 27, 41], ["CIITA", "OBSERVATION", 27, 32]]], ["As CD19 is a known target of PAX5 in B cell signaling and lineage maintenance, it was included in the final pathway.", [["B cell", "ANATOMY", 37, 43], ["CD19", "GENE_OR_GENE_PRODUCT", 3, 7], ["PAX5", "GENE_OR_GENE_PRODUCT", 29, 33], ["B cell", "CELL", 37, 43], ["lineage", "CELL", 58, 65], ["CD19", "PROTEIN", 3, 7], ["PAX5", "PROTEIN", 29, 33], ["PAX5 in B cell signaling", "TREATMENT", 29, 53], ["lineage maintenance", "TREATMENT", 58, 77], ["cell signaling", "OBSERVATION", 39, 53], ["lineage maintenance", "OBSERVATION", 58, 77]]], ["The \"Complement System\" pathway was left unmodified.Cell-Type AnalysisCell-type analysis and scoring in nSolver software was performed for each of the covariate groups ( Figure 3) .", [["Cell", "ANATOMY", 52, 56], ["Cell", "CELL", 52, 56], ["Cell", "TEST", 52, 56], ["nSolver software", "TEST", 104, 120], ["left", "ANATOMY_MODIFIER", 36, 40]]], ["A significant correlation between immune cell type-specific gene set expression over all samples was used to determine the validity of the cell-type score, indicating the relative abundance of a given cell type.", [["immune cell", "ANATOMY", 34, 45], ["samples", "ANATOMY", 89, 96], ["cell", "ANATOMY", 139, 143], ["cell", "ANATOMY", 201, 205], ["immune cell", "CELL", 34, 45], ["cell", "CELL", 139, 143], ["cell type", "CELL", 201, 210], ["all samples", "TEST", 85, 96], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["cell type", "OBSERVATION", 201, 210]]], ["A significant correlation between CD8A and CD8B was used to estimate the abundance of CD8+ T cells (p=0.01), and the B cell population was estimated using a correlation between CD19 and Membrane Spanning 4-Domains A1 (MS4A1) (p=0).", [["CD8+ T cells", "ANATOMY", 86, 98], ["B cell", "ANATOMY", 117, 123], ["CD8A", "GENE_OR_GENE_PRODUCT", 34, 38], ["CD8B", "GENE_OR_GENE_PRODUCT", 43, 47], ["CD8", "GENE_OR_GENE_PRODUCT", 86, 89], ["B cell", "CELL", 117, 123], ["CD19", "GENE_OR_GENE_PRODUCT", 177, 181], ["Membrane", "CELLULAR_COMPONENT", 186, 194], ["4-Domains A1", "GENE_OR_GENE_PRODUCT", 204, 216], ["CD8A", "PROTEIN", 34, 38], ["CD8B", "PROTEIN", 43, 47], ["CD8", "PROTEIN", 86, 89], ["T cells", "CELL_TYPE", 91, 98], ["B cell population", "CELL_TYPE", 117, 134], ["CD19", "PROTEIN", 177, 181], ["Membrane Spanning 4-Domains A1", "PROTEIN", 186, 216], ["MS4A1", "PROTEIN", 218, 223], ["CD8A", "TEST", 34, 38], ["CD8B", "TEST", 43, 47], ["CD8+ T cells", "PROBLEM", 86, 98], ["the B cell population", "PROBLEM", 113, 134], ["CD19", "TEST", 177, 181], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["cell population", "OBSERVATION", 119, 134]]], ["Cell-type scores were then log2 transformed, and gaussian statistical analysis t-tests were performed with homogeneous variances.Cell-Type Analysis.", [["Cell", "ANATOMY", 0, 4], ["Cell", "ANATOMY", 129, 133], ["Cell", "CELL", 0, 4], ["Cell", "CELL", 129, 133], ["Cell-type scores", "TEST", 0, 16], ["gaussian statistical analysis t-tests", "TEST", 49, 86]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintCell-Type AnalysisThe copyright holder for this this version posted September 18, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["To justify our statistical analysis, we took an unbiased approach to assign the clinical samples into groups and performed an unsupervised hierarchical clustering analysis (HCA) of all 32 clinical samples by similarities in global gene expression profiles ( Figure 1A) .", [["samples", "ANATOMY", 197, 204], ["samples", "CANCER", 197, 204], ["our statistical analysis", "TEST", 11, 35]]], ["Visually, the left 15 columns showed increased global immune transcript expression (higher proportion of yellow) compared to the other 17 columns (higher proportion of blue).Cell-Type AnalysisAll healthy control (HC) samples clustered together two branch points down, and, surprisingly, group 1 (case 1 days (d)4-6) co-clustered with the HC group off of the first branch point away from all of the other case samples, implying that despite all other factors (relation, time of illness, etc.), the unweighted global immune profile during these days of infection of case 1 was more closely related to the HC group than the other COVID-19 samples.", [["Cell", "ANATOMY", 174, 178], ["samples", "ANATOMY", 217, 224], ["samples", "ANATOMY", 409, 416], ["samples", "ANATOMY", 636, 643], ["infection", "DISEASE", 551, 560], ["Cell", "CELL", 174, 178], ["HC", "CANCER", 603, 605], ["increased global immune transcript expression", "PROBLEM", 37, 82], ["illness", "PROBLEM", 477, 484], ["infection of case 1", "PROBLEM", 551, 570], ["the other COVID", "TEST", 617, 632], ["left", "ANATOMY_MODIFIER", 14, 18], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["global immune", "OBSERVATION", 47, 60], ["transcript expression", "OBSERVATION", 61, 82], ["branch", "OBSERVATION_MODIFIER", 248, 254], ["branch", "ANATOMY_MODIFIER", 364, 370]]], ["Group 1 displayed the most severe clinical symptoms of COVID-19 during this phase, with SO2 nadir on day 5.", [["SO2", "CHEMICAL", 88, 91], ["COVID-19", "CHEMICAL", 55, 63], ["SO2", "CHEMICAL", 88, 91], ["SO2", "SIMPLE_CHEMICAL", 88, 91], ["the most severe clinical symptoms", "PROBLEM", 18, 51], ["COVID", "TEST", 55, 60], ["SO2 nadir", "TEST", 88, 97]]], ["As expected, group 1 displayed a global increase in immune response-related transcripts, but, unexpectedly, this was the only cluster that had higher unweighted global gene expression levels of immune-response related transcripts than HC samples.Cell-Type Analysis.", [["HC samples", "ANATOMY", 235, 245], ["Cell", "ANATOMY", 246, 250], ["Cell", "CELL", 246, 250], ["a global increase in immune response", "PROBLEM", 31, 67], ["HC samples", "TEST", 235, 245], ["global", "OBSERVATION_MODIFIER", 33, 39], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["immune response", "OBSERVATION", 52, 67]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintCell-Type AnalysisThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["16.20115972 doi: medRxiv preprint 9Cell-Type AnalysisThe rest of the clinical samples clustered together on a separate tree, with group 2 (case 2 d6 and d7) clustering the closest to the tree with group 1 and HC.", [["samples", "ANATOMY", 78, 85], ["samples", "CANCER", 78, 85], ["tree", "ANATOMY_MODIFIER", 187, 191]]], ["The clinical course of case 2 was characterized by mild symptoms without the presence of a fever, so it may be expected that samples from this case would cluster closer to the HC group.", [["samples", "ANATOMY", 125, 132], ["fever", "DISEASE", 91, 96], ["HC", "CANCER", 176, 178], ["mild symptoms", "PROBLEM", 51, 64], ["a fever", "PROBLEM", 89, 96], ["mild", "OBSERVATION_MODIFIER", 51, 55], ["fever", "OBSERVATION", 91, 96]]], ["Sharing a node two levels down with group 2 are group 3 (case 2 d8-10) and group X (all samples from case 3).", [["node", "ANATOMY", 10, 14], ["samples", "ANATOMY", 88, 95], ["node", "OBSERVATION", 10, 14]]], ["The clustering of groups 3 and X implies that despite the genetic differences between these unrelated cases, the course of the viral infection was most similar between mild case 2 and mild-moderate case 3, many days after the onset of COVID-19 symptoms.Cell-Type AnalysisIn a separate sub-cluster, group 4 (case 1 d7-9) shares a second-down branch point with group 5 (case 2 d12, d13, and d19) and group 6 (case 1 d11, d12, and d18 and case 2 d11).", [["Cell", "ANATOMY", 253, 257], ["viral infection", "DISEASE", 127, 142], ["COVID", "DISEASE", 235, 240], ["Cell", "CELL", 253, 257], ["d13", "PROTEIN", 380, 383], ["d19", "PROTEIN", 389, 392], ["d12", "PROTEIN", 419, 422], ["d18", "PROTEIN", 428, 431], ["d11", "PROTEIN", 443, 446], ["the viral infection", "PROBLEM", 123, 142], ["mild-moderate case 3", "PROBLEM", 184, 204], ["COVID-19 symptoms", "PROBLEM", 235, 252], ["d13", "TREATMENT", 380, 383], ["d12", "TREATMENT", 419, 422], ["viral", "OBSERVATION_MODIFIER", 127, 132], ["infection", "OBSERVATION", 133, 142], ["mild", "OBSERVATION_MODIFIER", 184, 188], ["moderate", "OBSERVATION_MODIFIER", 189, 197]]], ["The distant separation of clusters corresponding to group 1 (case 1 d4-6) and group 4 (case 1 d7-9) may be due to either the effects of the antiviral medication or the natural course of infection, despite their temporal nature.", [["infection", "DISEASE", 186, 195], ["the antiviral medication", "TREATMENT", 136, 160], ["infection", "PROBLEM", 186, 195], ["distant", "OBSERVATION_MODIFIER", 4, 11], ["separation", "OBSERVATION_MODIFIER", 12, 22], ["infection", "OBSERVATION", 186, 195]]], ["It appears that the final phase of infection for both clinically distinct cases 1 and 2 begins on day 11, at which time both case 1 and case 2 d11 converge into one closely related cluster.Cell-Type AnalysisPrincipal component (PC) analysis ranked each sample by the strength of similarity and showed that groups that were defined based on hierarchical clustering also associated with each other over PC1 and PC2, which represented 31% and 22% of the variation between samples, respectively ( Figure 1B ).", [["Cell", "ANATOMY", 189, 193], ["samples", "ANATOMY", 469, 476], ["infection", "DISEASE", 35, 44], ["Cell", "CELL", 189, 193], ["PC2", "GENE_OR_GENE_PRODUCT", 409, 412], ["PC1", "DNA", 401, 404], ["infection", "PROBLEM", 35, 44], ["Cell-Type AnalysisPrincipal component", "TREATMENT", 189, 226], ["PC) analysis", "TEST", 228, 240], ["PC2", "TEST", 409, 412], ["infection", "OBSERVATION", 35, 44]]], ["Based on the expression of genes captured by the first principal component (PC1x-axis), group 1 closely associated with HC samples and was positioned between HC and the rest of the COVID-19 samples, unlike in the hierarchal clustering analysis.Cell-Type AnalysisWhen similarities were weighted along the second component that contributed the secondhighest level of variance in gene expression between samples (PC2y-axis), the group 1 cluster .", [["HC samples", "ANATOMY", 120, 130], ["samples", "ANATOMY", 190, 197], ["Cell", "ANATOMY", 244, 248], ["samples", "ANATOMY", 401, 408], ["HC samples", "CANCER", 120, 130], ["Cell", "CELL", 244, 248], ["PC1x", "PROTEIN", 76, 80], ["COVID", "DNA", 181, 186], ["HC samples", "TEST", 120, 130], ["HC", "TEST", 158, 160], ["the hierarchal clustering analysis", "TEST", 209, 243]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintCell-Type AnalysisThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["16.20115972 doi: medRxiv preprint showed the highest degree of separation from HC and group 5, which corresponds temporally to the latest samples collected from case 2 (d12-13, d19).Cell-Type AnalysisGroup 1 (case 1 d4-6) represented the earliest samples collected from the most severe patient, and thus we selected for further analysis differentially expressed transcripts based on the significance of differential expression between HC and group 1 (p<0.01).", [["samples", "ANATOMY", 138, 145], ["Cell", "ANATOMY", 182, 186], ["samples", "ANATOMY", 247, 254], ["Cell", "CELL", 182, 186], ["samples", "CANCER", 247, 254], ["patient", "ORGANISM", 286, 293], ["patient", "SPECIES", 286, 293], ["further analysis", "TEST", 320, 336], ["HC", "TEST", 435, 437], ["highest degree", "OBSERVATION_MODIFIER", 45, 59], ["separation", "OBSERVATION", 63, 73]]], ["The top 20 differentially increased and decreased transcripts in group 1 represented diverse genes encompassing several facets of innate, adaptive, and other related immune responses (S1 Table) .Cell-Type AnalysisThe topmost differentially increased gene in group 1 was also significantly increased in groups 2 and X, and thus all three cases during their clinical courses experienced an increased abundance of serine protease inhibitor (serpin) family G, member 1 (SERPING1).", [["Cell", "ANATOMY", 195, 199], ["serine", "CHEMICAL", 411, 417], ["Cell", "CELL", 195, 199], ["serine protease inhibitor (serpin) family G, member 1", "GENE_OR_GENE_PRODUCT", 411, 464], ["SERPING1", "GENE_OR_GENE_PRODUCT", 466, 474], ["serine protease inhibitor (serpin) family G, member 1", "PROTEIN", 411, 464], ["SERPING1", "PROTEIN", 466, 474], ["serine protease inhibitor", "TREATMENT", 411, 436], ["top", "OBSERVATION_MODIFIER", 4, 7], ["20 differentially", "OBSERVATION_MODIFIER", 8, 25], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["decreased", "OBSERVATION_MODIFIER", 40, 49], ["transcripts", "OBSERVATION_MODIFIER", 50, 61], ["differentially", "OBSERVATION_MODIFIER", 225, 239], ["increased", "OBSERVATION_MODIFIER", 240, 249], ["significantly", "OBSERVATION_MODIFIER", 275, 288], ["increased", "OBSERVATION_MODIFIER", 289, 298], ["increased", "OBSERVATION_MODIFIER", 388, 397]]], ["SERPING1 is transcriptionally regulated by IFN-gamma (IFNG) activation of STAT-1 (12) , and Cameron et al.Cell-Type Analysisshowed that SERPING1 transcripts were increased in whole blood mRNA sampled from SARS-CoV-1 patients (9) .", [["Cell", "ANATOMY", 106, 110], ["whole blood", "ANATOMY", 175, 186], ["SARS", "DISEASE", 205, 209], ["SERPING1", "GENE_OR_GENE_PRODUCT", 0, 8], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 43, 52], ["IFNG", "GENE_OR_GENE_PRODUCT", 54, 58], ["STAT-1", "GENE_OR_GENE_PRODUCT", 74, 80], ["Cell", "CELL", 106, 110], ["SERPING1", "GENE_OR_GENE_PRODUCT", 136, 144], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["SARS-CoV-1", "ORGANISM", 205, 215], ["patients", "ORGANISM", 216, 224], ["SERPING1", "PROTEIN", 0, 8], ["IFN", "PROTEIN", 43, 46], ["IFNG", "PROTEIN", 54, 58], ["STAT", "PROTEIN", 74, 78], ["SERPING1 transcripts", "RNA", 136, 156], ["whole blood mRNA", "RNA", 175, 191], ["patients", "SPECIES", 216, 224], ["SARS-CoV-1", "SPECIES", 205, 215], ["STAT", "TEST", 74, 78], ["SERPING1 transcripts", "TREATMENT", 136, 156], ["whole blood mRNA", "TEST", 175, 191], ["SARS", "TEST", 205, 209], ["CoV", "TEST", 210, 213], ["increased", "OBSERVATION_MODIFIER", 162, 171]]], ["Further, Hadjadj et al. reported a significant increase SERPING1 when comparing whole blood mRNA collected from 11 COVID-19 patients to 13 HC (10).Cell-Type AnalysisDifferences were not reported for comparisons between severe and critical patients compared to HC samples; thus, we performed an independent analysis and observed a significant increase in SERPING1 abundance in all three COVID-19 severity groups, mild/moderate, severe, and critical, compared to HC (log2 fold-ratio COVID-19 vs healthy controls, FDR<0.01; mild/moderate: 5.30-fold; severe: 5.33-fold; critical: 4.81-fold). .", [["whole blood", "ANATOMY", 80, 91], ["Cell", "ANATOMY", 147, 151], ["HC samples", "ANATOMY", 260, 270], ["SERPING1", "GENE_OR_GENE_PRODUCT", 56, 64], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["patients", "ORGANISM", 124, 132], ["Cell", "CELL", 147, 151], ["patients", "ORGANISM", 239, 247], ["SERPING1", "GENE_OR_GENE_PRODUCT", 354, 362], ["SERPING1", "PROTEIN", 56, 64], ["whole blood mRNA", "RNA", 80, 96], ["SERPING1", "PROTEIN", 354, 362], ["patients", "SPECIES", 124, 132], ["patients", "SPECIES", 239, 247], ["a significant increase SERPING1", "PROBLEM", 33, 64], ["whole blood mRNA", "TEST", 80, 96], ["COVID", "TEST", 115, 120], ["HC samples", "TEST", 260, 270], ["an independent analysis", "TEST", 291, 314], ["a significant increase in SERPING1 abundance", "PROBLEM", 328, 372], ["COVID", "TEST", 386, 391], ["mild/moderate, severe", "PROBLEM", 412, 433], ["HC", "TEST", 461, 463], ["fold", "TEST", 470, 474], ["ratio", "TEST", 475, 480], ["COVID", "TEST", 481, 486], ["FDR", "TEST", 511, 514], ["mild/moderate: 5.30-fold", "PROBLEM", 521, 545], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["increase", "OBSERVATION_MODIFIER", 47, 55], ["SERPING1", "OBSERVATION", 56, 64], ["significant", "OBSERVATION_MODIFIER", 330, 341], ["increase", "OBSERVATION_MODIFIER", 342, 350], ["mild", "OBSERVATION_MODIFIER", 412, 416], ["moderate", "OBSERVATION_MODIFIER", 417, 425], ["severe", "OBSERVATION_MODIFIER", 427, 433], ["moderate", "OBSERVATION_MODIFIER", 526, 534]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintCell-Type AnalysisThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["16.20115972 doi: medRxiv preprint Additionally, C1-INH was significantly increased in non-severe COVID-19 patients when compared to healthy controls (11) .", [["C1-INH", "CHEMICAL", 48, 54], ["C1-INH", "CHEMICAL", 48, 54], ["C1-INH", "GENE_OR_GENE_PRODUCT", 48, 54], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["non-severe COVID", "TEST", 86, 102], ["significantly", "OBSERVATION_MODIFIER", 59, 72], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["non-severe", "OBSERVATION_MODIFIER", 86, 96]]], ["C1-INH suppresses activation of complement, coagulation, inflammation, and fibrinolysis through inhibition of the contact system (14).", [["C1-INH", "CHEMICAL", 0, 6], ["inflammation", "DISEASE", 57, 69], ["C1-INH", "CHEMICAL", 0, 6], ["C1-INH", "GENE_OR_GENE_PRODUCT", 0, 6], ["coagulation", "PROBLEM", 44, 55], ["inflammation", "PROBLEM", 57, 69], ["fibrinolysis", "PROBLEM", 75, 87], ["inflammation", "OBSERVATION", 57, 69], ["fibrinolysis", "OBSERVATION", 75, 87]]], ["This system is termed the contact system because the serine protease, factor XII (FXII) is activated by contact with anionic surfaces resulting in 1) the activation of the Kallikrein-Kinin pathway that drives bradykinin-associated inflammation, 2) cleavage of FXI, resulting in increased thrombin, fibrin formation, and fibrin clot formation, 3) activation of complement through C1r and C1s, and C4) promotion of fibrinolysis (14).Cell-Type AnalysisSARS-CoV-2 infection may be associated with hypercoagulopathy, and this possibility has become one of the major focuses of COVID-19 research (1-6).", [["fibrin clot", "ANATOMY", 320, 331], ["Cell", "ANATOMY", 431, 435], ["bradykinin", "CHEMICAL", 209, 219], ["inflammation", "DISEASE", 231, 243], ["infection", "DISEASE", 460, 469], ["hypercoagulopathy", "DISEASE", 493, 510], ["serine", "CHEMICAL", 53, 59], ["bradykinin", "CHEMICAL", 209, 219], ["factor XII", "GENE_OR_GENE_PRODUCT", 70, 80], ["FXII", "GENE_OR_GENE_PRODUCT", 82, 86], ["Kallikrein-Kinin", "GENE_OR_GENE_PRODUCT", 172, 188], ["bradykinin", "SIMPLE_CHEMICAL", 209, 219], ["FXI", "GENE_OR_GENE_PRODUCT", 260, 263], ["thrombin", "GENE_OR_GENE_PRODUCT", 288, 296], ["fibrin", "GENE_OR_GENE_PRODUCT", 298, 304], ["fibrin", "GENE_OR_GENE_PRODUCT", 320, 326], ["clot", "CELLULAR_COMPONENT", 327, 331], ["C1r", "GENE_OR_GENE_PRODUCT", 379, 382], ["C1s", "GENE_OR_GENE_PRODUCT", 387, 390], ["Cell", "CELL", 431, 435], ["serine protease", "PROTEIN", 53, 68], ["factor XII", "PROTEIN", 70, 80], ["FXII", "PROTEIN", 82, 86], ["FXI", "PROTEIN", 260, 263], ["thrombin", "PROTEIN", 288, 296], ["C1r", "PROTEIN", 379, 382], ["C1s", "PROTEIN", 387, 390], ["C4", "PROTEIN", 396, 398], ["the serine protease", "TREATMENT", 49, 68], ["the Kallikrein-Kinin pathway", "TREATMENT", 168, 196], ["bradykinin", "PROBLEM", 209, 219], ["associated inflammation", "PROBLEM", 220, 243], ["cleavage of FXI", "PROBLEM", 248, 263], ["increased thrombin", "PROBLEM", 278, 296], ["fibrin formation", "PROBLEM", 298, 314], ["fibrin clot formation", "PROBLEM", 320, 341], ["activation of complement through C1r and C1s", "TREATMENT", 346, 390], ["fibrinolysis", "PROBLEM", 413, 425], ["Cell", "TEST", 431, 435], ["AnalysisSARS", "TEST", 441, 453], ["CoV-2 infection", "PROBLEM", 454, 469], ["hypercoagulopathy", "PROBLEM", 493, 510], ["COVID", "TEST", 572, 577], ["inflammation", "OBSERVATION", 231, 243], ["FXI", "OBSERVATION", 260, 263], ["increased", "OBSERVATION_MODIFIER", 278, 287], ["thrombin", "OBSERVATION", 288, 296], ["fibrin formation", "OBSERVATION", 298, 314], ["fibrin clot", "OBSERVATION", 320, 331], ["C1s", "ANATOMY", 387, 390], ["fibrinolysis", "OBSERVATION", 413, 425], ["infection", "OBSERVATION", 460, 469], ["may be associated with", "UNCERTAINTY", 470, 492], ["hypercoagulopathy", "OBSERVATION", 493, 510]]], ["As C1-INH is the primary inhibitor of FXIIa, it broadly inhibits inflammation, coagulation, complement activation, and fibrinolysis (14).", [["C1-INH", "CHEMICAL", 3, 9], ["inflammation", "DISEASE", 65, 77], ["C1-INH", "CHEMICAL", 3, 9], ["C1-INH", "SIMPLE_CHEMICAL", 3, 9], ["FXIIa", "GENE_OR_GENE_PRODUCT", 38, 43], ["FXIIa", "PROTEIN", 38, 43], ["FXIIa", "PROBLEM", 38, 43], ["inflammation", "PROBLEM", 65, 77], ["fibrinolysis", "TEST", 119, 131], ["FXIIa", "OBSERVATION", 38, 43], ["inflammation", "OBSERVATION", 65, 77]]], ["However, excess plasma levels of serpin-protein family members that also regulate FXIIa have been shown to inappropriately reduce fibrinolysis and are associated with increased risk of arterial thrombosis (15) .", [["plasma", "ANATOMY", 16, 22], ["arterial", "ANATOMY", 185, 193], ["FXIIa", "CHEMICAL", 82, 87], ["arterial thrombosis", "DISEASE", 185, 204], ["plasma", "ORGANISM_SUBSTANCE", 16, 22], ["serpin", "GENE_OR_GENE_PRODUCT", 33, 39], ["FXIIa", "GENE_OR_GENE_PRODUCT", 82, 87], ["arterial", "MULTI-TISSUE_STRUCTURE", 185, 193], ["serpin-protein family members", "PROTEIN", 33, 62], ["FXIIa", "PROTEIN", 82, 87], ["plasma levels", "TEST", 16, 29], ["FXIIa", "PROBLEM", 82, 87], ["fibrinolysis", "PROBLEM", 130, 142], ["arterial thrombosis", "PROBLEM", 185, 204], ["arterial", "ANATOMY", 185, 193], ["thrombosis", "OBSERVATION", 194, 204]]], ["Deficiency of C1-INH in humans causes hereditary angioedema, for which one treatment is human plasma-derived C1-INH (16) .", [["plasma", "ANATOMY", 94, 100], ["C1-INH", "CHEMICAL", 14, 20], ["hereditary angioedema", "DISEASE", 38, 59], ["C1-INH", "CHEMICAL", 109, 115], ["C1-INH", "CHEMICAL", 14, 20], ["C1-INH", "CHEMICAL", 109, 115], ["C1-INH", "GENE_OR_GENE_PRODUCT", 14, 20], ["humans", "ORGANISM", 24, 30], ["human", "ORGANISM", 88, 93], ["plasma", "ORGANISM_SUBSTANCE", 94, 100], ["C1-INH", "SIMPLE_CHEMICAL", 109, 115], ["humans", "SPECIES", 24, 30], ["human", "SPECIES", 88, 93], ["humans", "SPECIES", 24, 30], ["human", "SPECIES", 88, 93], ["Deficiency of C1-INH in humans", "PROBLEM", 0, 30], ["hereditary angioedema", "PROBLEM", 38, 59], ["human plasma", "TEST", 88, 100], ["C1", "ANATOMY", 14, 16], ["INH", "OBSERVATION", 17, 20], ["hereditary", "OBSERVATION_MODIFIER", 38, 48], ["angioedema", "OBSERVATION", 49, 59]]], ["Thromboembolic events have been reported with C1-INH treatment (16) .", [["C1-INH", "CHEMICAL", 46, 52], ["C1-INH", "CHEMICAL", 46, 52], ["C1-INH", "SIMPLE_CHEMICAL", 46, 52], ["Thromboembolic events", "PROBLEM", 0, 21], ["C1-INH treatment", "TREATMENT", 46, 62]]], ["These data implicate that SERPING1mediated increases in C1-INH in plasma may shift the balance between coagulation and fibrinolysis that may result in increased fibrin clots.", [["plasma", "ANATOMY", 66, 72], ["fibrin clots", "ANATOMY", 161, 173], ["C1-INH", "CHEMICAL", 56, 62], ["C1-INH", "CHEMICAL", 56, 62], ["SERPING1", "GENE_OR_GENE_PRODUCT", 26, 34], ["C1-INH", "GENE_OR_GENE_PRODUCT", 56, 62], ["plasma", "ORGANISM_SUBSTANCE", 66, 72], ["fibrin", "GENE_OR_GENE_PRODUCT", 161, 167], ["clots", "ORGANISM_SUBSTANCE", 168, 173], ["SERPING1", "PROTEIN", 26, 34], ["SERPING1mediated increases in C1-INH in plasma", "PROBLEM", 26, 72], ["fibrinolysis", "TREATMENT", 119, 131], ["increased fibrin clots", "PROBLEM", 151, 173], ["increases", "OBSERVATION_MODIFIER", 43, 52], ["C1", "ANATOMY", 56, 58], ["increased", "OBSERVATION_MODIFIER", 151, 160], ["fibrin clots", "OBSERVATION", 161, 173]]], ["If increased plasma C1-INH acts to inhibit fibrinolysis and contributes to hypercoagulopathy in COVID-19 patients, plasma C1-INH concentration may provide insight as a biomarker of thrombophilia in infected individuals, even in patients with mild symptoms and no fever, such as case 2 in our study.", [["plasma", "ANATOMY", 13, 19], ["plasma", "ANATOMY", 115, 121], ["C1-INH", "CHEMICAL", 20, 26], ["hypercoagulopathy", "DISEASE", 75, 92], ["C1-INH", "CHEMICAL", 122, 128], ["thrombophilia", "DISEASE", 181, 194], ["fever", "DISEASE", 263, 268], ["C1-INH", "CHEMICAL", 20, 26], ["C1-INH", "CHEMICAL", 122, 128], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["C1-INH", "GENE_OR_GENE_PRODUCT", 20, 26], ["patients", "ORGANISM", 105, 113], ["plasma", "ORGANISM_SUBSTANCE", 115, 121], ["C1-INH", "GENE_OR_GENE_PRODUCT", 122, 128], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 228, 236], ["increased plasma C1-INH acts", "PROBLEM", 3, 31], ["fibrinolysis", "PROBLEM", 43, 55], ["hypercoagulopathy", "PROBLEM", 75, 92], ["COVID", "TEST", 96, 101], ["plasma C1-INH concentration", "TREATMENT", 115, 142], ["thrombophilia in infected individuals", "PROBLEM", 181, 218], ["mild symptoms", "PROBLEM", 242, 255], ["fever", "PROBLEM", 263, 268], ["our study", "TEST", 288, 297], ["thrombophilia", "OBSERVATION", 181, 194], ["infected", "OBSERVATION", 198, 206], ["no", "UNCERTAINTY", 260, 262]]], ["SERPING1-encoded C1-INH is the only known natural inhibitor of the complement proteins C1r and C1s, such that they are unable to form the C1 complement activating complex .", [["INH", "CHEMICAL", 20, 23], ["SERPING1", "GENE_OR_GENE_PRODUCT", 0, 8], ["C1-INH", "GENE_OR_GENE_PRODUCT", 17, 23], ["C1r", "GENE_OR_GENE_PRODUCT", 87, 90], ["C1s", "GENE_OR_GENE_PRODUCT", 95, 98], ["C1 complement activating complex", "GENE_OR_GENE_PRODUCT", 138, 170], ["SERPING1", "PROTEIN", 0, 8], ["complement proteins", "PROTEIN", 67, 86], ["C1r", "PROTEIN", 87, 90], ["C1s", "PROTEIN", 95, 98], ["C1 complement activating complex", "PROTEIN", 138, 170], ["SERPING1", "TEST", 0, 8], ["C1", "ANATOMY", 17, 19], ["INH", "OBSERVATION", 20, 23]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Complement-associated transcripts significantly increased more than two-fold in our dataset, resulting in both a significantly increased complement pathway score for groups 1-4, 6, and X compared to HC and increases in components of the canonical IPA pathway \"Complement System\" (S2 Table, Figure 1C , Figure 2A and C).Cell-Type AnalysisSERPING1 is an IFN-stimulated gene (ISG) and acts in a negative-feedback loop to control contact and complement system activation to avoid damage to healthy host cells (20).", [["Cell", "ANATOMY", 319, 323], ["cells", "ANATOMY", 499, 504], ["Complement", "GENE_OR_GENE_PRODUCT", 0, 10], ["Cell", "CELL", 319, 323], ["IFN-stimulated gene", "GENE_OR_GENE_PRODUCT", 352, 371], ["ISG", "GENE_OR_GENE_PRODUCT", 373, 376], ["host cells", "CELL", 494, 504], ["Complement-associated transcripts", "PROTEIN", 0, 33], ["IFN-stimulated gene", "DNA", 352, 371], ["ISG", "DNA", 373, 376], ["healthy host cells", "CELL_TYPE", 486, 504], ["HC", "TEST", 199, 201], ["damage to healthy host cells", "PROBLEM", 476, 504], ["significantly", "OBSERVATION_MODIFIER", 34, 47], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["significantly", "OBSERVATION_MODIFIER", 113, 126], ["increased", "OBSERVATION_MODIFIER", 127, 136], ["increases", "OBSERVATION_MODIFIER", 206, 215], ["IPA pathway", "OBSERVATION", 247, 258]]], ["CR1, CR3, and CR4 complexes inhibit complement activation, and components of these complexes were differentially increased in group 1 (S2 Table) .", [["CR1", "GENE_OR_GENE_PRODUCT", 0, 3], ["CR3", "GENE_OR_GENE_PRODUCT", 5, 8], ["CR4", "GENE_OR_GENE_PRODUCT", 14, 17], ["complement", "GENE_OR_GENE_PRODUCT", 36, 46], ["CR1", "PROTEIN", 0, 3], ["CR3", "PROTEIN", 5, 8], ["CR4 complexes", "PROTEIN", 14, 27], ["CR1", "TEST", 0, 3], ["CR3", "TEST", 5, 8], ["increased", "OBSERVATION_MODIFIER", 113, 122]]], ["Increased differential expression of complement-activating proteins C2 and C1QB (20) between HC and groups 1-3 and X implies complement activation.", [["complement-activating proteins C2", "GENE_OR_GENE_PRODUCT", 37, 70], ["C1QB (20)", "GENE_OR_GENE_PRODUCT", 75, 84], ["HC", "CANCER", 93, 95], ["1-3", "GENE_OR_GENE_PRODUCT", 107, 110], ["X", "GENE_OR_GENE_PRODUCT", 115, 116], ["complement", "GENE_OR_GENE_PRODUCT", 125, 135], ["complement-activating proteins", "PROTEIN", 37, 67], ["C2", "PROTEIN", 68, 70], ["C1QB (20", "PROTEIN", 75, 83], ["C1QB", "TEST", 75, 79], ["HC", "TEST", 93, 95]]], ["Notably, in the mild and moderate cases 2 and X, the complement inhibitor transcripts were either not regulated or decreased (S2 Table) .", [["the mild and moderate cases 2", "PROBLEM", 12, 41], ["the complement inhibitor transcripts", "TREATMENT", 49, 85], ["mild", "OBSERVATION_MODIFIER", 16, 20], ["moderate", "OBSERVATION_MODIFIER", 25, 33], ["decreased", "OBSERVATION_MODIFIER", 115, 124]]], ["We found a notable overlap between increased transcripts in cases 1 and 2 when we superimposed COVID-19 serum protein levels that were differentially abundant compared to healthy controls (FDR<0.01) (11) onto the IPA complement system pathway ( Figure 2B and D).", [["serum", "ANATOMY", 104, 109], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["COVID", "PROTEIN", 95, 100], ["increased transcripts", "PROBLEM", 35, 56], ["superimposed COVID", "TEST", 82, 100], ["serum protein levels", "TEST", 104, 124], ["FDR", "TEST", 189, 192], ["notable", "OBSERVATION_MODIFIER", 11, 18], ["overlap", "OBSERVATION", 19, 26], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["transcripts", "OBSERVATION", 45, 56]]], ["Increased levels of members of the membrane attack complex support that complement is activated in COVID-19 patients (11) .Cell-Type AnalysisIn SARS-CoV-2 patients, increased SERPING1-encoded C1-INH may be interpreted as an attempt by the host to inhibit inappropriate complement activation.", [["membrane", "ANATOMY", 35, 43], ["Cell", "ANATOMY", 123, 127], ["membrane", "CELLULAR_COMPONENT", 35, 43], ["patients", "ORGANISM", 108, 116], ["Cell", "CELL", 123, 127], ["SARS-CoV-2", "ORGANISM", 144, 154], ["patients", "ORGANISM", 155, 163], ["SERPING1", "GENE_OR_GENE_PRODUCT", 175, 183], ["C1-INH", "GENE_OR_GENE_PRODUCT", 192, 198], ["membrane attack complex", "PROTEIN", 35, 58], ["SERPING1", "PROTEIN", 175, 183], ["C1", "PROTEIN", 192, 194], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 155, 163], ["the membrane attack complex support", "TREATMENT", 31, 66], ["Cell", "TEST", 123, 127], ["CoV", "TEST", 149, 152], ["increased SERPING1", "PROBLEM", 165, 183]]], ["Activated complementassociated microvascular injury by fibrin deposition and neutrophil permeation has been observed in severe COVID-19 patients that experienced respiratory failure and purpuric skin .", [["microvascular", "ANATOMY", 31, 44], ["neutrophil", "ANATOMY", 77, 87], ["respiratory", "ANATOMY", 162, 173], ["skin", "ANATOMY", 195, 199], ["microvascular injury", "DISEASE", 31, 51], ["COVID", "DISEASE", 127, 132], ["respiratory failure", "DISEASE", 162, 181], ["microvascular", "TISSUE", 31, 44], ["fibrin", "GENE_OR_GENE_PRODUCT", 55, 61], ["neutrophil", "CELL", 77, 87], ["patients", "ORGANISM", 136, 144], ["skin", "ORGAN", 195, 199], ["fibrin", "PROTEIN", 55, 61], ["neutrophil", "CELL_TYPE", 77, 87], ["patients", "SPECIES", 136, 144], ["Activated complementassociated microvascular injury", "PROBLEM", 0, 51], ["fibrin deposition", "PROBLEM", 55, 72], ["neutrophil permeation", "PROBLEM", 77, 98], ["respiratory failure", "PROBLEM", 162, 181], ["purpuric skin", "PROBLEM", 186, 199], ["microvascular", "ANATOMY", 31, 44], ["injury", "OBSERVATION", 45, 51], ["fibrin deposition", "OBSERVATION", 55, 72], ["neutrophil permeation", "OBSERVATION", 77, 98], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["respiratory", "ANATOMY", 162, 173], ["failure", "OBSERVATION", 174, 181], ["purpuric", "OBSERVATION_MODIFIER", 186, 194], ["skin", "ANATOMY", 195, 199]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintCell-Type AnalysisThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.16.20115972 doi: medRxiv preprint 13 rashes (2).", [["CC", "CHEMICAL", 0, 2], ["rashes", "DISEASE", 367, 373], ["med", "ANATOMY", 102, 105]]], ["A recent pre-print showed that in vitro C1-INH attenuates SARS-CoV-2 nucleocapsid protein-mediated complement activation (21), and treatment of COVID-19 patients with complement inhibitors may be a viable therapeutic option (21-23).COVID-19 elicited interferon type-I signaling response regardless of symptom severityConsistent with positive complement system scores, more than 50% of IFN type I (IFN-I)-and IFN-II-related transcripts increased, resulting in significantly positive pathway scores (S3 Table and Figure 1D and E).", [["INH", "CHEMICAL", 43, 46], ["COVID-19", "CHEMICAL", 232, 240], ["C1-INH", "CHEMICAL", 40, 46], ["COVID-19", "CHEMICAL", 232, 240], ["C1-INH", "SIMPLE_CHEMICAL", 40, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 58, 68], ["patients", "ORGANISM", 153, 161], ["COVID-19", "GENE_OR_GENE_PRODUCT", 232, 240], ["interferon type-I", "GENE_OR_GENE_PRODUCT", 250, 267], ["IFN type I", "GENE_OR_GENE_PRODUCT", 385, 395], ["IFN-I", "GENE_OR_GENE_PRODUCT", 397, 402], ["IFN-II", "GENE_OR_GENE_PRODUCT", 408, 414], ["SARS-CoV-2 nucleocapsid protein", "PROTEIN", 58, 89], ["IFN", "PROTEIN", 397, 400], ["IFN-II", "PROTEIN", 408, 414], ["patients", "SPECIES", 153, 161], ["A recent pre-print", "TEST", 0, 18], ["vitro C1", "TEST", 34, 42], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66], ["nucleocapsid protein", "TEST", 69, 89], ["COVID", "TREATMENT", 144, 149], ["complement inhibitors", "TREATMENT", 167, 188], ["COVID", "TEST", 232, 237], ["symptom severity", "PROBLEM", 301, 317], ["positive complement system scores", "PROBLEM", 333, 366], ["IFN type I", "PROBLEM", 385, 395], ["IFN", "TEST", 397, 400], ["IFN", "PROBLEM", 408, 411], ["related transcripts", "PROBLEM", 415, 434], ["significantly positive pathway scores", "PROBLEM", 459, 496], ["increased", "OBSERVATION_MODIFIER", 435, 444]]], ["IFN signaling effectively controls viral infection; however, viruses have evolved defense mechanisms to evade IFN-mediated viral clearance (24).", [["IFN", "CHEMICAL", 0, 3], ["viral infection", "DISEASE", 35, 50], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["IFN", "GENE_OR_GENE_PRODUCT", 110, 113], ["IFN", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 110, 113], ["IFN signaling effectively controls viral infection", "PROBLEM", 0, 50], ["viruses", "PROBLEM", 61, 68], ["viral", "OBSERVATION_MODIFIER", 35, 40], ["infection", "OBSERVATION", 41, 50]]], ["In bronchoalveolar lavage fluid from COVID-19 patients, ISGs were strongly increased, implying a robust IFN response (25).", [["bronchoalveolar lavage fluid", "ANATOMY", 3, 31], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 3, 31], ["patients", "ORGANISM", 46, 54], ["ISGs", "PROTEIN", 56, 60], ["IFN", "PROTEIN", 104, 107], ["patients", "SPECIES", 46, 54], ["bronchoalveolar lavage fluid", "TEST", 3, 31], ["COVID", "TEST", 37, 42], ["ISGs", "TREATMENT", 56, 60], ["bronchoalveolar", "OBSERVATION", 3, 18], ["lavage fluid", "OBSERVATION", 19, 31]]], ["Both IFN-I and -II pathway scores were significantly increased compared to HC in groups 1 (severe) and 2 (mild) ( Figure 1D and E).", [["IFN-I", "GENE_OR_GENE_PRODUCT", 5, 10], ["-II", "GENE_OR_GENE_PRODUCT", 15, 18], ["IFN", "PROTEIN", 5, 8], ["significantly", "OBSERVATION_MODIFIER", 39, 52], ["increased", "OBSERVATION_MODIFIER", 53, 62]]], ["IFN responses between groups 1 and 2 were strikingly similar, with 13 shared transcripts more than two-fold increased.COVID-19 elicited interferon type-I signaling response regardless of symptom severityFurthermore, IFN-induced transmembrane family member 1 (IFITM-1), IFN induced protein 35 (IFI35), and C-X-C motif chemokine ligand 10 (CXCL10), all ISGs, were differentially increased in both groups 1 and 2.", [["COVID-19", "CHEMICAL", 118, 126], ["COVID-19", "GENE_OR_GENE_PRODUCT", 118, 126], ["interferon type-I", "GENE_OR_GENE_PRODUCT", 136, 153], ["IFN-induced transmembrane family member 1", "GENE_OR_GENE_PRODUCT", 216, 257], ["IFITM-1", "GENE_OR_GENE_PRODUCT", 259, 266], ["IFN induced protein 35", "GENE_OR_GENE_PRODUCT", 269, 291], ["IFI35", "GENE_OR_GENE_PRODUCT", 293, 298], ["C-X-C motif chemokine ligand 10", "GENE_OR_GENE_PRODUCT", 305, 336], ["CXCL10", "GENE_OR_GENE_PRODUCT", 338, 344], ["IFN", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 216, 219], ["transmembrane family member 1", "PROTEIN", 228, 257], ["IFITM", "PROTEIN", 259, 264], ["IFN induced protein 35", "PROTEIN", 269, 291], ["IFI35", "PROTEIN", 293, 298], ["C-X-C motif chemokine ligand 10", "PROTEIN", 305, 336], ["CXCL10", "PROTEIN", 338, 344], ["ISGs", "PROTEIN", 351, 355], ["COVID", "TEST", 118, 123], ["symptom", "PROBLEM", 187, 194], ["IFITM", "TEST", 259, 264], ["IFN induced protein", "TEST", 269, 288], ["C", "TEST", 305, 306], ["motif chemokine ligand", "TEST", 311, 333], ["CXCL10", "TEST", 338, 344], ["all ISGs", "TEST", 347, 355], ["increased", "OBSERVATION_MODIFIER", 108, 117], ["differentially", "OBSERVATION_MODIFIER", 362, 376], ["increased", "OBSERVATION_MODIFIER", 377, 386]]], ["These data imply that although afebrile with a mild cough and sore throat, case 2 experienced a significant IFN response to SARS-CoV-2 infection.Consistently, Hadjadj et al. observed robust IFN-I and IFN-II responses in mild/moderateCOVID-19 patients (10) .Consistently, Hadjadj et al. observed robust IFN-I and IFN-II responses in mild/moderateAlthough upregulated by IFN-\uf067, MHC class II receptors (HLA-DMB/OB/PB1/RA/RB1/RB3) and the MHC class II upstream transcriptional regulator CIITA were strongly decreased compared to HC in group 1 (early, severe), and at least one HLA gene was significantly decreased in all groups (S4 Table) .", [["afebrile", "DISEASE", 31, 39], ["cough", "DISEASE", 52, 57], ["sore throat", "DISEASE", 62, 73], ["SARS", "DISEASE", 124, 128], ["infection", "DISEASE", 135, 144], ["SARS-CoV-2", "ORGANISM", 124, 134], ["IFN-I", "GENE_OR_GENE_PRODUCT", 190, 195], ["IFN-II", "GENE_OR_GENE_PRODUCT", 200, 206], ["patients", "ORGANISM", 242, 250], ["IFN-I", "GENE_OR_GENE_PRODUCT", 302, 307], ["IFN-II", "GENE_OR_GENE_PRODUCT", 312, 318], ["IFN-\uf067", "GENE_OR_GENE_PRODUCT", 369, 374], ["MHC class II", "GENE_OR_GENE_PRODUCT", 376, 388], ["HLA-DMB", "GENE_OR_GENE_PRODUCT", 400, 407], ["PB1", "GENE_OR_GENE_PRODUCT", 411, 414], ["RA", "GENE_OR_GENE_PRODUCT", 415, 417], ["RB1", "GENE_OR_GENE_PRODUCT", 418, 421], ["RB3", "GENE_OR_GENE_PRODUCT", 422, 425], ["MHC class II", "GENE_OR_GENE_PRODUCT", 435, 447], ["CIITA", "GENE_OR_GENE_PRODUCT", 483, 488], ["HLA", "GENE_OR_GENE_PRODUCT", 573, 576], ["IFN", "PROTEIN", 108, 111], ["IFN", "PROTEIN", 190, 193], ["IFN", "PROTEIN", 200, 203], ["IFN", "PROTEIN", 302, 305], ["IFN", "PROTEIN", 312, 315], ["IFN", "PROTEIN", 369, 372], ["MHC class II receptors", "PROTEIN", 376, 398], ["HLA", "PROTEIN", 400, 403], ["DMB", "PROTEIN", 404, 407], ["OB", "PROTEIN", 408, 410], ["PB1", "PROTEIN", 411, 414], ["RA", "PROTEIN", 415, 417], ["RB1", "DNA", 418, 421], ["RB3", "PROTEIN", 422, 425], ["MHC class II upstream transcriptional regulator", "PROTEIN", 435, 482], ["CIITA", "PROTEIN", 483, 488], ["HLA gene", "DNA", 573, 581], ["patients", "SPECIES", 242, 250], ["SARS-CoV", "SPECIES", 124, 132], ["afebrile", "PROBLEM", 31, 39], ["a mild cough", "PROBLEM", 45, 57], ["sore throat", "PROBLEM", 62, 73], ["a significant IFN response", "PROBLEM", 94, 120], ["SARS", "PROBLEM", 124, 128], ["CoV-2 infection", "PROBLEM", 129, 144], ["II responses", "TEST", 204, 216], ["mild/moderateCOVID", "PROBLEM", 220, 238], ["mild/moderate", "PROBLEM", 332, 345], ["IFN", "TEST", 369, 372], ["HLA", "TEST", 400, 403], ["DMB", "TEST", 404, 407], ["OB", "TEST", 408, 410], ["PB1", "TEST", 411, 414], ["RA", "TEST", 415, 417], ["RB1", "TEST", 418, 421], ["RB3", "TEST", 422, 425], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["cough", "OBSERVATION", 52, 57], ["sore throat", "ANATOMY", 62, 73], ["infection", "OBSERVATION", 135, 144], ["robust", "OBSERVATION_MODIFIER", 183, 189], ["IFN", "OBSERVATION", 190, 193], ["mild", "OBSERVATION_MODIFIER", 220, 224], ["mild", "OBSERVATION_MODIFIER", 332, 336], ["moderate", "OBSERVATION_MODIFIER", 337, 345], ["OB", "ANATOMY", 408, 410], ["RA", "ANATOMY", 415, 417], ["regulator CIITA", "OBSERVATION", 473, 488], ["decreased", "OBSERVATION_MODIFIER", 503, 512], ["severe", "OBSERVATION_MODIFIER", 547, 553], ["significantly", "OBSERVATION_MODIFIER", 586, 599], ["decreased", "OBSERVATION_MODIFIER", 600, 609]]], ["The decrease in CIITA in group 1 was .", [["CIITA", "GENE_OR_GENE_PRODUCT", 16, 21], ["CIITA", "PROTEIN", 16, 21], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["CIITA", "OBSERVATION", 16, 21]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Although increases in adaptive and innate immune system-related transcripts occurred in groups 1 and 2, these gene sets were significantly decreased compared to HC in the later phases of recovery for .", [["immune system", "ANATOMICAL_SYSTEM", 42, 55], ["innate immune system", "TREATMENT", 35, 55], ["increases", "OBSERVATION_MODIFIER", 9, 18], ["significantly", "OBSERVATION_MODIFIER", 125, 138], ["decreased", "OBSERVATION_MODIFIER", 139, 148]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintCOVID-19 negatively affected estimated B cell abundance, and globally depressed adaptive and innate immune-related transcripts as SARS-CoV-2 infection resolvedThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.16.20115972 doi: medRxiv preprint groups 5, 6, and X, implying global suppression of innate and adaptive immune responses as SARS-CoV-2 infection resolves ( Figure 3C and D).COVID-19 negatively affected estimated B cell abundance, and globally depressed adaptive and innate immune-related transcripts as SARS-CoV-2 infection resolvedIt is tempting to speculate that mild case 2 may have had an extended viral load because of an insufficient humoral immune response, and in a comparison study, asymptomatic COVID-19 patients displayed a prolonged SARS-CoV-2 viral load and decreased levels of viral specific IgG versus those that were symptomatic (29).", [["B cell", "ANATOMY", 247, 253], ["B cell", "ANATOMY", 684, 690], ["CC", "CHEMICAL", 0, 2], ["depressed", "DISEASE", 278, 287], ["infection", "DISEASE", 349, 358], ["infection", "DISEASE", 607, 616], ["depressed", "DISEASE", 715, 724], ["infection", "DISEASE", 786, 795], ["preprintCOVID-19", "CHEMICAL", 200, 216], ["preprintCOVID-19", "SIMPLE_CHEMICAL", 200, 216], ["B cell", "CELL", 247, 253], ["SARS-CoV-2", "ORGANISM", 338, 348], ["SARS-CoV-2", "ORGANISM", 596, 606], ["COVID-19", "GENE_OR_GENE_PRODUCT", 645, 653], ["B cell", "CELL", 684, 690], ["SARS-CoV-2", "ORGANISM", 775, 785], ["patients", "ORGANISM", 986, 994], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 1017, 1027], ["IgG", "GENE_OR_GENE_PRODUCT", 1078, 1081], ["preprintCOVID-19", "DNA", 200, 216], ["COVID-19", "DNA", 645, 653], ["viral specific IgG", "PROTEIN", 1063, 1081], ["patients", "SPECIES", 986, 994], ["SARS-CoV-2", "SPECIES", 596, 606], ["preprintCOVID", "TEST", 200, 213], ["affected estimated B cell abundance", "PROBLEM", 228, 263], ["globally depressed adaptive", "PROBLEM", 269, 296], ["innate immune", "TREATMENT", 301, 314], ["SARS", "PROBLEM", 338, 342], ["2 infection", "PROBLEM", 347, 358], ["medRxiv preprint groups", "TREATMENT", 488, 511], ["SARS", "TEST", 596, 600], ["CoV", "TEST", 601, 604], ["2 infection", "PROBLEM", 605, 616], ["COVID", "TEST", 645, 650], ["affected estimated B cell abundance", "PROBLEM", 665, 700], ["globally depressed adaptive", "PROBLEM", 706, 733], ["innate immune", "TREATMENT", 738, 751], ["SARS", "PROBLEM", 775, 779], ["2 infection", "PROBLEM", 784, 795], ["mild case 2", "PROBLEM", 837, 848], ["an extended viral load", "PROBLEM", 862, 884], ["a comparison study", "TEST", 944, 962], ["asymptomatic COVID", "TEST", 964, 982], ["a prolonged SARS", "PROBLEM", 1005, 1021], ["CoV", "TEST", 1022, 1025], ["2 viral load", "PROBLEM", 1026, 1038], ["decreased levels", "PROBLEM", 1043, 1059], ["viral specific IgG", "PROBLEM", 1063, 1081], ["med", "ANATOMY", 102, 105], ["cell abundance", "OBSERVATION", 249, 263], ["infection", "OBSERVATION", 349, 358], ["B cell abundance", "OBSERVATION", 684, 700], ["infection", "OBSERVATION", 786, 795], ["mild", "OBSERVATION_MODIFIER", 837, 841], ["humoral immune response", "OBSERVATION", 912, 935]]], ["Extended viral shedding has been observed for SARS-CoV-1, Middle East Respiratory Syndrome (MERS), and SARS-CoV-2 (29-31).COVID-19 negatively affected estimated B cell abundance, and globally depressed adaptive and innate immune-related transcripts as SARS-CoV-2 infection resolvedRemarkably, SARS-CoV-1 viral RNA and SARS-CoV-1-specific antibodies have been found simultaneously in plasma from patients with varying disease severities (31).", [["B cell", "ANATOMY", 161, 167], ["plasma", "ANATOMY", 383, 389], ["Middle East Respiratory Syndrome", "DISEASE", 58, 90], ["SARS", "DISEASE", 103, 107], ["depressed", "DISEASE", 192, 201], ["infection", "DISEASE", 263, 272], ["SARS-CoV-1", "ORGANISM", 46, 56], ["Middle East Respiratory", "ORGANISM", 58, 81], ["SARS-CoV-2", "ORGANISM", 103, 113], ["COVID-19", "GENE_OR_GENE_PRODUCT", 122, 130], ["B cell", "CELL", 161, 167], ["SARS-CoV-2", "ORGANISM", 252, 262], ["SARS-CoV-1", "ORGANISM", 293, 303], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 318, 328], ["plasma", "ORGANISM_SUBSTANCE", 383, 389], ["patients", "ORGANISM", 395, 403], ["COVID-19", "DNA", 122, 130], ["SARS-CoV-1 viral RNA", "RNA", 293, 313], ["SARS-CoV-1-specific antibodies", "PROTEIN", 318, 348], ["CoV-1", "SPECIES", 298, 303], ["patients", "SPECIES", 395, 403], ["SARS-CoV-1", "SPECIES", 46, 56], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 58, 97], ["SARS-CoV-2", "SPECIES", 103, 113], ["SARS-CoV-1", "SPECIES", 293, 303], ["SARS-CoV-1", "SPECIES", 318, 328], ["Extended viral shedding", "PROBLEM", 0, 23], ["SARS", "PROBLEM", 46, 50], ["CoV", "TEST", 51, 54], ["Middle East Respiratory Syndrome", "PROBLEM", 58, 90], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111], ["COVID", "TEST", 122, 127], ["negatively affected estimated B cell abundance", "PROBLEM", 131, 177], ["globally depressed adaptive", "PROBLEM", 183, 210], ["SARS", "TEST", 252, 256], ["CoV", "TEST", 257, 260], ["2 infection", "PROBLEM", 261, 272], ["SARS", "TEST", 293, 297], ["CoV", "TEST", 298, 301], ["viral RNA", "TEST", 304, 313], ["SARS", "TEST", 318, 322], ["CoV", "TEST", 323, 326], ["specific antibodies", "TEST", 329, 348], ["varying disease severities", "PROBLEM", 409, 435], ["viral shedding", "OBSERVATION", 9, 23], ["Middle", "ANATOMY_MODIFIER", 58, 64], ["Respiratory Syndrome", "OBSERVATION", 70, 90], ["cell abundance", "OBSERVATION", 163, 177], ["varying", "OBSERVATION_MODIFIER", 409, 416], ["disease", "OBSERVATION", 417, 424]]], ["Moreover, urine samples collected from such patients were able to infect susceptible kidney cells in vitro (31).COVID-19 negatively affected estimated B cell abundance, and globally depressed adaptive and innate immune-related transcripts as SARS-CoV-2 infection resolvedThese data call into question whether SARS-specific antibodies mount an immune response sufficient to protect against reinfection.", [["urine samples", "ANATOMY", 10, 23], ["kidney cells", "ANATOMY", 85, 97], ["B cell", "ANATOMY", 151, 157], ["depressed", "DISEASE", 182, 191], ["infection", "DISEASE", 253, 262], ["urine samples", "ORGANISM_SUBSTANCE", 10, 23], ["patients", "ORGANISM", 44, 52], ["kidney cells", "CELL", 85, 97], ["COVID-19", "GENE_OR_GENE_PRODUCT", 112, 120], ["B cell", "CELL", 151, 157], ["SARS-CoV-2", "ORGANISM", 242, 252], ["susceptible kidney cells", "CELL_TYPE", 73, 97], ["COVID-19", "DNA", 112, 120], ["SARS-specific antibodies", "PROTEIN", 309, 333], ["patients", "SPECIES", 44, 52], ["urine samples", "TEST", 10, 23], ["COVID", "TEST", 112, 117], ["affected estimated B cell abundance", "PROBLEM", 132, 167], ["globally depressed adaptive", "PROBLEM", 173, 200], ["innate immune", "TREATMENT", 205, 218], ["SARS", "PROBLEM", 242, 246], ["2 infection", "PROBLEM", 251, 262], ["SARS", "PROBLEM", 309, 313], ["specific antibodies", "TEST", 314, 333], ["reinfection", "PROBLEM", 389, 400], ["B cell abundance", "OBSERVATION", 151, 167], ["infection", "OBSERVATION", 253, 262]]], ["Furthermore, there remains a question as to how long SARS-CoV-2 immunity lasts, as there has now been a confirmed case of reinfection of an individual with a strain of SARS-CoV-2 distinct from his original infection, just 4.5 months later (32).Concluding statementsAlthough these data are from a limited number of patients, we observed remarkably parallel immune responses in case 1 and his son, case 2, despite starkly different clinical courses.Concluding statementsCase 1 was hospitalized for an extended period and required supplemental oxygen, whereas his son's symptoms were mild, and he was without fever over 29 days of SARS-CoV-2 infection.Concluding statementsAll three cases showed signs of global immune depression, and we speculate that a potential dramatic increase of SERPING1-encoded C1-INH may drive increased fibrin clot formation as well as global immune depression and may be viewed as a biological response to the .", [["fibrin clot", "ANATOMY", 827, 838], ["SARS", "DISEASE", 53, 57], ["SARS", "DISEASE", 168, 172], ["infection", "DISEASE", 206, 215], ["oxygen", "CHEMICAL", 541, 547], ["fever", "DISEASE", 606, 611], ["SARS-CoV-2 infection", "DISEASE", 628, 648], ["immune depression", "DISEASE", 709, 726], ["INH", "CHEMICAL", 803, 806], ["immune depression", "DISEASE", 867, 884], ["oxygen", "CHEMICAL", 541, 547], ["CoV-2", "ORGANISM", 58, 63], ["SARS-CoV-2", "ORGANISM", 168, 178], ["patients", "ORGANISM", 314, 322], ["oxygen", "SIMPLE_CHEMICAL", 541, 547], ["CoV-2", "ORGANISM", 633, 638], ["SERPING1", "GENE_OR_GENE_PRODUCT", 783, 791], ["C1-INH", "GENE_OR_GENE_PRODUCT", 800, 806], ["fibrin", "GENE_OR_GENE_PRODUCT", 827, 833], ["clot", "ORGANISM_SUBSTANCE", 834, 838], ["SERPING1", "PROTEIN", 783, 791], ["C1", "PROTEIN", 800, 802], ["patients", "SPECIES", 314, 322], ["SARS-CoV", "SPECIES", 168, 176], ["CoV", "TEST", 58, 61], ["reinfection", "PROBLEM", 122, 133], ["SARS", "PROBLEM", 168, 172], ["CoV", "TEST", 173, 176], ["his original infection", "PROBLEM", 193, 215], ["supplemental oxygen", "TREATMENT", 528, 547], ["his son's symptoms", "PROBLEM", 557, 575], ["fever", "PROBLEM", 606, 611], ["SARS", "PROBLEM", 628, 632], ["CoV-2 infection", "PROBLEM", 633, 648], ["All three cases", "TEST", 670, 685], ["global immune depression", "PROBLEM", 702, 726], ["SERPING1", "TEST", 783, 791], ["increased fibrin clot formation", "PROBLEM", 817, 848], ["global immune depression", "PROBLEM", 860, 884], ["infection", "OBSERVATION", 206, 215], ["mild", "OBSERVATION_MODIFIER", 581, 585], ["infection", "OBSERVATION", 639, 648], ["signs of", "UNCERTAINTY", 693, 701], ["global immune depression", "OBSERVATION", 702, 726], ["dramatic", "OBSERVATION_MODIFIER", 762, 770], ["increase", "OBSERVATION_MODIFIER", 771, 779], ["fibrin clot", "OBSERVATION", 827, 838], ["immune depression", "OBSERVATION", 867, 884]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.AcknowledgmentsThe authors would like to thank Rick Calvo for his input into the hierarchical clustering and principal component analyses used in this study and Erica Sercy for proofreading and editing of the manuscript.Acknowledgments.", [["CC", "CHEMICAL", 0, 2], ["this study", "TEST", 304, 314], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintAcknowledgmentsThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.16.20115972 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["medRxiv preprint", "TREATMENT", 344, 360], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintAcknowledgmentsThe copyright holder for this this version posted September 18, 2020. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintAcknowledgmentsThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.16.20115972 doi: medRxiv preprint gene names are displayed, although these data represent differentially abundant serum proteins.AcknowledgmentsGrayed molecules are in the dataset but do not meet the cutoff of FDR<0.01.", [["serum", "ANATOMY", 536, 541], ["CC", "CHEMICAL", 0, 2], ["serum", "ORGANISM_SUBSTANCE", 536, 541], ["serum proteins", "PROTEIN", 536, 550], ["Grayed molecules", "PROTEIN", 566, 582], ["differentially abundant serum proteins", "PROBLEM", 512, 550], ["FDR", "TEST", 632, 635], ["med", "ANATOMY", 102, 105], ["med", "ANATOMY", 197, 200]]], ["Supporting information S1 Genes are categorized in \"gene sets,\" which are transcripts grouped together by the NanoString, .", [["NanoString", "DNA", 110, 120]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintAcknowledgmentsThe copyright holder for this this version posted September 18, 2020. . https://doi.org/10.1101/2020.09.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Selection for further analysis of differentially expressed transcripts was based on the significance of differential expression between HC and group 1 (FDR<0.01).", [["further analysis", "TEST", 14, 30], ["HC", "TEST", 136, 138], ["FDR", "TEST", 152, 155]]], ["Differentially expressed transcripts that were greater than two-fold increased are highlighted orange, whereas greater than two-fold decreased transcripts are highlighted in blue.", [["greater", "OBSERVATION_MODIFIER", 47, 54], ["increased", "OBSERVATION_MODIFIER", 69, 78]]], ["Interferon Type-I and -II Signaling Gene Sets.", [["Interferon Type-I", "GENE_OR_GENE_PRODUCT", 0, 17], ["-II", "GENE_OR_GENE_PRODUCT", 22, 25], ["Interferon Type-I and -II Signaling Gene Sets", "DNA", 0, 45]]], ["Genes listed comprise the NanoString Technologies, Inc. \"gene set\" for Interferon Type I and II signaling and are categorized by all other associated gene sets.", [["Interferon Type I", "GENE_OR_GENE_PRODUCT", 71, 88], ["Interferon Type I and II signaling", "PROBLEM", 71, 105]]], ["The \"type\" of interferon signaling according to NanoString Technologies, Inc. is listed.", [["interferon", "GENE_OR_GENE_PRODUCT", 14, 24], ["interferon", "PROTEIN", 14, 24], ["interferon signaling", "TREATMENT", 14, 34]]], ["The table is sorted in descending order according to differential regulation in group 1.", [["descending", "ANATOMY_MODIFIER", 23, 33]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["MHC II signaling and CIITA regulating genes referenced in Figure 2 .", [["MHC II", "GENE_OR_GENE_PRODUCT", 0, 6], ["CIITA", "GENE_OR_GENE_PRODUCT", 21, 26], ["MHC II", "PROTEIN", 0, 6], ["CIITA regulating genes", "DNA", 21, 43]]], ["All HLA transcripts from the NanoString Technologies, Inc. human immunology V2 array are listed along with genes identified by ingenuity pathway analysis as 1) upstream regulators of CIITA (STAT 1-3, BCL6, IRF1, PML, RELB, and PAX5), 2) upstream regulators of PAX5 (LEF1 and ETS1) and 3) a downstream target of PAX5 (CD19), which were also represented in the dataset.", [["human", "ORGANISM", 59, 64], ["CIITA", "GENE_OR_GENE_PRODUCT", 183, 188], ["STAT 1-3", "GENE_OR_GENE_PRODUCT", 190, 198], ["BCL6", "GENE_OR_GENE_PRODUCT", 200, 204], ["IRF1", "GENE_OR_GENE_PRODUCT", 206, 210], ["PML", "GENE_OR_GENE_PRODUCT", 212, 215], ["RELB", "GENE_OR_GENE_PRODUCT", 217, 221], ["PAX5", "GENE_OR_GENE_PRODUCT", 227, 231], ["PAX5", "GENE_OR_GENE_PRODUCT", 260, 264], ["LEF1", "GENE_OR_GENE_PRODUCT", 266, 270], ["ETS1", "GENE_OR_GENE_PRODUCT", 275, 279], ["PAX5", "GENE_OR_GENE_PRODUCT", 311, 315], ["CD19", "GENE_OR_GENE_PRODUCT", 317, 321], ["HLA transcripts", "RNA", 4, 19], ["Inc. human immunology V2 array", "DNA", 54, 84], ["upstream regulators", "PROTEIN", 160, 179], ["CIITA", "PROTEIN", 183, 188], ["STAT 1-3", "PROTEIN", 190, 198], ["BCL6", "PROTEIN", 200, 204], ["IRF1", "PROTEIN", 206, 210], ["PML", "PROTEIN", 212, 215], ["RELB", "PROTEIN", 217, 221], ["PAX5", "PROTEIN", 227, 231], ["upstream regulators", "PROTEIN", 237, 256], ["PAX5", "PROTEIN", 260, 264], ["LEF1", "PROTEIN", 266, 270], ["ETS1", "PROTEIN", 275, 279], ["PAX5", "PROTEIN", 311, 315], ["CD19", "PROTEIN", 317, 321], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["CIITA", "TEST", 183, 188], ["BCL6", "TEST", 200, 204], ["IRF1", "TEST", 206, 210], ["PML", "TEST", 212, 215], ["PAX5", "TEST", 260, 264]]], ["Key to IPA \"Complement Scomplement ystem\" genes.", [["Complement Scomplement ystem", "GENE_OR_GENE_PRODUCT", 12, 40], ["IPA \"Complement Scomplement ystem\" genes", "DNA", 7, 47]]], ["Columns reference the symbol used in Figure 2 , the Entrez gene name, the subcellular location according to IPA, the designated molecular family according to IPA, drugs known to target that particular gene/protein, and the numerical Entrez gene ID for human.S5.", [["subcellular", "ANATOMY", 74, 85], ["IPA", "CHEMICAL", 158, 161], ["human", "ORGANISM", 252, 257], ["S5", "GENE_OR_GENE_PRODUCT", 258, 260], ["Entrez gene name", "DNA", 52, 68], ["Entrez gene ID", "DNA", 233, 247], ["S5", "PROTEIN", 258, 260], ["human", "SPECIES", 252, 257], ["human", "SPECIES", 252, 257], ["drugs", "TREATMENT", 163, 168]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 18, 2020. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 18, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Table 2 Transcript is also in Interferon Signaling Table .", [["Interferon", "PROTEIN", 30, 40]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 18, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]]], "b76ec86bbef60b7e9e3620a869c196825349f4a4": [["Toll-like receptors (TLRs) recognize conserved microbial structures called pathogen-associated molecular patterns.", [["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 0, 19], ["TLRs", "GENE_OR_GENE_PRODUCT", 21, 25], ["Toll-like receptors", "PROTEIN", 0, 19], ["TLRs", "PROTEIN", 21, 25], ["pathogen", "PROBLEM", 75, 83], ["molecular patterns", "OBSERVATION", 95, 113]]], ["Signaling from TLRs leads to upregulation of co-stimulatory molecules for better priming of T cells and secretion of inflammatory cytokines by innate immune cells [1] [2] [3] [4] .", [["T cells", "ANATOMY", 92, 99], ["immune cells", "ANATOMY", 150, 162], ["TLRs", "GENE_OR_GENE_PRODUCT", 15, 19], ["T cells", "CELL", 92, 99], ["innate immune cells", "CELL", 143, 162], ["TLRs", "PROTEIN", 15, 19], ["co-stimulatory molecules", "PROTEIN", 45, 69], ["T cells", "CELL_TYPE", 92, 99], ["inflammatory cytokines", "PROTEIN", 117, 139], ["innate immune cells", "CELL_TYPE", 143, 162], ["upregulation of co-stimulatory molecules", "TREATMENT", 29, 69], ["inflammatory cytokines", "PROBLEM", 117, 139], ["innate immune cells", "TEST", 143, 162], ["inflammatory", "OBSERVATION_MODIFIER", 117, 129]]], ["Lymphocytedeficient hosts often die of acute infection, presumably owing to their lack of an adaptive immune response to effectively clear pathogens.", [["infection", "DISEASE", 45, 54], ["acute infection", "PROBLEM", 39, 54], ["effectively clear pathogens", "PROBLEM", 121, 148], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["infection", "OBSERVATION", 45, 54], ["pathogens", "OBSERVATION", 139, 148]]], ["However, we show here that an unleashed innate immune response due to the absence of residential T cells can also be a direct cause of death.", [["T cells", "ANATOMY", 97, 104], ["death", "DISEASE", 135, 140], ["T cells", "CELL", 97, 104], ["residential T cells", "CELL_TYPE", 85, 104], ["residential T cells", "PROBLEM", 85, 104], ["death", "PROBLEM", 135, 140]]], ["Viral infection or administration of poly(I:C), a ligand for TLR3, led to cytokine storm in T-cell-or lymphocyte-deficient mice in a fashion dependent on NK cells and tumor necrosis factor.", [["T-cell", "ANATOMY", 92, 98], ["lymphocyte", "ANATOMY", 102, 112], ["NK cells", "ANATOMY", 154, 162], ["Viral infection", "DISEASE", 0, 15], ["poly(I:C", "CHEMICAL", 37, 45], ["tumor", "DISEASE", 167, 172], ["necrosis", "DISEASE", 173, 181], ["poly(I:C", "CHEMICAL", 37, 45], ["poly(I:C", "SIMPLE_CHEMICAL", 37, 45], ["TLR3", "GENE_OR_GENE_PRODUCT", 61, 65], ["T-cell", "CELL", 92, 98], ["lymphocyte", "CELL", 102, 112], ["mice", "ORGANISM", 123, 127], ["NK cells", "CELL", 154, 162], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 167, 188], ["TLR3", "PROTEIN", 61, 65], ["cytokine", "PROTEIN", 74, 82], ["NK cells", "CELL_TYPE", 154, 162], ["tumor necrosis factor", "PROTEIN", 167, 188], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 123, 127], ["Viral infection", "PROBLEM", 0, 15], ["TLR3", "TREATMENT", 61, 65], ["cytokine storm", "TEST", 74, 88], ["lymphocyte-deficient mice", "TREATMENT", 102, 127], ["NK cells", "PROBLEM", 154, 162], ["tumor necrosis factor", "PROBLEM", 167, 188], ["infection", "OBSERVATION", 6, 15], ["NK cells", "OBSERVATION", 154, 162], ["tumor", "OBSERVATION_MODIFIER", 167, 172], ["necrosis", "OBSERVATION", 173, 181]]], ["We have further shown, through the depletion of CD4 + and CD8 + cells in wild-type mice and the transfer of T lymphocytes into Rag-1deficient mice, respectively, that T cells are both necessary and sufficient to temper the early innate response.", [["CD4 + and CD8 + cells", "ANATOMY", 48, 69], ["T lymphocytes", "ANATOMY", 108, 121], ["T cells", "ANATOMY", 167, 174], ["CD4", "GENE_OR_GENE_PRODUCT", 48, 51], ["CD8", "GENE_OR_GENE_PRODUCT", 58, 61], ["mice", "ORGANISM", 83, 87], ["T lymphocytes", "CELL", 108, 121], ["Rag-1deficient mice", "ORGANISM", 127, 146], ["T cells", "CELL", 167, 174], ["CD4", "PROTEIN", 48, 51], ["CD8", "PROTEIN", 58, 61], ["T lymphocytes", "CELL_TYPE", 108, 121], ["T cells", "CELL_TYPE", 167, 174], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 142, 146], ["CD4", "TEST", 48, 51], ["CD8 + cells", "PROBLEM", 58, 69]]], ["In addition to the effects of natural regulatory T cells, close contact of resting CD4 + CD25 -Foxp3or CD8 + T cells with innate cells could also suppress the cytokine surge by various innate cells in an antigen-independent fashion.", [["T cells", "ANATOMY", 49, 56], ["CD4 + CD25 -Foxp3or CD8 + T cells", "ANATOMY", 83, 116], ["cells", "ANATOMY", 129, 134], ["cells", "ANATOMY", 192, 197], ["T cells", "CELL", 49, 56], ["CD4", "GENE_OR_GENE_PRODUCT", 83, 86], ["CD25", "GENE_OR_GENE_PRODUCT", 89, 93], ["CD8", "GENE_OR_GENE_PRODUCT", 103, 106], ["innate cells", "CELL", 185, 197], ["natural regulatory T cells", "CELL_TYPE", 30, 56], ["CD4", "PROTEIN", 83, 86], ["CD25", "PROTEIN", 89, 93], ["Foxp3or CD8 + T cells", "CELL_TYPE", 95, 116], ["innate cells", "CELL_TYPE", 122, 134], ["cytokine", "PROTEIN", 159, 167], ["innate cells", "CELL_TYPE", 185, 197], ["natural regulatory T cells", "PROBLEM", 30, 56], ["resting CD4", "TEST", 75, 86], ["CD25", "TEST", 89, 93], ["T cells", "PROBLEM", 109, 116], ["innate cells", "PROBLEM", 122, 134]]], ["Therefore, adaptive immune cells have an unexpected role in tempering initial innate responses.", [["immune cells", "ANATOMY", 20, 32], ["immune cells", "CELL", 20, 32], ["adaptive immune cells", "CELL_TYPE", 11, 32], ["adaptive immune cells", "TREATMENT", 11, 32]]]], "441d5a1f9d8c134a26c0dd241f3df4fa0f3392ff": [["IMMUNOSENESCENCE AND SARS-CoV-2 VACCINE DEVELOPMENT.To the excellent summary by Graepel et al. . of the need to balance expediency and scientific rigor in SARS-CoV-2 vaccine development (1) there is one additional aspect which merits urgent research attention and funding, namely the problem of immunosenescence.IMMUNOSENESCENCE AND SARS-CoV-2 VACCINE DEVELOPMENT.The multifactorial reduction of immune function in the elderly may well prove to be the Achilles heel of SARS-CoV-2 vaccine development, since such vaccines, if they do not adequately protect the population at highest risk of Covid-related death, are likely to have little impact on COVID-related mortality, stress on ICU capacity and economic impact.IMMUNOSENESCENCE AND SARS-CoV-2 VACCINE DEVELOPMENT.The over-65 age group responds poorly to most vaccines, and to-date, efforts to overcome this by increasing dosage or adding adjuvants have had only limited success.", [["SARS", "DISEASE", 155, 159], ["SARS", "DISEASE", 469, 473], ["death", "DISEASE", 604, 609], ["SARS-CoV-2", "ORGANISM", 469, 479], ["scientific rigor", "PROBLEM", 135, 151], ["SARS", "PROBLEM", 155, 159], ["CoV-2 vaccine development", "TREATMENT", 160, 185], ["immune function", "PROBLEM", 396, 411], ["SARS", "PROBLEM", 469, 473], ["CoV-2 vaccine", "TREATMENT", 474, 487], ["such vaccines", "TREATMENT", 507, 520], ["Covid-related death", "PROBLEM", 590, 609], ["stress on ICU capacity", "PROBLEM", 672, 694], ["economic impact", "PROBLEM", 699, 714], ["adjuvants", "TREATMENT", 892, 901], ["multifactorial", "OBSERVATION_MODIFIER", 368, 382], ["reduction", "OBSERVATION_MODIFIER", 383, 392], ["immune function", "OBSERVATION", 396, 411]]], ["The likelihood of protecting the elderly by raising herd immunity through vaccination of the younger age groups is low, since the necessary vaccine coverage rate would probably need to reach >90% as with measles, a rate difficult to achieve given current vaccine hesitancy and antivaccination attitudes prevalent in the United States and Europe.", [["measles", "DISEASE", 204, 211], ["herd", "ORGANISM_SUBDIVISION", 52, 56], ["vaccination", "TREATMENT", 74, 85], ["the necessary vaccine coverage rate", "TREATMENT", 126, 161], ["measles", "PROBLEM", 204, 211], ["current vaccine hesitancy", "TREATMENT", 247, 272]]]], "5d0d0bd116976e1412c10a84902894999df4a342": [["A novel coronavirus from Wuhan in central China, named 2019-nCoV, has recently caused an epidemic of pneumonia in humans and posed a huge threat to global public health.", [["pneumonia", "DISEASE", 101, 110], ["coronavirus", "ORGANISM", 8, 19], ["humans", "ORGANISM", 114, 120], ["coronavirus", "SPECIES", 8, 19], ["humans", "SPECIES", 114, 120], ["humans", "SPECIES", 114, 120], ["A novel coronavirus", "PROBLEM", 0, 19], ["pneumonia", "PROBLEM", 101, 110], ["coronavirus", "OBSERVATION", 8, 19], ["epidemic", "OBSERVATION_MODIFIER", 89, 97], ["pneumonia", "OBSERVATION", 101, 110]]], ["1 , 2 To the date 06/02/2020, 2019-nCoV has led to more than 31,0 0 0 confirmed cases and 637 deaths in China according to National Health Commission of the People's Republic of China ( http://en.nhc.gov. cn/index.html ).", [["deaths", "DISEASE", 94, 100], ["cn", "PROTEIN", 205, 207], ["index.html", "PROTEIN", 208, 218]]], ["As a consequence, it is urgent to develop effective measures to control this novel coronavirus on the basis of its pathogenesis.", [["coronavirus", "DISEASE", 83, 94], ["coronavirus", "ORGANISM", 83, 94], ["effective measures", "TREATMENT", 42, 60], ["this novel coronavirus", "PROBLEM", 72, 94]]]], "PMC7323438": [["INTRODUCTIONThe outbreak of COVID\u201019, which was initially conceived as a Chinese\u2010centric shock, has now been understood to be a global crisis.", [["COVID", "DISEASE", 28, 33], ["shock", "DISEASE", 89, 94], ["a Chinese\u2010centric shock", "PROBLEM", 71, 94], ["a global crisis", "PROBLEM", 126, 141], ["shock", "OBSERVATION", 89, 94], ["global", "OBSERVATION_MODIFIER", 128, 134], ["crisis", "OBSERVATION", 135, 141]]], ["With the number of cases increasing rapidly, the World Health Organization (WHO) on March 12, declared COVID\u201019 as a global pandemic.", [["increasing", "OBSERVATION_MODIFIER", 25, 35], ["rapidly", "OBSERVATION_MODIFIER", 36, 43]]], ["The unprecedented outbreak of the virus has brought considerable human sufferings to every sphere of human lives.", [["human", "ORGANISM", 65, 70], ["human", "ORGANISM", 101, 106], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 101, 106], ["the virus", "PROBLEM", 30, 39]]], ["In addition to the public health emergency, the crisis has unpredictably hit the world economy.", [["the crisis", "PROBLEM", 44, 54]]], ["The operations of the world economy have substantially come to a halt.", [["The operations", "TREATMENT", 0, 14]]], ["The economically challenging measures adopted across the countries such as bans on traveling, imposing restrictions on labor mobility, shutting down manufacturing companies, and sharp cutbacks in service sector activities to contain the disease, have produced enormous adverse effects on the economy.", [["labor mobility", "PROBLEM", 119, 133], ["the disease", "PROBLEM", 233, 244], ["enormous adverse effects", "PROBLEM", 260, 284], ["economically", "OBSERVATION_MODIFIER", 4, 16], ["challenging", "OBSERVATION", 17, 28], ["disease", "OBSERVATION", 237, 244], ["enormous", "OBSERVATION_MODIFIER", 260, 268], ["adverse", "OBSERVATION_MODIFIER", 269, 276]]], ["However, an accurate empirical assessment about the size and persistence of the pandemic and its likely impact on the world economy is yet unknowable.", [["an accurate empirical assessment", "TEST", 9, 41], ["the pandemic", "PROBLEM", 76, 88], ["size", "OBSERVATION_MODIFIER", 52, 56], ["pandemic", "OBSERVATION", 80, 88]]], ["The earlier pandemics (SARS, Avian Flu, MERS) had affected particularly those countries that were economically less dominant; moreover, the magnitude of the previous pandemics was much smaller than COVID\u201019.", [["SARS", "DISEASE", 23, 27], ["SARS", "PROBLEM", 23, 27], ["the previous pandemics", "PROBLEM", 153, 175]]], ["The effect of this virus is, however, economically different.", [["this virus", "PROBLEM", 14, 24], ["virus", "OBSERVATION", 19, 24]]], ["The number of infections is frequently changing on an hourly basis.", [["infections", "DISEASE", 14, 24], ["infections", "PROBLEM", 14, 24], ["number", "OBSERVATION_MODIFIER", 4, 10], ["infections", "OBSERVATION", 14, 24]]], ["The top most affected economies out of the outbreak are United States, Italy, China, Spain, France, United Kingdom, and Germany.", [["top", "OBSERVATION_MODIFIER", 4, 7], ["most affected", "OBSERVATION_MODIFIER", 8, 21], ["economies", "OBSERVATION", 22, 31]]], ["G7 economies have witnessed exponential growth in the number of confirmed cases.", [["exponential growth", "PROBLEM", 28, 46], ["exponential", "OBSERVATION_MODIFIER", 28, 39], ["growth", "OBSERVATION_MODIFIER", 40, 46]]], ["Therefore, there is a saying going around that while these large economies sneeze, the rest of the world will get the cold.", [["large", "OBSERVATION_MODIFIER", 59, 64], ["economies", "OBSERVATION", 65, 74]]], ["UNCTAD projects that the slowdown in the world economy as a result of the outbreak of COVID\u201019 will cost around 1 trillion dollars.", [["COVID", "DISEASE", 86, 91], ["slowdown", "OBSERVATION_MODIFIER", 25, 33]]], ["According to the United Nations, the sudden decline in oil prices has been the major contributing factor to the global economic slowdown.", [["oil", "ANATOMY", 55, 58], ["oil", "ORGANISM_SUBSTANCE", 55, 58], ["the sudden decline", "PROBLEM", 33, 51], ["oil prices", "TREATMENT", 55, 65], ["the global economic slowdown", "PROBLEM", 108, 136], ["oil prices", "OBSERVATION", 55, 65], ["global", "OBSERVATION_MODIFIER", 112, 118], ["economic", "OBSERVATION_MODIFIER", 119, 127], ["slowdown", "OBSERVATION", 128, 136]]], ["Figure 1 highlights the loss in GDP growth worldwide.INTRODUCTIONAlthough the pandemic is likely to affect the advanced economies, most, emerging economies like India cannot stand unaffected.", [["GDP", "CHEMICAL", 32, 35], ["GDP", "CHEMICAL", 32, 35], ["GDP", "SIMPLE_CHEMICAL", 32, 35], ["the loss in GDP growth worldwide", "PROBLEM", 20, 52], ["loss", "OBSERVATION_MODIFIER", 24, 28], ["GDP", "OBSERVATION_MODIFIER", 32, 35], ["growth", "OBSERVATION_MODIFIER", 36, 42], ["worldwide", "OBSERVATION_MODIFIER", 43, 52], ["likely to", "UNCERTAINTY", 90, 99], ["advanced", "OBSERVATION_MODIFIER", 111, 119], ["economies", "OBSERVATION", 120, 129]]], ["Governments in many countries have expressed their concern and imposed lockdown to mitigate the rapid spread.", [["the rapid spread", "PROBLEM", 92, 108]]], ["The current situation of COVID\u201019 clubbed with plummeting economic growth has pushed the developing countries like India into a volatile market condition.", [["COVID\u2010", "TREATMENT", 25, 31], ["plummeting economic growth", "PROBLEM", 47, 73]]], ["Among all South Asian countries, India has recorded the maximum number of active coronavirus cases.", [["coronavirus", "DISEASE", 81, 92], ["coronavirus", "ORGANISM", 81, 92], ["active coronavirus", "OBSERVATION", 74, 92]]], ["As of April 13, there has been total 9,241 number of COVID\u201019 cases in India with 331 deaths.", [["deaths", "DISEASE", 86, 92]]], ["Before the outbreak of COVID\u201019, Indian economy had already been experiencing economic slowdown over the past few quarters.", [["economic slowdown", "PROBLEM", 78, 95], ["economic", "OBSERVATION_MODIFIER", 78, 86], ["slowdown", "OBSERVATION", 87, 95]]], ["The economy was already reeling under rising unemployment, low consumption, and weakening industrial output and prices.", [["weakening industrial output", "PROBLEM", 80, 107], ["low consumption", "OBSERVATION_MODIFIER", 59, 74], ["industrial output", "OBSERVATION", 90, 107]]], ["Pre\u2010COVID\u201019, the economy was witnessing sluggish economic growth, compounding the existing problems of rural distress, malnutrition, and widespread inequality.INTRODUCTIONFurthermore, India's vast informal sector is particularly vulnerable.", [["malnutrition", "DISEASE", 120, 132], ["sluggish economic growth", "PROBLEM", 41, 65], ["rural distress", "PROBLEM", 104, 118], ["malnutrition", "PROBLEM", 120, 132], ["rural distress", "OBSERVATION", 104, 118], ["malnutrition", "OBSERVATION", 120, 132], ["widespread", "OBSERVATION_MODIFIER", 138, 148], ["inequality", "OBSERVATION_MODIFIER", 149, 159]]], ["These economic constraints, along with the current supply side shock, have put the economy on an adverse situation.", [["shock", "DISEASE", 63, 68], ["These economic constraints", "PROBLEM", 0, 26], ["the current supply side shock", "TREATMENT", 39, 68]]], ["It will be challenging to predict the scale and speed of the effect of COVID\u201019 on any economies; however, there is no doubt that the impact will be much pronounced than the demonetization in 2016 and 2017 GST rollout.", [["GST", "GENE_OR_GENE_PRODUCT", 206, 209], ["COVID\u2010", "TREATMENT", 71, 77], ["no doubt", "UNCERTAINTY", 116, 124]]], ["It appears to be apparent now that these two events that caused shocks to the economy and yet not recovered fully, there is another shock ahead for the economy to face.", [["shock", "DISEASE", 132, 137], ["appears to be", "UNCERTAINTY", 3, 16], ["shock", "OBSERVATION", 132, 137]]], ["The similarity with the 2016s demonetization and 2017s GST does not end at their economic impact.", [["GST", "GENE_OR_GENE_PRODUCT", 55, 58], ["2017s GST", "PROTEIN", 49, 58]]], ["In the events of declining domestic investment and mean consumption rate, several monetary and fiscal policy measures were taken to recover the growth rate at the end of the last quarter.", [["mean consumption rate", "TEST", 51, 72], ["fiscal policy measures", "TREATMENT", 95, 117]]], ["RBI in its biannual monetary policy report has emphasized that the outbreak of COVID\u201019 pandemic has drastically altered the outlook of the Indian economy and it has been the high time for the policymakers to formulate some monetary and fiscal measures to curb the economic slowdown in India.1 As the situation has not turned normal and the number of cases is increasing worldwide as well as at national level, it has been anticipated that the occurrence of the virus will further deteriorate the recovery process in the near to medium term.", [["COVID", "DISEASE", 79, 84], ["fiscal measures", "TREATMENT", 237, 252], ["the virus", "PROBLEM", 458, 467], ["increasing", "OBSERVATION_MODIFIER", 360, 370], ["virus", "OBSERVATION", 462, 467]]], ["The outbreak has put a new set of challenges before the country by spreading its dangerous effect on both demand and supply side.INTRODUCTIONFrom a public health perspective, the ability to contain the outbreak in India will primarily depend upon the strength of the public health system in India.", [["dangerous effect", "OBSERVATION", 81, 97]]], ["India's expenditure on health as a percentage of GDP is lower than the poorest countries in the world.", [["GDP", "CHEMICAL", 49, 52], ["GDP", "SIMPLE_CHEMICAL", 49, 52]]], ["According to the National Health Profile in 2019, India spends only 1.28% of its GDP as public health expenditure.2 World Health Organization ranks India 145 among 195 countries in terms of health care access and quality.", [["GDP", "CHEMICAL", 81, 84], ["GDP", "CHEMICAL", 81, 84], ["GDP", "SIMPLE_CHEMICAL", 81, 84]]], ["The human resources and physical infrastructures of the public health system in India stand at an inferior stage.", [["human", "ORGANISM", 4, 9], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["inferior", "ANATOMY_MODIFIER", 98, 106]]], ["While the private health care system is flourishing in India, more than 65% population does not have health insurance, putting massive pressure on the public hospitals.", [["massive", "OBSERVATION_MODIFIER", 127, 134], ["pressure", "OBSERVATION_MODIFIER", 135, 143]]], ["The main objective of the lockdown was to maintain social distancing and suspend all forms of travel so that it can prevent the spread of infection from the infected at the community level.", [["infection", "DISEASE", 138, 147], ["infection", "PROBLEM", 138, 147], ["main", "OBSERVATION_MODIFIER", 4, 8], ["infection", "OBSERVATION", 138, 147], ["infected", "OBSERVATION", 157, 165]]], ["Maharashtra, which has witnessed the maximum number of coronavirus cases in India, has only one hospital for every 1.6 lakh population.", [["coronavirus", "DISEASE", 55, 66], ["coronavirus", "ORGANISM", 55, 66], ["coronavirus cases", "OBSERVATION", 55, 72]]], ["Statistics also reveal that on average, there is only one doctor for 10,700 people in India.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82]]], ["Given this poor medical condition in India, a genuine question arises, how well prepared is India's public health system to deal with this crisis.3 While testing needs to be an essential part to fight the crisis and contain the spread, India does not have enough kits to test most of its population for the new coronavirus.", [["coronavirus", "DISEASE", 311, 322], ["coronavirus", "ORGANISM", 311, 322], ["this poor medical condition", "PROBLEM", 6, 33], ["this crisis", "PROBLEM", 134, 145], ["the crisis", "PROBLEM", 201, 211], ["the new coronavirus", "PROBLEM", 303, 322]]], ["As of April 9, India has conducted a total of 1,44,920 tests recording lowest test rates per capita in the world.", [["tests recording", "TEST", 55, 70]]]], "6fffd29da38651e79d21fe3d018164d10d336653": [["IntroductionCOVID-19, the coronavirus-transmitted infectious disease, has caused a worldwide pandemic.", [["IntroductionCOVID-19", "CHEMICAL", 0, 20], ["coronavirus-transmitted infectious disease", "DISEASE", 26, 68], ["coronavirus", "ORGANISM", 26, 37], ["IntroductionCOVID", "TEST", 0, 17], ["the coronavirus", "PROBLEM", 22, 37], ["transmitted infectious disease", "PROBLEM", 38, 68], ["a worldwide pandemic", "PROBLEM", 81, 101], ["infectious", "OBSERVATION", 50, 60], ["worldwide", "OBSERVATION_MODIFIER", 83, 92], ["pandemic", "OBSERVATION", 93, 101]]], ["Smoking 1 2 and e-cigarette use 3 increase risk and severity of pulmonary infections because of damage to upper airways and a decrease in pulmonary immune function.", [["pulmonary", "ANATOMY", 64, 73], ["upper airways", "ANATOMY", 106, 119], ["pulmonary", "ANATOMY", 138, 147], ["pulmonary infections", "DISEASE", 64, 84], ["pulmonary", "ORGAN", 64, 73], ["upper airways", "ORGANISM_SUBDIVISION", 106, 119], ["pulmonary", "ORGAN", 138, 147], ["pulmonary infections", "PROBLEM", 64, 84], ["damage to upper airways", "PROBLEM", 96, 119], ["a decrease in pulmonary immune function", "PROBLEM", 124, 163], ["pulmonary", "ANATOMY", 64, 73], ["infections", "OBSERVATION", 74, 84], ["upper", "ANATOMY_MODIFIER", 106, 111], ["airways", "ANATOMY", 112, 119], ["decrease", "OBSERVATION_MODIFIER", 126, 134], ["pulmonary", "ANATOMY", 138, 147], ["immune function", "OBSERVATION", 148, 163]]], ["In particular, smokers have a higher risk of infection and mortality from Cov-MERS.", [["infection", "DISEASE", 45, 54], ["smokers", "ORGANISM", 15, 22], ["infection", "PROBLEM", 45, 54], ["infection", "OBSERVATION", 45, 54]]], ["4 Two reviews 5 6 of the first 5 papers presenting data on smoking and COVID-19 reached different conclusions.", [["COVID", "TREATMENT", 71, 76]]], ["Another review described 6 published case series presenting data on smoking among COVID-19 patients but did not draw a conclusion about the association of severity of COVID-19 with smoking.", [["smoking", "CHEMICAL", 68, 75], ["smoking", "CHEMICAL", 181, 188], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99]]], ["7 We reviewed and summarized 12 papers presenting data on the association between smoking and severity of COVID-19.MethodsWe conducted a systematic search using PubMed database on April 6, 2020, with the search term: ((smoking) OR (characteristics) OR (risk factors) OR (outcomes) OR (smoker*)) AND ((COVID-19) OR (COVID) OR (coronavirus) OR (sars cov-2) OR (sars cov 2)) for studies published between January 1, 2020 and April 6, 2020.", [["COVID", "TEST", 106, 111]]], ["There were no language restrictions.", [["no", "UNCERTAINTY", 11, 13], ["language restrictions", "OBSERVATION", 14, 35]]], ["A total of 396 studies were retrieved through the search, of which 12, 10 from China, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 1 from Korea, 18 and 1 from the US, 19 included data on smoking behavior and COVID-19 disease progression (Table 1 ).", [["[8] [9] [10] [11] [12] [13] [14] [15] [16", "CHEMICAL", 86, 127], ["[8] [9] [10] [11] [12] [13] [14] [15] [16", "SIMPLE_CHEMICAL", 86, 127], ["396 studies", "TEST", 11, 22], ["Korea", "TEST", 141, 146], ["the US", "TEST", 162, 168], ["smoking behavior", "TEST", 190, 206], ["COVID", "TEST", 211, 216], ["disease progression", "PROBLEM", 220, 239]]], ["Ten studies 8 10-18 were based on hospitalized patients and two 9 19 included both hospitalized patients and outpatients.MethodsThe exposure group is those who had a history of smoking (current smokers or former smokers) and unexposed group was never smokers.", [["smoking", "CHEMICAL", 177, 184], ["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 96, 104], ["outpatients", "ORGANISM", 109, 120], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 96, 104], ["outpatients", "SPECIES", 109, 120], ["Ten studies", "TEST", 0, 11]]], ["Five studies 8 10 12 14 17 assessed whether the patient was a \"current smoker,\" three studies 9 16 19 assessed whether the patient was a current or All rights reserved.", [["patient", "ORGANISM", 48, 55], ["patient", "ORGANISM", 123, 130], ["patient", "SPECIES", 48, 55], ["patient", "SPECIES", 123, 130], ["Five studies", "TEST", 0, 12]]], ["No reuse allowed without permission.Methods(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.MethodsThe copyright holder for this preprint this version posted April 16, 2020. . https://doi.org/10.1101/2020.04.", [["med", "ANATOMY", 122, 125]]], ["13.20063669 doi: medRxiv preprint former smoker (as separate categories), and four studies 11 13 15 18 assessed whether the patent had a \"history of smoking\" (current or former).MethodsOutcome is progression of COVID-19 to more severe or critical conditions or death (Table 1) .", [["smoking", "CHEMICAL", 149, 156], ["death", "DISEASE", 261, 266], ["four studies", "TEST", 78, 90], ["COVID", "TEST", 211, 216], ["critical conditions", "PROBLEM", 238, 257], ["death", "PROBLEM", 261, 266], ["patent", "OBSERVATION", 124, 130], ["progression", "OBSERVATION_MODIFIER", 196, 207]]], ["Two studies 14 16 categorized the outcome as severe (respiratory distress with respiratory rate \u226530/min, or oxygen saturation \u226493% at rest, or oxygenation index \u2264300 mmHg, based on the diagnostic and treatment guideline for SARS-CoV-2 issued by Chinese National Health Committee 16 ) or mild, three 8 11 12 categorized the outcome as progression or improvement, two 10 19 categorized the outcome as ICU admission or non-ICU admission, one 9 categorized the outcome as the primary composite end point (ICU admission, the use of mechanical ventilation, or death) or not, two 15 17 categorized the outcome as death or survivor, one 13 categorized the outcome as the occurrence of severe cases (without defining severe) or death or mild, and one 18 categorized the outcome as clinical deterioration during the hospitalization and needed supplemental oxygen therapy.MethodsWe computed unadjusted odds ratios (OR) and 95% confidence interval (CI) for each study using the number of smokers (current and former) and never smokers with and without disease progression.", [["respiratory", "ANATOMY", 53, 64], ["respiratory distress", "DISEASE", 53, 73], ["oxygen", "CHEMICAL", 108, 114], ["SARS", "DISEASE", 224, 228], ["death", "DISEASE", 554, 559], ["death", "DISEASE", 606, 611], ["death", "DISEASE", 719, 724], ["oxygen", "CHEMICAL", 846, 852], ["oxygen", "CHEMICAL", 108, 114], ["oxygen", "CHEMICAL", 846, 852], ["oxygen", "SIMPLE_CHEMICAL", 108, 114], ["oxygen", "SIMPLE_CHEMICAL", 846, 852], ["Two studies", "TEST", 0, 11], ["severe (respiratory distress", "PROBLEM", 45, 73], ["respiratory rate", "TEST", 79, 95], ["oxygen saturation", "TEST", 108, 125], ["oxygenation index", "TEST", 143, 160], ["treatment guideline", "TREATMENT", 200, 219], ["SARS", "PROBLEM", 224, 228], ["mechanical ventilation", "TREATMENT", 527, 549], ["severe cases", "PROBLEM", 677, 689], ["death", "PROBLEM", 719, 724], ["clinical deterioration", "PROBLEM", 772, 794], ["supplemental oxygen therapy", "TREATMENT", 833, 860], ["each study", "TEST", 945, 955], ["disease progression", "PROBLEM", 1040, 1059], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["respiratory distress", "OBSERVATION", 53, 73], ["mild", "OBSERVATION_MODIFIER", 287, 291], ["mild", "OBSERVATION_MODIFIER", 728, 732], ["oxygen therapy", "OBSERVATION", 846, 860], ["without", "UNCERTAINTY", 1032, 1039]]], ["Random effects meta-analysis was performed using the Stata 14.0 metan command and using metabias command with Harbord and Peters to test for the presence of publication bias.MethodsPatients or the public were not involved in the design, or conduct, or reporting of our research.", [["the Stata", "TEST", 49, 58]]], ["No reuse allowed without permission.Methods(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.MethodsThe copyright holder for this preprint this version posted April 16, 2020. . https://doi.org/10.1101/2020.04.13.20063669 doi: medRxiv preprintResultsA total of 9,025 COVID-19 patients included in our meta-analysis, 878 of whom (9.7%) experienced disease progression and 495 with a history of smoking (5.5%).", [["smoking", "CHEMICAL", 477, 484], ["patients", "ORGANISM", 360, 368], ["patients", "SPECIES", 360, 368], ["COVID", "TEST", 351, 356], ["disease progression", "PROBLEM", 431, 450], ["med", "ANATOMY", 122, 125]]], ["A total of 88 patients with a history of smoking (17.8%) experienced disease progression, compared with 9.3% of never smoking patients.ResultsThe meta-analysis showed an association between smoking and COVID-19 progression (OR 2.25, 95% CI 1.49-3.39, p=0.001) ( Figure 1 ).", [["smoking", "CHEMICAL", 41, 48], ["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 126, 134], ["disease progression", "PROBLEM", 69, 88], ["The meta-analysis", "TEST", 142, 159], ["COVID", "TEST", 202, 207], ["CI", "TEST", 237, 239], ["p", "TEST", 251, 252]]], ["There was not significant heterogeneity among the studies (I 2 =28.9%, p=0.162) or publication bias (Harbord's p=0.155, Peters' p=0.668).DiscussionOur analysis confirms that smoking is a risk factor for progression of COVID-19, with smokers having 2.25-times the odds of severe COVID-19 outcomes than never smokers.", [["smoking", "CHEMICAL", 174, 181], ["significant heterogeneity", "PROBLEM", 14, 39], ["the studies", "TEST", 46, 57], ["I", "TEST", 59, 60], ["p", "TEST", 71, 72], ["publication bias", "TEST", 83, 99], ["Harbord's p", "TEST", 101, 112], ["Peters' p", "TEST", 120, 129], ["DiscussionOur analysis", "TEST", 137, 159], ["severe COVID", "PROBLEM", 271, 283], ["not", "UNCERTAINTY", 10, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["heterogeneity", "OBSERVATION", 26, 39]]], ["This finding contrasts with an earlier meta-analysis, 6 which included only 5 studies and used a nonstandard method to compute the meta-analysis.", [["an earlier meta-analysis", "TEST", 28, 52], ["5 studies", "TEST", 76, 85], ["the meta-analysis", "TEST", 127, 144]]], ["The finding that smoking is associated with COVID-19 progression is not surprising because of the adverse effects of smoking on pulmonary immune function.", [["pulmonary", "ANATOMY", 128, 137], ["smoking", "CHEMICAL", 17, 24], ["smoking", "CHEMICAL", 117, 124], ["pulmonary", "ORGAN", 128, 137], ["pulmonary immune function", "TREATMENT", 128, 153], ["pulmonary", "ANATOMY", 128, 137], ["immune function", "OBSERVATION", 138, 153]]], ["1 2 Our study has several limitations.DiscussionThe definition of \"smoking\" sometimes includes former smokers and sometimes does not.", [["Our study", "TEST", 4, 13]]], ["Only three studies 9 16 19 separated current and former smokers in different categories, which was not enough data to do a meta-analysis for current and former smokers separately.", [["three studies", "TEST", 5, 18]]], ["Because the lung recovers after someone stops smoking, including former smokers in the exposed group biases the effect estimate to the null.DiscussionAll rights reserved.", [["lung", "ANATOMY", 12, 16], ["smoking", "CHEMICAL", 46, 53], ["lung", "ORGAN", 12, 16], ["lung", "ANATOMY", 12, 16]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 125, 128]]], ["20 18.5% in the Korean patients vs. 21.1% 21 (37.0% for men and 5.2% for women) in 2017, and 3.6% in the US patients vs. 13.7% 22 (15.6% for men and 12.0% for women) in 2018.", [["patients", "ORGANISM", 23, 31], ["men", "ORGANISM", 56, 59], ["women", "ORGANISM", 73, 78], ["patients", "ORGANISM", 108, 116], ["men", "ORGANISM", 141, 144], ["women", "ORGANISM", 159, 164], ["patients", "SPECIES", 23, 31], ["men", "SPECIES", 56, 59], ["women", "SPECIES", 73, 78], ["patients", "SPECIES", 108, 116], ["men", "SPECIES", 141, 144], ["women", "SPECIES", 159, 164]]], ["It is highly likely that many smokers were misclassified as nonsmokers, which also biases the risk estimate toward the null.DiscussionWe computed and assessed unadjusted odds ratios based on the numbers of patients reported in the studies.", [["smokers", "ORGANISM", 30, 37], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["the studies", "TEST", 227, 238], ["highly likely", "UNCERTAINTY", 6, 19], ["many", "OBSERVATION_MODIFIER", 25, 29], ["smokers", "OBSERVATION", 30, 37]]], ["Only one 11 None of these studies assessed e-cigarette use.DiscussionAll these limitations suggest that this analysis underestimates the risk of smoking in terms of increasing COVID-19 severity.DiscussionAll 12 studies were of patients who had already developed COVID-19, so the risk estimate we report does not represent the effect of smoking on the risk of contracting COVID-19 in the general population.", [["e-cigarette", "CHEMICAL", 43, 54], ["smoking", "CHEMICAL", 145, 152], ["smoking", "CHEMICAL", 336, 343], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235], ["these studies", "TEST", 20, 33], ["this analysis", "TEST", 104, 117], ["increasing COVID", "TREATMENT", 165, 181], ["COVID", "TEST", 262, 267], ["contracting COVID", "TEST", 359, 376]]], ["As population-level testing ramps up, it would be useful to collect data on smoking and e-cigarette use to determine what risks these behaviors impose in terms of infection.ConclusionsSmoking is associated with COVID-19 disease progression.", [["smoking", "CHEMICAL", 76, 83], ["infection", "DISEASE", 163, 172], ["Smoking", "DISEASE", 184, 191], ["population-level testing ramps", "TEST", 3, 33], ["infection", "PROBLEM", 163, 172], ["COVID-19 disease progression", "PROBLEM", 211, 239], ["infection", "OBSERVATION", 163, 172], ["disease", "OBSERVATION", 220, 227]]], ["Physicians and public health professionals should collect data on smoking and, given the pulmonary effects of e-cigarettes, 3 e-All rights reserved.", [["pulmonary", "ANATOMY", 89, 98], ["smoking", "CHEMICAL", 66, 73], ["pulmonary", "ORGAN", 89, 98], ["pulmonary", "ANATOMY", 89, 98]]], ["No reuse allowed without permission.Conclusions(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionsThe copyright holder for this preprint this version posted April 16, 2020.All authors have completed the Unified Competing Interest form (available on requestfrom the corresponding author) and declare that the work was supported as described in the funding statement above.", [["The copyright holder", "TREATMENT", 193, 213], ["med", "ANATOMY", 126, 129]]], ["The authors have no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and no other relationships or activities that could appear to have influenced the submitted work.CONTRIBUTORSHIPRP developed the idea for the study, collected, analyzed the data, and wrote the first draft of the manuscript.", [["the study", "TEST", 283, 292]]], ["SAG assisted with revising and refining the manuscript.", [["SAG", "CHEMICAL", 0, 3]]], ["Both authors affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.CONTRIBUTORSHIPAll rights reserved.", [["the study", "TEST", 91, 100], ["the study", "TEST", 146, 155], ["the study", "TEST", 207, 216]]], ["No reuse allowed without permission.CONTRIBUTORSHIP(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DATA SHARING STATEMENTAll data used to prepare this paper are available from the cited sources.DATA SHARING STATEMENTAll rights reserved.", [["med", "ANATOMY", 130, 133]]], ["No reuse allowed without permission.DATA SHARING STATEMENT(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 137, 140], ["med", "ANATOMY", 273, 276]]], ["Smoking and COVID-19 Progression All rights reserved.", [["COVID", "TEST", 12, 17]]], ["No reuse allowed without permission.DATA SHARING STATEMENT(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DATA SHARING STATEMENTThe copyright holder for this preprint this version posted April 16, 2020. . https://doi.org/10.1101/2020.04.", [["The copyright holder", "TREATMENT", 215, 235], ["med", "ANATOMY", 137, 140]]]], "PMC7458827": [], "a321a6de35a988b185d31e5dfe1c1a494a190612": [["A chronic colitis which ulcerates is a common, almost universal finding in the 11 species and hybrids of the 1584 Callitrichidae we have necropsied and studied histologically since 1966.", [["colitis", "DISEASE", 10, 17], ["ulcerates", "DISEASE", 24, 33], ["A chronic colitis", "PROBLEM", 0, 17], ["chronic", "OBSERVATION_MODIFIER", 2, 9], ["colitis", "OBSERVATION", 10, 17], ["common", "OBSERVATION_MODIFIER", 39, 45]]], ["In Table 1 the number of necropsies we have done are tabulated by calendar year by species.", [["necropsies", "TREATMENT", 25, 35]]], ["The variable numbers reflect largely population changes in species that have comprised the marmoset research colony over the years.", [["marmoset", "ORGANISM", 91, 99], ["largely population changes in species", "PROBLEM", 29, 66], ["variable", "OBSERVATION_MODIFIER", 4, 12], ["numbers", "OBSERVATION_MODIFIER", 13, 20], ["largely", "OBSERVATION_MODIFIER", 29, 36], ["population", "OBSERVATION", 37, 47], ["marmoset", "OBSERVATION_MODIFIER", 91, 99], ["research", "OBSERVATION_MODIFIER", 100, 108], ["colony", "OBSERVATION_MODIFIER", 109, 115]]], ["For example, up until 1979, Saguinus fuscicoIlis illigeri and related subspecies (the socalled white-lipped tamarins) were the most numerous animals under study; they have been outnumbered by Saguinus oedipus oedipus (the cotton-top tamarin) only since 1975, when the S. f. subspecies were purposely reduced in numbers to permit an increase in the number of cotton-tops available for study.", [["Saguinus fuscicoIlis illigeri", "ORGANISM", 28, 57], ["tamarins", "ORGANISM", 108, 116], ["Saguinus oedipus oedipus", "ORGANISM", 192, 216], ["S. f. subspecies", "ORGANISM", 268, 284], ["Saguinus fuscicoIlis illigeri", "SPECIES", 28, 57], ["Saguinus oedipus oedipus", "SPECIES", 192, 216], ["S. f.", "SPECIES", 268, 273], ["Saguinus fuscicoIlis illigeri", "SPECIES", 28, 57], ["white-lipped tamarins", "SPECIES", 95, 116], ["Saguinus oedipus oedipus", "SPECIES", 192, 216], ["cotton-top tamarin", "SPECIES", 222, 240], ["S. f. subspecies", "SPECIES", 268, 284], ["Saguinus fuscicoIlis illigeri", "PROBLEM", 28, 57], ["the socalled white-lipped tamarins", "TREATMENT", 82, 116], ["the cotton-top tamarin", "TREATMENT", 218, 240], ["study", "TEST", 384, 389], ["subspecies", "OBSERVATION_MODIFIER", 70, 80], ["increase", "OBSERVATION_MODIFIER", 332, 340]]], ["The table also shows the colony census of live animals by species on April 1, 1984 , and the total numbers of each species necropsied.", [["colony", "OBSERVATION", 25, 31]]], ["This paper, describing the histology of marmoset colitis, rests principally upon 764 S. f. illigeri, 290 S. f. subspecies, 352 S. o. oedipus, and 138 CaUithrix jacchus (the common marmoset) necropsy observations.", [["marmoset colitis", "DISEASE", 40, 56], ["marmoset", "ORGANISM", 40, 48], ["colitis", "PATHOLOGICAL_FORMATION", 49, 56], ["S.", "ORGANISM", 85, 87], ["f. illigeri", "ORGANISM", 88, 99], ["S. f. subspecies", "ORGANISM", 105, 121], ["S. o. oedipus", "ORGANISM", 127, 140], ["CaUithrix jacchus", "ORGANISM", 150, 167], ["marmoset", "ORGANISM", 180, 188], ["S.", "SPECIES", 85, 87], ["f. illigeri", "SPECIES", 88, 99], ["S. f.", "SPECIES", 105, 110], ["S. o. oedipus", "SPECIES", 127, 140], ["CaUithrix jacchus", "SPECIES", 150, 167], ["S. f. illigeri", "SPECIES", 85, 99], ["S. f. subspecies", "SPECIES", 105, 121], ["S. o. oedipus", "SPECIES", 127, 140], ["CaUithrix jacchus", "SPECIES", 150, 167], ["marmoset colitis", "PROBLEM", 40, 56], ["marmoset colitis", "OBSERVATION", 40, 56]]], ["TECHNIQUES Complete necropsies were done as soon as possible after death.", [["death", "DISEASE", 67, 72], ["death", "PROBLEM", 67, 72]]], ["Only rarely was a dead animal not examined both grossly and microscopically.", [["grossly", "OBSERVATION_MODIFIER", 48, 55]]], ["From 1966 to 1976, all tissues were fixed in Gomori's 1-2-3 fixative, and after 1976 in 10% neutral formalin.", [["tissues", "ANATOMY", 23, 30], ["formalin", "CHEMICAL", 100, 108], ["formalin", "CHEMICAL", 100, 108], ["tissues", "TISSUE", 23, 30], ["formalin", "SIMPLE_CHEMICAL", 100, 108]]], ["Fixed tissues were embedded in paraffin and 4 to 6 p~m sections were cut and routinely stained with PAS-hematoxylin (2).", [["tissues", "ANATOMY", 6, 13], ["sections", "ANATOMY", 55, 63], ["paraffin", "CHEMICAL", 31, 39], ["hematoxylin", "CHEMICAL", 104, 115], ["tissues", "TISSUE", 6, 13], ["PAS-hematoxylin", "SIMPLE_CHEMICAL", 100, 115], ["PAS", "PROTEIN", 100, 103], ["Fixed tissues", "PROBLEM", 0, 13], ["paraffin", "TEST", 31, 39], ["PAS", "TEST", 100, 103], ["tissues", "ANATOMY", 6, 13]]]]}